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lucocorticoid Receptor (GR) is a typical steroid hormone receptor. GR has a
disordered N-terminal domain that binds transcriptional cofactors, a DNA-
binding domain, and a steroid binding domain. Most work for the past forty years
has been focused on the latter two domains that are structured and amenable
to characterization. Yet, the disordered N-terminus makes up more than half of
the protein and is absolutely required for transcriptional activation (repression
can occur regardless). There are also translational isoforms with truncated
N-termini that alter the resulting activity of GR. How the disordered isoforms
of the N-terminus couple to cofactors and transcriptional activity is currently
unclear. In this thesis, I sought organizing principles to explain the varying
activities of GR translational isoforms. I found that a transcriptional cofactor,
tumor susceptibility gene 101 (TSG101), can bind and fold the disordered N-
terminus of GR. TSG101’s binding is allosterically coupled to binding of DNA,
but the exact mechanism differs between different isoforms of GR. In this thesis I
ii
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also characterized the thermodynamic stability of the TSG101 coiled-coil, which
binds GR, and I used computational docking to develop novel drug-leads targeted
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CHAPTER 1. INTRODUCTION TO NUCLEAR HORMONE RECEPTOR BIOLOGY
1.1 Abstract
N
uclear Hormone Receptors (NHRs) must respond to a variety of chemical
cues to selectively induce or repress pertinent genes. Each domain
of these multidomain proteins is capable of binding to various large or small
molecules, and such binding may alter the activity of both the local and remote
domains. These allosteric effects are essential for proper NHR function; yet until
recently very little was known about their mechanism. Recent well-documented
findings show that protein dynamics and intrinsic disorder mediate allosteric
signals. I discuss the recently proposed Ensemble Allosteric Model, which can be
used to mechanistically dissect perplexing and sometimes paradoxical allosteric
phenomena. Finally, I close with how this model can be specifically applied to
NHRs and how its use can enhance future studies.
Physiological and molecular biological studies have dominated nuclear hor-
mone receptor (NHR) research for the past half century. Many experiments have
demonstrated that NHRs function as allosteric proteins. Recent thermodynamic
studies have begun to show how NHRs modulate their biological response by
using allostery, wherein an energetic perturbation at one site mediates a func-
tional response at a physically distinct site [201, 219, 242]. These energetic
perturbations can be affected by many physical phenomena, including but not
limited to: ligand binding, post-translational modifications, and different NHR
2
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protein isoforms [292,345,435]. It has become clear that transcription factors,
generally [106,251], and NHRs specifically [201,219,242], utilize intrinsic disor-
der to modify their allosteric responses. This chapter will first describe dynamics
and intrinsic disorder in NHRs, and then show this intrinsic disorder is poised to
maximize allosteric coupling in nuclear hormone receptors.
1.2 Dynamics and Intrinsic Disorder in NHR’s
One of the most rapidly expanding fields in protein biophysics is the study of
intrinsic disorder in proteins [410]. In the past decade, it was realized that
these intrinsically disordered proteins (IDPs) and intrinsically disordered regions
(IDRs) are in perhaps two-thirds of eukaryotic transcription factors [251]. As a
major class of transcription factors, NHRs are no exception and all NHRs show
some disorder propensity [214]. Most NHRs are multidomain proteins consisting
of ligand-binding (LBD), DNA-binding (DBD) and sometimes, N-terminal (NTD)
domains Figure 1.1.
The LBD contains several dynamic regions that are predominantly near the
ligand-binding pocket. Some of the earliest research on the dynamic nature
of the LBD is from the O’Malley lab in the 1990’s. Working with progesterone
and estrogen receptors, they found that the LBD undergoes a conformational
change upon binding hormone [9,9,40]. Subsequent X-ray crystallography and
3
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Figure 1.1 – The Domain Organization of NHR’s
The diagram reads N-terminus on the left, C-terminus on the right. The N-terminal domain (NTD)
is intrinsically disorder and often binds cofactor proteins. The DNA-binding domain (DBD) binds
response elements. The ligand-binding domain (LBD) binds small molecules, such as steroids, and
some cofactor proteins. The NTD length is highly variable and its sequence is poorly conserved.
The DBD and LBD together are on the order of 300 amino acids total and are well conserved.
Example structures are shown above the box diagram (GR DBD and LBD are pdb:1glu and 1p93,
respectively).
fluorescence anisotropy experiments demonstrated that when the LBD binds
ligand, helix-12 undergoes a conformational change and becomes less dynamic
[53,190,341,423]. This conformational change varies depending on the ligand
bound; hence different ligands can promote specific conformations that bind
corepressors or coactivators [59,298]. Researchers have also shown that cofactor
fragments that bind the LBD can stabilize the LBD interaction with certain
ligands [119,190], demonstrating an allosteric communication between cofactor
and ligand binding. The cofactor thus acts as an allosteric effector/ligand.
The DBD also has regions that are dynamic. Estrogen and glucocorticoid
receptor DBDs are partially disordered in solution [43,363], and become more
ordered when bound to DNA [263,362]. Spolar and Record first described this
transition on thermodynamic grounds [379], and their analysis hinted at the
4
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possibility of different DNA sequences having different effects on the DBD. Indeed,
the sequence of DNA does modulate this conformational change [30,257,278].
Specifically, the DNA sequence can change both the binding affinity to the
DBD and the propensity for dimerization of the DBD [126, 163, 444]. It has
been speculated that response elements cause allosteric effects beyond the
DBD—possibly changing the conformation of the NTD [238,383], a point that
will be revisited in the next section.
The steroid hormone receptor (SHR) subclass of NHRs contains large NTDs
of varying size and sequence, which are perhaps the best example of dynamics
and disorder in the NHR family of proteins [214]. Each type of SHR contains a
large amount of ID in the N-terminus, as determined by a myriad of biophysical
methods [28,29,79,108,218,230,304]. It is not yet clear why SHR N-termini
are disordered, but folding of these domains appears to be key to understanding
their function. Many disordered proteins undergo coupled folding and binding to
perform their biological role [417], and in 1999, the Thompson lab presented the
first evidence that the NTD of an SHR could fold into a tertiary structure, either
because of the DBD binding a response element or because of high concentrations
of an osmolyte [38,215]. When so folded, the NTD showed enhanced binding
of known partner proteins [216]; thus, the folded state of an SHR NTD is likely
the biologically functional state. Since then, many groups have used various
osmolytes, such as tri-methyl amine N-oxide (TMAO; see [48]) to fold the NTDs
5
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of NHRs and have demonstrated that they fold cooperatively, a hallmark of a
naturally evolved, folded state [433].
Glucocorticoid, androgen, and mineralocorticoid receptors’ NTDs all fold
cooperatively in the presence of molar concentrations of TMAO [38,108,242,
338]. This is evidence of a major folded conformation or an ensemble of folded
conformations. As mentioned above, the folded state is the presumed biologically
active state of the NTD because of studies showing that the NTD folds upon
binding transcriptional cofactors. The NTDs of SHRs bind numerous cofactor
proteins [255], and studies on estrogen, glucocorticoid, and androgen receptors
have shown that the NTDs become more ordered upon binding cofactor proteins
[75,201,219,338,430]. This suggests a coupled folding and binding mechanism
regulates SHR activity.
In sum, all NHR domains—even the relatively structured LBDs and DBDs—are
dynamic and exist as conformational ensembles of states. Upon binding a ligand,
domains are stabilized in one or another globular state of a more limited ensemble.
These ligand-specific effects have functional consequences on the co-regulators
bound, and on transcriptional function. By varying the transcriptional function of
a receptor, ligands can alter cellular and clinical outcomes. “Ligand” thus refers
to all binding partners—protein, DNA, steroidal or other small molecules—as
they interact with their respective domains.
6
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1.3 Inter- and Intra-domain Coupling in NHR’s
Binding of a ligand in one NHR domain not only affects the conformational
ensemble of that domain, but also the conformational ensembles of the other
domains. This allosteric coupling between domains is crucial for the function of
NHR’s.
1.3.1 DNA response elements as allosteric effectors
Early glucocorticoid research raised a fundamental question [175]—how does
a NHR activate a multitude of genes to different degrees? One possibility is
that each response element could modify the activity of a bound NHR. This idea
was supported by research on glucocorticoid, estrogen, and thyroid hormone
receptors [9,126,238,269,353,383]. In particular, work from Yamamoto and
colleagues demonstrated that glucocorticoid receptor activity was dependent on
the response element sequence [353] and also speculated that a conformational
change was occurring upon DNA binding.
Ikeda and colleagues provided the first evidence of different response ele-
ments inducing different conformational changes in NHRs [167]. They found
that transcriptionally active response elements induced a change in thyroid hor-
mone/retinoid X receptor dimers, such that the complex was resistant to protease
digestion, relative to protein dimers on inactive response elements [167]. Later
7
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studies found similar effects with estrogen and androgen response elements and
their cognate receptors [122,257,443,444].
The limited proteolysis experiments described above demonstrate DNA re-
sponse element dependent protection patterns. However, which portions of the
molecule were undergoing conformational changes was still an open question.
In 1999, Kumar and colleagues published the first manuscript demonstrating
that when an NHR, glucocorticoid receptor, binds DNA its NTD undergoes a
conformational change [215]. Kumar used a combination of circular dichroism
and tryptophan fluorescence to demonstrate that folding was occurring in the
NTD. Subsequent studies have revealed similar phenomena in progesterone
receptor [28,29], estrogen receptor alpha [131], and androgen receptor [58].
The inferred significance of these observations is that binding of DNA coupled
to folding of the NTD would recruit transcriptional cofactors, as proposed by
Thompson and coworkers [75,403].
1.3.2 LBD ligands as allosteric effectors
Different ligands binding to the LBD can elicit specific transcriptional responses.
Early results on this matter are conflicting. Several studies suggested that
binding of hormone increased the binding affinity for DNA [26,39,450] while
others did not [206,436]. Some of these ambiguities are likely due to different
DNA response elements used by different labs. As shown byMeyer and coworkers,
8
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different response elements can modulate the effect of a given hormone. They
demonstrated that RU486, a known antagonist, of the progesterone receptor A
isoform could activate the B isoform. Furthermore, this activation only occurred
on one of two promoter sequences that they tested [281]. This is an example of
selective response modification by an NHR, in which a ligand modifies receptor
activity in a manner dependent on the DNA bound [121]. By this and probably
other mechanisms, selective sets of genes are activated or repressed by specific
steroids acting through their cognate receptors. Such ligands activate distinct,
but usually overlapping sets of genes.
Selective response modifiers exert their effects through a number of mecha-
nisms. Besides affecting DNA binding, ligands also change subsequent events.
Different ligands alter recruitment of NTD binding partners to estrogen and
glucocorticoid receptors [118, 345, 366]. Furthermore, ligands can also alter
dimerization of NHRs, as seen in the formation of PPARα-RXRα heterodimers on
DNA [109]. Regardless of the variety of mechanisms, what is clear from these
examples is that ligand binding at the LBD causes allosteric effects on the DBD
and NTD.
9
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1.3.3 Splicing and translational isoformsmodulate allosteric
communication
Expression of tissue-specific protein isoforms has the potential to dictate what
makes a liver a liver or a heart a heart, and recent work has shown that tissue-
specific coding exons are enriched in intrinsic disorder and protein binding
motifs [61]. Interestingly, NTDs of NHRs are often intrinsically disordered, full
of co-regulator binding sites, and can exist in multiple isoforms [69, 214, 260,
359,399,411]. Several studies have also demonstrated that NHR isoforms differ
in their transcriptional activities [260, 281, 292]. However, it is rarely made
clear how isoforms have different transcriptional activities or specificities. One
possibility is that each isoform contains a unique system of allosteric coupling
and disorder. If so, this raises the possibility that tissues tune the activity of a
NHR by expressing varying amounts of its NTD isoforms.
Three steroid receptors are known to possess alternative NTD isoforms (pro-
gesterone, glucocorticoid, and ecdysone receptors; see: [196,260,399]). Of the
three ecdysone receptor isoforms, two have very similar NTD lengths and yet
vastly different effects on transcriptional activity [88,292]. Similar effects have
been reported for progesterone and glucocorticoid receptors [260, 281], and
in the case of glucocorticoid receptor this change in NTD length has an effect
on the folding free energy of this disordered domain [242]. Interestingly, the
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isoform with the lowest folding energy is transcriptionally the most active. This
is most readily explained by coupled folding of NTD with binding of coregulators
because a more stable isoform will bind to coregulators more strongly.
LBD isoforms also occur. For example, the glucocorticoid receptor has three
exon splice-variant isoforms that alter the LBD length [350]. Of these, only
GRα is able to bind hormone. The other two (β and P) have truncated LBDs and
markedly different effects on transcriptional regulation [86,351]. Mechanistically,
the shorter LBDs ablate the ability of hormone to induce a change in the receptor.
However, it is unclear how these changes affect LBD allosteric coupling to the
other receptor domains.
In sum, NHRs use inter- and intra-domain coupling to govern their responses
to a variety of allosteric effector ligands and thus determine the specificity of
their function. Binding of its ligand at any given domain (NTD, DBD, LBD) can
affect the stability and binding affinity of their ligands at other domains. These
allosteric changes have been understood from a phenomenological view for many
years. Only recently has a model been developed that explains these phenomena
in testable, quantitative terms. Below I will discuss this general model of allostery
(the Ensemble Allosteric Model) that can be used to glean mechanistic insight
into NHR allostery.
11
CHAPTER 1. INTRODUCTION TO NUCLEAR HORMONE RECEPTOR BIOLOGY
1.4 The Ensemble Allosteric Model: Application
in the Case of NHR’s
How allostery works is a century-old question [2,36] that was initially addressed
with hemoglobin. Monod, Wyman, and Changeux proposed arguably the most
influential allosteric model using macroscopic, thermodynamic concepts to take
into account a conformational change within the subunits of hemoglobin [286].
Other influential models have been proposed that explain most of the available
data on hemoglobin [144,211]. However, all these models have limitations as they
are phenomenological and do not address “how” allostery is mediated between
distal sites [289]. Crystallographic or other structural data has been used to
elucidate bond paths linking the binding site of the allosteric effector with a
distant responsive site [254,313–315,397]. Even though it has been suggested
that these allosteric pathways may be dominant [80], they do not explain the
following: all of the available data on hemoglobin [375], proteins in which no
bond path can be found between the allosteric effector binding site and the
distant response region, or the perplexing observation of protein dynamic- and
disorder- mediated allostery [106,316,337].
The Hilser lab recently proposed a model that alleviates some of these issues
by articulating allostery in terms of the intrinsic energetics of a protein – the
12
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Ensemble Allosteric Model (EAM) [150,289]. Because it applies to all proteins,
the EAM can be used to describe allostery in NHRs. In particular, it can explain
perplexing phenomena, such as the ability of a single ligand to be an agonist or
an antagonist to NHR function in different cells [13,442].
The EAM is grounded in two well-established observations from protein
allostery: The ability of allosteric proteins to exist in multiple conformations
in solution, and their segregation of binding sites into different domains. Such
domains can communicate with one another, the essence of allostery. From these
simple and well-established facts, it is possible to develop the model and ask
quantitative questions about allostery.
Figure 1.2 – Cartoon of an Allosterically Cou-
pled Protein with Three Subunits
The three subunits (1, 2, 3) bind to one ligand each
(A, B, C) and are capable of allosteric communica-
tion. In the context of NHR’s, the three subunits
are the NTD, DBD, and LBD binding to coregulator,
DNA, and ligand, respectively. Modified from [289]
with permission.
Consider an allosteric protein con-
sisting of three interacting domains
(Figure 1.2). The simplest conforma-
tional ensemble of each domain is a
two state equilibrium between at least
one high affinity (H) and low affin-
ity (L) state. The L state of a domain
can be either intrinsically disordered
or an ensemble of somewhat ordered
conformers that bind its ligand with
lower affinity than does the H conformation. The H and L states for each domain
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have a free energy difference (i.e. ΔGi), which determines how often the molecule
is in the H or L conformation in the absence of influences from other domains.
Because the domains communicate to one another, there must be an interaction
energy between them. When one domain goes to its L conformation it either
stabilizes (i.e. Δg1, 2 < 0) or destabilizes (i.e. Δg1, 2 > 0) the H state of the other
domain(s) to which it is coupled (Figure 1.2 and Table 1.1).
From this simple articulation, enumeration of all combinations of H and
L domain states in addition to their relative free energies is straightforward.
Table 1.1 lists every possible combination of domains 1, 2, and 3 being in either
the H or L conformation. The free energy of each state is simply the sum of
the conformational energy and the interaction energy. Taking the statistical
weight of each state from Table 1.1 and summing it, yields the partition function





Sj = SHHH + SHH L + SH LH + SLH H + SH LL + SLLH + SLH L + SLLL
(1.1)
With this, it is possible to reproduce basic allosteric phenomena and ask
basic questions. For instance, what happens when ligand A is introduced? The
H conformation of each domain will preferentially bind its proper ligand at its
introduction into the system [445]; thus, introduction of ligand A will stabilize
14
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State Σ ΔGi Σ Δgi,j Si Probability
HHH 0 0 1 SHHH / Q
LHH ΔG1 Δg12 + Δg13 K1φ12φ13 SLHH / Q
HLH ΔG2 Δg12 + Δg23 K2φ12φ23 SHLH / Q
HHL ΔG3 Δg13 + Δg23 K3φ13φ23 SHHL / Q
HLL ΔG2 + ΔG3 Δg12 + Δg13 + Δg23 K2K3φ12φ13φ23 SHLL / Q
LHL ΔG1 + ΔG3 Δg12 + Δg13 + Δg23 K1K3φ12φ13φ23 SLHL / Q
LLH ΔG1 + ΔG2 Δg12 + Δg13 + Δg23 K1K2φ12φ13φ23 SLLH / Q
LLL ΔG1 + ΔG2 + ΔG3 Δg12 + Δg13 + Δg23 K1K2K3φ12φ13φ23 SLLL / Q
Table 1.1 – Breakdown of Allosteric States and Energies
This table is modified from [289]. ΔGi is the free energy difference between the high (H) affinity and
the low (L) affinity state of domain i. Δgi,j is the energy of interaction between two subunits, i and j.
Si is the statistical weight for a given state, where Ki and φi are the statistical weights for individual






each microstate in Table 1.1 that has domain 1 in the H conformation by a free
energy of:
∆gLigA = –RT ∗ ln(1 +Ka[A]) = –RT ∗ ln(ZLig,A) (1.2)
The term ZLig,A = (1 + Ka ∗ [A]), is the effect of A on the statistical weights
describing domain 1 in the H conformation. Specifically, the partition function in
the presence of ligand A is now:
Q w/ A = ZLig,A(SHHH +SHH L+SH LH +SH LL)+SLH H +SLLH +SLH L+SLLL
(1.3)
where ZLig,A acts as a weighting term that takes into account the increase in the
probability of the H conformation of domain 1 in the presence of A. Note that at
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A = 0 this equation reduces to the original partition function.
Ligand binding to domain 1 changes the statistical weight of some states, but
in turn this will change the probability of all states. Of particular interest is the
change in probability of the H state of an “active site” (Domain 1; e.g. the binding
site for a coregulator protein in the NTD). The probability of domain 1 being in
the high affinity, active state without A present is simply the statistical weight of
states where domain 1 is in the H state divided by the partition function:
P1,H ([A] = 0) =
SHHH + SH LH + SLH H + SLLH
Q
(1.4)
With A present, all states with domain 1 in the H state will be redistributed:
P1,H ([A] > 0) =
ZLig,A(SHHH + SH LH ) + SLH H + SLLH
Q w/ A
(1.5)
Upon binding domain 1, ligand A will redistribute the ensemble and will either
increase or decrease the probability of domain 2 being active. To relate the
change in probability to the amount of energetic perturbation, I define a value
called the Coupling Response (CR) [150] which is the change in probability of a
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A positive CR indicates that ligand A binding to its own domain increases the
probability of domain 3 being in the active or H conformation. The opposite is
true for negative CR values, which represent negative effects on the stability of
a domain (Figure 1.3).
Figure 1.3 – Examples of CR for Single Ligand Binding
A positive CR3, A indicates that binding of ligand A to domain 1 stabilizes states where domain 2 is
in its high affinity conformation. Domains 1, 2, and 3 are displayed as the top left, right, and bottom
of the circle, respectively. The parameters of the positive CR3, A are: ΔG1 = −1.7, ΔG2 = 2.0, ΔG3 =
−0.9, Δg12 = −2.3, Δg23 = 0.1, Δg13 = 1.5, and ΔgLig, A = −5.0 in kcal/mol. The parameters of the
negative CR3, A are: ΔG1 = − 2.1, ΔG2 = 1.0, ΔG3 = 1.2, Δg12 = − 1.7, Δg23 = 0.6, Δg13 = − 2.7,
and ΔgLig, A = − 5.0 in kcal/mol. From [289] with permission.
In this three-domain protein example, one can consider how an additional
ligand that binds domain 2 would affect the allosteric response of domain 3.
When ligand B binds domain 2 it can change the magnitude of the response of
domain 3 to ligand A bound in domain 1. The coupling response of other domains
to ligand A:Domain 1 binding can change from positive to negative and visa-versa.
In a similar manner as before, one can consider the CR of domain 3 when ligand
A is added while ligand B is already present:
CR3,A(B > 0) =
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Note that this equation takes into account the effect of ligand B by itself, thus
the CR being described tells us how ligand B changes the allosteric response to
ligand A. With two ligands present one can begin to see that some combinations
of parameters exist such that ligand A can act as either a positive or a negative
regulator of domain 3, a paradoxical observation that has been noted in the NHR
field and is discussed in the following section (Figure 1.4).
Figure 1.4 – Positive-Negative Response Switching
In case 1, ligand A acts as a positive regulator of domain 2. In case 2 the presence of ligand B
causes ligand A to act as a negative regulator of domain 2. The parameters used: ΔG1 = −6.75,
ΔG2, B=0 (case 1) = − 4.4, ΔG2, B> 0 (case 2) = 0.6, ΔG3 = − 2.7, Δg12 = 6.8, Δg23 = 4.8, Δg13 = −
1.9, and ΔgLig,A = − 5.0 kcal/mol. Domains 1, 2, and 3 are displayed as the top left, right, and bottom
of the circle, respectively. From [289] with permission.
18
CHAPTER 1. INTRODUCTION TO NUCLEAR HORMONE RECEPTOR BIOLOGY
1.5 The Ensemble Allosteric Model may Recon-
cile Puzzling Observations in NHR’s
The above model is general and applicable to all allosteric systems, including the
three domain SHRs. Each of the three domains of an SHR has binding sites for
multiple binding partners, similar to the articulation of the EAM. The C-terminal
LBD binds small steroidal and synthetic ligands; it also binds a variety of co-
regulatory proteins. The central DBD binds DNA sequences and other proteins;
DNA acts as a ligand and can have sequence specific effects on transcription
and DBD stability. The NTD also binds co-regulators. Application of the EAM
to the SHRs at once makes it apparent that all these binding partners must be
considered ligands, as the preceding discussion explains. Furthermore, a simpler
version of the EAM obviously applies to the two domain group of NHRs [150].
The model has the potential to explain some perplexing observations in NHR
research that have important implications for practical applications and drug
development. Tamoxifen is known to inhibit breast cancer and yet promote
uterine cancer [442], glucocorticoids exert cell-specific anti-inflammatory ef-
fects [13], and a number of other NHR’s have effects in a tissue or isoform specific
manner [138,415,426]. Furthermore, many steroidal and non-steroidal ligands
for the LBD act as selective response modifiers (SRMs), meaning that they alter
19
CHAPTER 1. INTRODUCTION TO NUCLEAR HORMONE RECEPTOR BIOLOGY
the transcription of selected, though overlapping, sets of genes, in a cell-specific
way.
These phenomena may be understood in terms of thermodynamic ensembles.
In different cellular contexts, the equilibria of the ensemble could be tuned by
perturbations including but not limited to: (1) type and accessibility of DNA
response elements; (2) abundance and type of natural/synthetic ligands to LBD
(3) the type and abundance of coregulators to NTD and LBD; (4) different distri-
bution of NHR splicing and translational isoforms; (5) different post-translational
modifications to the NHR; (6) effects of intracellular pH, small ion and organic
osmolyte levels. All of these will affect the energetic landscape of the ensemble.
As mentioned previously in this chapter, there are known allosteric effects
of DNA sequence on the DBD and on NHR function [28,167,278,444]. Binding
to different gene elements may bias an NHR to bind certain coregulators. This
represents a ligand-based effect on the thermodynamics of another domain.
Since it has been shown for glucocorticoid and progesterone receptors that DBD
binding of DNA results in acquisition of structure and function in the NTD, there
is physical evidence to support this allosteric effect [28,215,218].
Recent results suggest that the response element itself is part of the concen-
tration limiting step of transcriptional induction [46], thus gene elements may be
a sensitive area of regulation. Gene elements could vary in accessibility because
of different DNA methylation patterns in tissues (for review [116]), expression
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of different histones [136], or different post-translational modifications of his-
tones [136]. NHR actions do appear to be linked to DNA methylation and to
histone modifications [161,193,300], and how this affects NHR function is still an
active area of research. Put together, there is a large repertoire of perturbations
that can modulate the energetics of DNA binding and thus the macroscopic,
biological effect.
Nature may also produce different NHR activities through LBD binding of
structural variants of hormones [90,305]. Hormone:LBD binding affects both LBD
and NTD stability and their subsequent binding of co-regulators. While the major
steroid-producing glands are the source of most circulating steroid hormones,
it is now clear that local, tissue-specific steroid synthesis and metabolism can
cause the local concentration and type of steroid ligand to vary dramatically.
In addition, cell and tissue variations of SHR isoforms and concentrations can
vary. The concentration of SHR in a cell can shift the dose-response curve to its
cognate ligand by up to an order of magnitude [395,396]. All of these different
hormonal effects would change the probabilities in the conformational ensemble
of the LBD. This in turn would affect the distribution of states for other domains
of a given NHR.
Binding of different coregulators is a third way to vary NHR activity. There
are a large number of NHR coregulators [16,179], and differential expression
between tissues could cause variation in NHR response. It is worthwhile to note,
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however, that most NHR co-regulators appear to be rather general. The authors
know of only one example of a tissue specific co-regulator; PGC-1 appears to
exist exclusively in muscle, kidney, and liver cells [210]. Until further evidence
of tissue specific co-regulators is identified, it must remain speculation that
they are the chief explanation for selective response modifier effects. Moreover,
coregulators do not act singly, but in large heteromeric collections that are bound
to each other and to the NHR by one or a few “platform” coregulators. Cell-
specific actions could be determined by the collective action of each heteromeric
group. This in turn, would be driven by the presence and concentration of each
coregulator [46]. The EAM shows how ligands could alter the choice or affinity for
platform coregulators by positive or negative cooperativity within the NHR; thus,
accounting for selective responses and even for cell/tissue-specific switching of
agonist to antagonist.
Expression of different protein isoforms is a fourth possibility to explain
different tissue activities of NHRs. Some NHRs have multiple isoforms of the
intrinsically disordered N-terminus. Each N-terminal isoform may have a dif-
ferent intrinsic stability, which will result in a different sensitivity to coregulators
[242], as shown for CBP and p300 interacting with GR [261]. Each isoform
may also have different energies of interaction with the other domains. Simply
expressing a different protein isoform could both change the sensitivity to NTD
binding partners and the coupling response to allosteric regulators. Since NHRs
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act as homo- or hetero-dimers, heteromers of NHR isoforms may alter the net
response to a given ligand.
Post-translational modifications of NHRs include phosphorylation [94,160,
318], sumoylation [232,325], ubiquitylation [1,424], and acetylation [112,247].
Each modification has the potential to change NHR turnover, binding of ligands,
and/or the coupling between NHR domains. For example, certain GR NTD
phosphorylations—known to alter its transcriptional activity—also stabilize the
NTD [435].
Considering the net effect of this long list of influences, the EAM may lead
to an understanding of how the paradox of cell-specific selective response to
a single steroid ligand occurs. EAM also explains how a given steroidal ligand
can act as an agonist in one cell and an antagonist in another. A scheme for the
application of EAM follows: First, the intrinsic coupling of a protein must be
determined. Most of the exact values need to be known, but EAM can be used
to estimate a few values if their sign and order of magnitude are known. Next,
the model can be used to simulate the probabilities of the high affinity (active)
states. These simulations can be done with and without ligands, and the effect of
mutations can also be tested. A given mutation could affect the allostery between
two domains (Δg of interaction) and/or the intrinsic stability of a domain (ΔG of
the domain). Note that in these simulations the high affinity state is proportional
to protein activity, or transcriptional activity in the case of NHRs. Lastly, after
23
CHAPTER 1. INTRODUCTION TO NUCLEAR HORMONE RECEPTOR BIOLOGY
simulating the results desired, one can test multiple mutations to find some that
match the predicted outcome. Alternatively, if the interest is in drugs, then one
can test multiple ligands for the desired coupling response.
1.6 Conclusions
The interplay between allostery and intrinsic disorder are just beginning to be
unraveled for NHRs specifically, and transcription factors generally. It is clear
thus far that these proteins use conformational dynamics to couple binding with
allosteric effects. This potentially strengthens the cross talk between different
receptor domains. The ensemble allosteric model is a theoretical framework that
describes how a change in ensembles could drive allosteric effects, and it gives
testable predictions for how NHRs should couple to their ligands and to them-
selves. Using the coupling response, the ensemble allosteric model allows one
to predict the biological effect of drugs and coregulator proteins that bind NHRs.
Positive regulators of transcriptional activity will have a positive coupling re-
sponse with NHR domains that mediate transcriptional activity, and the opposite
is predicted for negative regulators. This simple observation produces testable
predictions for allosteric drug design and targeting. It also yields predictions
that connect in vivo assays, measuring transcriptional activity, to in vitro assays,
measuring protein stability.
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ndosomal maturation is a multi-step process that ends with the formation
of a multivesicular body (MVB; see Figure 2.1). The internal vesicles of
MVBs are laden with membrane proteins targeted for degradation, and formation
of these internal vesicles was the first function ascribed to the Endosomal Sorting
Complex Required for Transport (ESCRT). Disregulation of the ESCRT system
can lead to cancerous growth and neuronal diseases, described herein [235,244].
Furthermore, many budding viruses hijack ESCRT proteins in order to exit the
cell [76, 140, 222, 277]. Understanding how the ESCRT system functions at a
basic level is necessary to understanding ESCRT disease etiology and potential
cures.
This chapter begins with a broad overview of endosomal membranes, the
ESCRT system as a whole, and the function of ESCRTs in endosomal maturation.
To that end, a large tableau has been made to help visualize endosomal matu-
ration for the reader (Figure 2.3). Subsequent sections deal with the disease
implications and the non-endosomal functions of the ESCRT proteins.
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Figure 2.1 – An Overview of Endosomal Maturation
A membrane protein (green oval) binds its ligand (yellow circle) and is internalized (top left). The
arrows show overall movement of protein/vesicles, not the exact membrane fission/fusion events.
For membrane receptors, binding a ligand is often coupled with ubiquitination and internalization,
see Figure 2.2 for details [180,264]. Ubiquitin acts as a signal that recruits the ESCRT complex, and
the critical ESCRT-mediated step is denoted by an asterisk. The multivesicular body (MVB) merges
with a lysosome/vacuole to deliver proteins for degradation.
2.2 Endosomal Membranes
Endosomal maturation depends entirely on endosomal membranes, and endoso-
mal membranes are contributed to by endocytosis—the process whereby cells
invaginate part of their cell membrane to generate cytoplasmic vesicles. Endocy-
tosis is a cellular mechanism to consume external materials and to downregulate,
recycle, or degrade membrane receptors [271, 280]. There are both clathrin-
dependent and independent forms of endocytosis [207,271], and the two forms
are regulated by over sixty proteins [280]. After endocytosis at the plasma
membrane, there are numerous membrane fusion and fission events in which
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Figure 2.2 – Activation of EGFR
An inactive EGFR dimer (blue and green) is at the top. After binding EGF (gray), the whole protein
goes through a large conformational change and the intracellular domains autophosphorylate. An
E3-ubiquitin ligase, such as Cbl, eventually binds the phosphorylated intracellular domains and
ubiquitinates EGFR [104,162,180,264]. The phospholipid bilayer is depicted as an outline with white
carbon, red oxygen, and orange phosphorous. The proteins are depicted with carbon as a darker
color than the non-carbon atoms, except the transmembrane domains and ubiquitin (cyan) which
are ribbons. Structures used here: [47,105,258,382,458]
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cargo are sorted for either recycling back to the cell membrane or degradation
in lysosomes. The author directs the interested reader to several reviews of
these topics [181,207,271,280]. For present consideration, it is the phospholipid
composition of vesicles, particularly phosphatidylinositol phosphate (PIP), that
defines endosomal membranes for the later recruitment of the ESCRT complex
and other endosomal proteins [310].
The typical PIPmodifications on the cell membrane are PI(4,5)P2 and PI(3,4,5)P3
[310]; whereas the early and late endosomes are defined by PI3P [125] and
PI(3,5)P2 [168,355], respectively. It is via PIP’s that much of the ESCRT machin-
ery is targeted to endosomes; thus, it is important to understand how eukaryotic
cells control phosphatidylinositol chemistry.
Initially, the PIP’s on an internalized vesicle are converted to PI3P. A small
GTPase protein called Rab5 recruits two phosphatases (4-Pase and 5-Pase) that
remove 4- and 5-phosphates of inositol [371]. These phosphatases produce PI3P
directly from PI(3,4,5)P3 of the cell membrane and indirectly via PI(4,5)P2 and a
kinase that is also recruited by Rab5 (or dynamin-2 in phagocytosis [205]). The
combination of the PI3 kinase, VPS34 [380], and the PIP phosphatases yields a
concerted conversion of the early endosomal PIP pool to PI3P. (For information
on the recruitment of Rab5: [7,208,209,460]).
The PI3P of early endosomes binds to the FYVE Zn-finger domains of several
ESCRT proteins and the PI5 kinase called PIKfyve [168,239,355] (FYVE is named
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after some of the proteins with the domain: Fab1p, YOTB, Vac1, EEA1). PIKfyve’s
conversion of the late endosomal membrane’s PI3P to PI(3,5)P2 is important
for the last stages of endosomal maturation. While the initial ESCRT complex
binds PI3P, the last complex of the ESCRT system binds PI(3,5)P2 ( [439] and
see ESCRT-III section below).1
2.3 Endosomal Maturation
The ESCRT proteins are broken up into roughly four complexes (ESCRT-0—III)
[142]. There are also at least two additional proteins that are required for proper
release of the ESCRT-III complex and the budding vesicle. All of these proteins
are presented in tabular format in Table 2.1. For the rest of this chapter, the
human nomenclature will be used. Please note that a few of the biochemical
details differ between yeast and humans [169], but by-and-large the ESCRT
system has been very highly conserved [241]. See Figure 2.3 for a structural
overview of the ESCRT pathway.
1Because this thesis concerns nuclear actions of an otherwise cytosolic ESCRT protein,
the author will briefly mention some of the nuclear actions of phosphoinositides (reviewed
here: [34,78,137,310]). Inositol-3-phosphate has been detected in nucleoli and VPS34 localizes
to both the cytosol and nucleus [62,125,185]. VPS34 activity is required for EGFR transport
to the nuclear membrane [85], but the exact function of VPS34 in the nucleus is still unclear.
Some other PI kinases or their products have been shown to regulate chromatin, histone factors,
and the transcriptional machinery [120,387,405]. Whether VPS34 is involved in any of these
activities remains to be seen.
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Figure 2.3 – Cartoon Schematic of ESCRT-0—II
Each complex is labeled in bold. Individual proteins are labeled with normal font and their subdomains
are given a smaller, italicized font and sticks to point at the respective domain. Unstructured loops
that connect domains are represented as arrows running from N- to C-termini and they are the
same color as the respective proteins. Lipid binding specificities are described beneath lipid binding
domains. Globular structures are depicted as atoms with carbon in a darker color. Helical structures
and ubiquitins (cyan) are depicted as ribbons. Most ubiquitins are directly from the structures. The
STAM-SH3 ubiquitin was roughly aligned with the NMR interaction surface, and the HRS-VHS
ubiquitin is from aligning the STAM-VHS bound ubiquitin with HRS-VHS. Structures used here: pdb
3ZYQ and [6,51,152,155,169–171,212,223,340,393].
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Vps23 (Stp22) TSG101 (VPS23)
Vps28 VPS28
Vps37 (Srn2) VPS37A, B, C, D
Mvb12 MVB12A, B or *UBAP1
ESCRT-II




Vps2 (Did4, Chm2) VPS2A, B (CHMP2A, B)
Vps20 (Chm6) VPS20 (CHMP6)
Vps24 VPS24 (CHMP3)
Snf7 (Vps32) SNF7A, B, C (CHMP4A, B, C)
Vps60 (Chm5) VPS60 (CHMP5)




Vps4 VPS4A, B (SKD1)
Vta1 VTA1 (LIP5)
Bro1/ALIX Bro1 (Vps31) ALIX (AIP1) and HD-PTP (PTPN23)
Table 2.1 – List of ESCRT proteins
Commonly used names are listed first, with any alternate names in parentheses. Some of the
metazoan proteins have duplicate genes that are listed by commas (A, B, etc.). This table is modified
from the 2010 review by Hurley: [166]. TSG101 is highlighted because it is the focus of a subsequent
chapter. *Even though UBAP1 is considerably different from the MVB12 genes, it can fulfill the
MVB12 role in mammalian ESCRT-I [5]. **Yeast may or may not have a CHMP7 homologue. When
CHMP7 was characterized, Yj1049wp was suggested to be a related protein in S. cere. [157].
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2.3.1 ESCRT-0: Signal Recognition
The first ESCRT complex identifies ubiquitinated membrane proteins and corrals
them onto the endosomal membrane, before passing the membrane proteins to
the ESCRT-I complex. ESCRT-0 is comprised of just two proteins, HRS and either
STAM1 or STAM2 (Hepatocyte growth factor-Regulated tyrosine kinase Sub-
strate, Signal Transducing Adaptor Molecule) [142]. HRS tethers itself and STAM
to the endosomal membrane, via its FYVE Zn-finger domain [381]. As stated
above, FYVE domains preferentially bind the phospholipid, phosphatidylinositol
3-phosphate (PI3P) [239], which is enriched on the endosomal membrane [125].
In order to recognize ubiquitinated membrane proteins, the ESCRT-0 complex
has multiple ubiquitin binding motifs. Both HRS and STAM have N-terminal VHS
domains that bind one ubiquitin each (named after proteins with the domain:
Vps27, HRS, STAM; [223,339]). Both proteins also have ubiquitin interacting
motifs (UIM), but the HRS version of UIM is able to bind two ubiquitins at once,
versus the one ubiquitin that the STAM UIM binds [152,284]. STAM also has a
SH3 domain that is able to interact with one ubiquitin, but the ubiquitin is readily
displaced by the deubiquitinating enzymes, UBPY and AMSH (Ubiquitin-Specific
Protease Y and Associated Molecule with a Src Homolgy 3 domain; [155,224]).
Deubiquitination by UBPY or AMSH early in endocytosis appears to promote
recycling or delays degradation of targeted membrane proteins: both can deu-
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biquitinate and promote recycling of EGFR [272, 283]. However, UBPY and
AMSH are also necessary for efficient degradation of ubiquitinated membrane
proteins [349,394]. This second activity appears to be necessary for maintaining
the pool of free ubiquitin [336] and is dependent on interactions with ESCRT-III
proteins that will be explained in the subsection on the ESCRT-III complex.
Even though only one ubiquitin is necessary for a membrane protein to
proceed through the ESCRT pathway [336], multiple ubiquitins likely assist the
initial recognition of ESCRT cargo. Binding of ubiquitin to the ESCRT-0 complex
is dependent partly on avidity (multiple binding events) and partly on the nature
of ubiquitin linkages (different lysines) [223]. Individually, the VHS, UIM, and
SH3 domains bind mono-ubiquitin with Kd’s between 100–1000 µM [224,339].
The ESCRT-0 complex as a whole binds mono-ubiquitin somewhat weakly, with
a Kd of ∼920 µM [339]. In contrast, binding of polyubiquitin chains can have
an apparent Kd closer to 20 µM [339], but this is highly dependent on the exact
nature of the polyubiquitin chain.
Ubiquitin chains link using free amines and C-termini (i.e. amine from lysine
of first ubiquitin→C-terminus of second ubiquitin). K63-linked ubiquitins have
typically been associated with endosomal targeting of membrane proteins [229],
but it is worth noting that some proteins can be targeted to lysosomes by ei-
ther K63 or K48-linked ubiquitins [457]. Consistent with in vivo observations,
the ESCRT-0 complex binds tetra-ubiquitin with the following linkage prefer-
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ences [339]: K63 > K48N-terminus (apparent Kd = 18 µM, 43 µM, 140 µM
respectively; Note: the author knows of no example where N-terminal linked
ubiquitin causes ESCRT targeting, but the linkage is used in cell-signaling and
proteasome targeting [342]).
Beyond the ubiquitin binding domains of both HRS and STAM are coiled-coil
domains that form the ESCRT-0 heterodimer [340]; though, it has recently been
reported that the lipid bound ESCRT-0 can form larger complexes on its own
or with cargo [270, 398]. Lastly, HRS has a clathrin-binding domain on its C-
terminus. HRS’s ability to bind clathrin allows it to recruit clathrin coated-pits
on endosomes [333], and this appears to help organize endocytosed receptors
on the endosome [332].
2.3.2 ESCRT-I: Signal Transduction
The ESCRT-I complex acts to bridge the cargo-sensing ESCRT-0 with the ESCRT-II
complex. ESCRT-I is assembled around one protein that acts as a central scaffold:
Tumor Susceptibility Gene 101 (TSG101) [212]. TSG101 is recruited by HRS
via the TSG101 ubiquitin E2 variant (UEV) domain [324]. The UEV domain is
an inactive E2-ligase that is missing the reactive cysteine residue [23]. This
allows the UEV domain to recognize ubiquitinated cargo without executing a
ubiquitination reaction [200]. The UEV domain also contains a pocket for binding
peptide motifs of the form “P T/S A P”, with the second position being variable.
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HRS contains a PSAP motif that is necessary for binding the TSG101 UEV domain,
and this is the major connection between ESCRT-0 and ESCRT-I [324].
Following TSG101’s UEV domain is a proline rich region that appears to be
conformationally flexible and a coiled-coil domain that forms the core of the
ESCRT-I complex [212]. To this core, two other proteins are recruited: MVB12
and VPS37 [212, 213]. Both MVB12 and VPS37 have non-specific membrane
binding domains on their N-termini [51,212], followed by coiled-coil domains
that bind TSG101’s coiled-coil, forming a heterotrimer. To the C-terminus of the
ESCRT-I coiled-coil, is a cluster of α-helical hairpins formed by the C-termini of
VPS37 and TSG101, and the N-terminus of VPS28 [212]. Lastly, the C-terminus
of VPS28 binds the ESCRT-II complex and the first subunit of ESCRT-III, though
the latter activity is not an absolute requirement for ESCRT-III recruitment
[54,73,320].
2.3.3 ESCRT-II: Signal Amplification
The purpose of ESCRT-II is both signal transduction and amplification. The
N-terminal GLUE domain (GRAM-like Ubiquitin binding in EAP45) of VPS36 and
a basic helix on the N-terminus of VPS22 bind PIP’s of the endosomal membrane,
thereby localizing ESCRT-II to endosomes [6,169,374], regardless the presence
of ESCRT-I [22]. The VPS36 GLUE domain also binds ubiquitin of targeted
membrane proteins [6,225], and immediately following the GLUE domain is a
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helix that binds the C-terminus of the ESCRT-I complex component, VPS28 [169]
(yeast maintain a slightly different mechanism [124]).
Following VPS36 and VPS22 are two VPS25 subunits that recruit ESCRT-
III [22, 169, 225]. Note that all the previous ESCRT complexes bind 1:1 with
each subsequent ESCRT complex. In contrast, for every ESCRT-II complex there
will be two VPS20 subunits of ESCRT-III recruited to adjacent ends of the Y-
shaped ESCRT-II structure [147, 169, 400] (Figure 2.3). Recruitment of two
VPS20 proteins may simply increase the probability of recruiting one strand of
ESCRT-III proteins or it may be necessary for formation of the native ESCRT-III
complex [71,369].
The binding of ESCRT-II to VPS20 also appears to prime the system for
vesicle formation. Either ESCRT-II or VPS20 alone will bind to flat membrane
surfaces, but the combination of ESCRT-II and VPS20 will preferentially bind
membranes that curve away from the proteins [113]. Adding in the next ESCRT-
III subunit, SNF7, even enables the complex to close open holes in a membrane
monolayer [113]. Preferential binding of curved membranes may be due to
conformational changes or wedging of the membrane by insertion of hydrophobic
domains [67], but more recent work suggests that steric clashing of membrane-
bound proteins is sufficient to explain membrane binding preferences [376].
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2.3.4 ESCRT-III: Wrapping Things Up
The ESCRT machinery is part of what defines eukaryotic life [241], but one of the
ESCRT complexes appears to be much more ancient than Eukarya. ESCRT-III
orthologues mediate membrane scission during cytokinesis in some Archaea
[92, 249] (a role conserved in Eukarya, as discussed later). Since the diver-
gence of Archaea and Eukarya, the functions of ESCRT-III have expanded beyond
cytokinesis. ESCRT-III executes the demand made by all the previous ESCRT com-
plexes: that a vesicle, studded with membrane proteins marked for destruction,
be cleaved off into the intralumenal space of the endosome.
Because all the ESCRT-III proteins have a similar domain architecture, it is
easiest to first consider the properties they have in common: 1) A core made
of several helical-hairpins that arrange into either an “open” or a “closed” con-
formation depending on the context [32,273,296,360], 2) a positively charged
surface on the core helices that binds phospholipid membranes [60,296,439],
3) a hydrophobic N-terminal sequence involved in membrane binding [60,453],
4) a C-terminal motif that binds VPS4 [3,139,369], and 5) a tendency to form
filamentous homo- and hetero-polymers with one another [123,143].
The field currently has only a incomplete picture of how membrane pro-
teins are corralled into a tight, sterically unfavorable space on the endosomal
membrane that is then exvaginated toward the lumen of the endosome by the
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ESCRT-III complex (see Figure 2.4). The following description is a somewhat
speculative reconstruction based on the most recent literature. A combination
of ESCRT-0—II organizes cargo onto one locus [3, 52, 54, 320], then ESCRT-II
binds two VPS20’s which recruit two filaments of SNF7 to encircle the targeted
membrane proteins [139, 143, 369, 400]. SNF7 polymerization continues and
eventually incorporates VPS24 and VPS2 [21, 143, 228]. The combination of
VPS24 and VPS2 causes the otherwise flat SNF7 spirals to deform into a three-
dimensional projection that punches into membranes [71,143]. At some point,
the ESCRT-III proteins bind deubiquitination enzymes that remove ubiquitin
from targeted membrane proteins [227, 349, 377] (ESCRT-0 can also recruit
deubiquitination enzymes [155,224]). The release of ubiquitin could achieve two
goals: recycling ubiquitin and release of any bound ESCRT-0—I [336]. Eventually,
VPS2 recruits VPS4 (next section) to constrict the ESCRT-III spirals further and
release the whole ESCRT-III complex [3,25,228,369].
The exact structure of ESCRT-III spirals is debatable. It is clear that the biolog-
ically relevant fibers involve an amalgamation of several ESCRT-III proteins that
vary between the width of one or two ESCRT-III proteins [21,71]. Most in vitro
electron microscopy (EM) has used just one or two ESCRT-III’s, often with the
C-termini deleted and frequently in the absence of the membrane phospholipids
that are integral to ESCRT-III function and structure [123,228,273]. Such studies
often show tightly coiled rods of ESCRT-III proteins that are plausibly reminiscent
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of structures seen in vivo in the last stages of vesicle formation [71,139], and
these protein aggregates are even reversible upon addition of VPS4 [123,228].
It has been comparatively more difficult to understand the less constricted, early
structures of ESCRT-III. A recent study using full-length SNF7 proteins assembled
on membranes demonstrated that SNF7 spirals inwards because it lowers the
free energy (∆G) of the spiraling filament [369]. Without VPS4 present, the SNF7
C-termini sterically prevented the spirals from constricting and lowering their
energy, but addition of catalytically inactive VPS4 (binds ESCRT-III C-termini)
released that energy and produced tight coils of SNF7 [369].
2.3.5 VPS4 and VTA1: Resolution of Exvaginating Vesicles
It was shown about two decades ago that VPS4 is necessary for efficient sorting
of membrane receptors to the yeast vacuole (mammalian lysosome equivalent)
[24,25]. VPS4 is a member of the AAA family of ATPases (ATPases Associated with
diverse cellular Activities) and it forms hexameric assemblies [25,391]. As long
as its ATPase activity is present, VPS4 can de-polymerize ESCRT-III polymers and
release nascent vesicles from the endosomal membrane [25,71,228] (Figure 2.4).
VPS4 has an N-terminal microtubule interacting and trafficking domain (MIT)
that binds MIT interacting motif domains (MIM) of ESCRT-III [25,83,202]. It is
primarily the MIM1 motif of VPS2 that is necessary for VPS4 recruitment, and
the role of the other MIM’s may be ancillary [3]. VPS4 is catalytically active in
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vitro, but maximal activity requires a cofactor protein. Binding of VTA1 dimers
around the VPS4 hexamer stimulates the ATPase activity of VPS4 [391,446], and
VTA1 also supports VPS4’s binding of ESCRT-III via its own MIT domain that
interacts with VPS60 and DID2 of the ESCRT-III complex [20].
2.3.6 ALIX
If Biology has a choice between doing something one way or two—it often errs
towards redundancy. The ESCRT system is no different and the protein ALIX
(Apoptosis Linked gene-2 Interacting protein X) is an alternative way for ESCRT-
III to be recruited [73].2 This alternative pathway was first described in viral
budding [95,388,422], but it appears to be a natural part of ubiquitin-dependent
and -independent endosomal maturation [73,93,198,301,311]. ALIX is similar
to ESCRT-II in that it can bridge ESCRT-I and ESCRT-III [268], but ALIX does
so in a completely different manner. In viral budding, ALIX binds ESCRT-I via
the N-terminus of TSG101, and ALIX then recruits ESCRT-III by binding the
C-terminus of SNF7 (ESCRT-II binds VPS28 and VPS20 instead) [197,198,274].
It has also been shown that ALIX can form dimers and that these dimers can
bridge ESCRT-III filaments, forming ladder-like structures [321].
When ALIX was first discovered, it seemed as if ALIX was recruited by binding
2It is worth noting that mammals also express a second protein related to ALIX, called HD-PTP
(His Domain Protein Tyrosine Phosphatase) [96]. HD-PTP seems to carry out functions similar to
ALIX, and it has also been shown to bridge ESCRT-0 and ESCRT-III [8].
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TSG101, and while this seems true in certain contexts (viral budding), the full
story is much more complicated. ALIX can also bind ubiquitin, with a strong
preference for the stereotypical K63 linkage seen on membrane proteins destined
for the endosome [95]. The ability of ALIX to bind ubiquitinated membrane
proteins is redundant with the ESCRT-0 complex, and to produce serious vacuolar
defects, onemust suppress both ALIX and ESCRT-0 [311]. Like ESCRT-0, ALIX can
also bind phospholipid membranes; though its preference is for the endosomal
lipid, lysobisphosphatidic acid (LBPA) [45]. With its combined ubiquitin, lipid,
and ESCRT-III binding, ALIX can act as a redundant arm of the ESCRT pathway.
2.4 Non-Endosomal Functions of ESCRTs
Besides endosomal maturation, ESCRT proteins are also involved in cytokine-
sis [32,65,73,234,249], autophagy [107,115,235,237,348], cell and nuclear
membrane repair [72, 89, 330], formation of exosomes [27, 347], formation of
the cSMAC immune complex [419], chromatin condensation [385], transcrip-
tion [74,192,293,358,370,431], and mRNA localization [173].
ESCRT involvement in cytokinesis proceeds in a manner very similar to
endosomal maturation, except TSG101 and ALIX are recruited by CEP55 to the
cytokinetic midbody [234]. The end result is recruitment of ESCRT-III to form
the cortical filaments that constrict during abscission [133]. ESCRT activity in
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Figure 2.4 – Speculative Cartoon of ESCRT-III Vesicle Formation
In the top left, ubiquitinated membrane proteins are corralled by uncertain mechanisms that likely
depend on ESCRT binding their ubiquitins. Initial ESCRT-III polymerization by SNF7 likely cordons off
the targeted proteins. Recruitment of later ESCRT-III proteins (VPS24/2), ALIX, and deubiquitinases
may lead to a situation like the top right image. ALIX forms ladders between ESCRT-III filaments
in vitro, but the in vivo significance and organization are unknown [321]. VPS24/2 promote three-
dimensional spiralling [143], and VPS2 recruits VPS4 that also constricts ESCRT-III spirals [369]—the
transition from the top right to bottom left is one possible rendition. In the last step, VPS4’s ATPase
activity disassembles ESCRT-III, releasing the monomers to solution [123,228]. The VPS4+VTA1
structure is shown as a ribbon cartoon in the center, with VPS4 as blue and white, VTA1 as red, and
ATP as orange. See also: [71,139,369,391].
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autophagy and membrane repair appears to proceed in a similar manner, just
with different initial recruitment steps that are still under investigation.
Exosomes and microvesicles are extracellular vesicles that are often filled
with proteins or RNA for the purpose of cell-to-cell signaling ( [334,418]). The
control of exosome formation is still poorly understood, but this is an exciting field
with much potential for cancer diagnostics because some cancers use exosomes
to promote tumor growth and metastasis [373]. Extra-cellular vesicles can form
directly on the cell membrane (microvesicles) or via fusion of an MVB with the
cell membrane (exosomes) [334]. While both of these processes sound exactly
like ESCRT activity, some exosomes require ESCRT [27,347], while others do
not [414].
ESCRT-II has some unexpected side-roles in metazoan cells. VPS36 binds
bicoidmRNA during metazoan development and is necessary for proper localiza-
tion of the mRNA [173]. The mammalian ESCRT-II can also bind a transcription
elongation factor (ELL) and promote its activity in vitro [192, 358], but after
almost twenty years no further work has been done and many details remain
unknown. For example, it is unknown whether VPS36 binds nascent mRNA
during transcription or why the entire ESCRT-II complex is involved. In a related
problem, TSG101 has been implicated in the transcriptional activity of steroid
hormone receptors; yet, it is unknown why. All current experiments have used
viral promoters or artificial transcriptional assays [74,153,293,431]. It is un-
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known what genes are controlled naturally by TSG101, nor is it known whether
TSG101 recruits other ESCRT proteins after binding to transcription factors. It is
tempting to think that TSG101 could indirectly recruit ESCRT-II for transcription
elongation, but no such interaction has been shown.
Besides ESCRT proteins having moonlighting functions, there are a large
number of endocytic proteins that also have secondary functions in the nucleus
or elsewhere (reviewed here: [319,328]).
2.5 Disease Implications
Inhibition or mutation of the ESCRT system can lead to membrane protein
mislocalization [25,343] and even cancerous growth [244,285]. The cancerous
phenotype seen in metazoans is likely due to upregulation of growth factor
receptors in the absence of the ESCRT system [23]. Disregulation of ESCRT or
its binding partners has also been associated with neuronal diseases, likely due
to autophagy or cytokinetic defects (frontotemporal dementia [235], hereditary
spastic paraplegias [352]).
As mentioned earlier, numerous budding viruses are known to hijack ESCRT
proteins in order to exit the cell membrane (in a microvesicle or exosome-like
manner). These viruses include some of the greatest scourges known to hu-
mankind: HIV, Ebola, Hepatitis B and C and E, Herpes, Rabies, Rous sarcoma
46
CHAPTER 2. REVIEW OF THE ENDOSOMAL SORTING COMPLEX REQUIRED
FOR TRANSPORT (ESCRT)
virus, and many others [76,140,222,248,277,297,388]. In an interesting twist,
Epstein-Barr virus even uses TSG101 to activate its genes and ESCRT to exit the
nucleus, as opposed to the cell membrane [74,233]. As terrible as these viruses
can be, early studies that used viruses as models of ESCRT action revealed a
great deal of what is now known about ESCRT. There have been attempts to
develop anti-virals based on ESCRT interactions [204], but the author knows of
no ESCRT-based anti-viral—nor would it be easy to develop a therapy without
side-effects because viruses have hijacked the very interactions necessary for
natural ESCRT function [324].
2.6 Conclusion
ESCRT proteins are a defining feature of eukaryotic life [241]. It is the ESCRT
complex that gives eukaryotes exquisite control over intracellular membranes,
thereby allowing me to segregate reactions or signals to/from neighboring cells
or give negative feedback to those same signals. With improved control over
cell-to-cell communication, eukaryotes have produced the most obvious examples
of multi-cellular life. It took millions of years to evolve, and yet, in just the past
thirty years, much has been discovered about the ESCRT complex. The author
looks forward to seeing what the next thirty years reveal.
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Structural Stability of the
coiled-coil domain of Tumor
Susceptibility Gene
(TSG)-101
This chapter is largely a quote of material published in Biochemistry with
Dmitri Toptygin, Randy Cohen, Natalie Murphy, and Vincent J Hilser. Dr.
Toptygin did the Time Correlated Single Photon Counting experiments
and related analyses detailed here. Mr. Cohen and Ms. Murphy assisted
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in protein purification. Prof. Hilser provided overall guidance, including




he Tumor Susceptibility Gene-101 coiled coil domain (TSG101cc) is an inte-
gral component of the endosomal maturation machinery and cytokinesis,
and also interacts with several transcription factors. The TSG101cc has been
crystallized as a homotetramer but is known to interact with two of its binding
partners as a heterotrimer. To investigate this apparent discrepancy, I examined
the solution thermodynamics of the TSG101cc. Here, I use circular dichroism,
differential scanning calorimetry, analytical ultracentrifugation, fluorescence,
and structural thermodynamic analysis to investigate the structural stability and
the unfolding of the TSG101cc. I demonstrate that TSG101cc exists in solution
primarily as a tetramer, which unfolds in a two-state manner. Surprisingly, no
homodimeric or homotrimeric species were detected. Structural thermodynamic
analysis of the homotetrameric structure and comparison with known oligomeric
coiled-coils suggests that the TSG101cc homotetramer is comparatively unstable
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on a per residue basis. Furthermore, the homotrimeric coiled-coil is predicted to
be much less stable than the functional heterotrimeric coiled-coil in the Endoso-
mal Sorting Complex Required for Transport-I (ESCRT-I). These results support
a model whereby the tetramer–monomer equilibrium of TSG101 serves as the
cellular reservoir of TSG101, which is effectively outcompeted when its binding
partners are present and the hetero-ternary complex can form.
3.2 Introduction
Tumor Susceptibility Gene-101 (TSG101, yeast homologue vps23) is a protein
with multiple roles in eukaryotic biology. As a member of the Endosomal Sorting
Complex Required for Transport-I (ESCRT-I) complex, TSG101 recruits other
proteins to maturing endosomes and assists in the formation of multivesicular
bodies [23,343,346] and many budding viruses [288]. TSG101 is also involved
in cytokinesis [102], and in mammals, TSG101 can act as a transcriptional
regulator [432]. The numerous roles of TSG101 are facilitated through its four
domains (Figure 3.1): The N-terminal UEV domain recruits TSG101 to membrane
proteins targeted for degradation [200], the proline-rich region recruits TSG101
to the cytokinetic furrow [102], the coiled-coil assembles most of the ESCRT-I
complex [212], and the steadiness (i.e., stability) box plays a role in forming
the bridge between the ESCRT-I and ESCRT-II complexes [124,212]. Of these,
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the coiled-coil domain is also of significance in transcriptional regulation, as it
is believed to interact with several transcription factors [293,432]. In spite of
the growing body of literature identifying novel binding partners and previously
unknown functions of TSG101, there is an incomplete picture regarding the
structural thermodynamics of the TSG101 coiled-coil and its role in modulating
the stoichiometry of interaction.
The coiled-coil of TSG101 (TSG101cc) has been crystallized as a homotetramer
(PDB 3iv1), but its oligomerization state has yet to be established in solution.
This issue is significant because contrary to the tetrameric form observed for
TSG101cc in isolation, the solution and crystal structures of the ESCRT-I coiled-
coil are heterotrimers of TSG101/vps23 (yeast homologue) and two binding
partners [212,287]. Note that other coiled-coils have been shown to adopt dif-
ferent structures or oligomeric states in crystal and in solution form [129,451].
Furthermore, ongoing studies in the Hilser lab suggest TSG101cc can also form a
heterodimer, with the human glucocorticoid receptor (to be published elsewhere).
Biological regulation through the modulation of the oligomeric state of a protein
has been reported in a number of other systems (morpheein proteins [176]),
including oligomerization of helix-loop-helix and coiled-coil peptides, interactions
in the mothers-against-decapentaplegic family of proteins, the hepatitis B viral
capsid protein, and porphobilinogen synthase among others [15,57,66,103,177,
389]. Here, I set out to determine the oligomeric state of TSG101cc in solution
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and to determine whether its oligomeric state is functionally modulated.
I show that TSG101cc in solution exists primarily as a tetramer that is in
equilibriumwith unfolded monomers. Despite the ability of TSG101cc to form het-
erotrimeric coiled-coils, no measurable homotrimeric (or homodimeric) species
were observed. Thermal unfolding of TSG101cc as a function of protein concentra-
tion and pH provided access to the thermodynamic mechanism of stabilization of
the tetramer. Furthermore, structural thermodynamic analyses of the TSG101cc
tetramer and ESCRT-I coiled-coil heterotrimer illuminates the structural basis of
the tetramer stability, and provides insight into the role of the homotetramer in





Figure 3.1 – Schematic of TSG101 Domain Organization
A) The domains pictured here are scaled to their length and the domain of interest is expanded in B)
The coiled-coil construct used in this study comprises amino acids 229-304 of the native sequence
(76 amino acids long plus 2 a.a. left by the N-terminal tag). Hydrophobic residues are colored green.
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3.3 Methods
3.3.1 Protein Expression and Purification
The sequence of my expression construct spans amino acids 229-304 of TSG101
(Figure 3.1, appendix, UniProt: Q99816). On the N-terminus is a 9xHis tag,
followed by a TEV protease cleavage site and an extra serine. Competent BL21
DE3 pLysS cells were made in house and used for expression (Novagen strain).
Growth proceeded in LB medium, with a 1 mM IPTG induction at an O.D.600
0.6-1.2, followed by growth at 37 ºC for four hours or overnight at 16 ºC. Little dif-
ference in expression was observed under these conditions. Cells were pelleted,
washed with PBS, and lysed by sonication (20 mM Tris, 6M Gdn, 20 mM imidazole,
500 mM NaCl, pH 8). After clearing the lysate at 15 krpm for an hour, the lysate
was purified using Ni-NTA. The His tag was cleaved off using TEV protease,
and protein was passed over an anion exchange column followed by Ni-NTA.
At this point TSG101cc was a single band by SDS-PAGE [68]. For differential
scanning calorimetry (DSC), protein was purified further using size exclusion
chromatography (SEC, HiLoad 16/600 Superdex 75 pg, GE). An example SDS-
PAGE of SEC purified TSG101cc is shown in Figure 3.2.
For pyrene labeled protein, used in analytical ultracentrifugation and fluo-
rescence (supplement), I purchased PMIA (N-(1-pyrenemethyl) iodoacetamide;
53
CHAPTER 3. STRUCTURAL STABILITY OF THE COILED-COIL DOMAIN OF
TUMOR SUSCEPTIBILITY GENE (TSG)-101
Figure 3.2 – SDS-PAGE gel of SEC purified TSG101cc
The protein shown here is unlabeled (lacks an engineered cysteine) and was used for DSC. Expected
MW is 9 kDa. Two peaks were often seen in SEC of unlabeled protein, supporting the two-state
hypothesis for TSG101cc.
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Setareh biotech). Quikchange PCR was used to change a serine to a cysteine
in my expression construct (supplement). The serine in question is part of the
N-terminal tag, not the native TSG101 sequence. This protein was purified as de-
scribed above, dialyzed to labeling buffer (50 mM HEPES and 1 mM TCEP at pH
7.3), then labeled for one hour at room temperature using 10 molar equivalents
of PMIA, relative to moles of protein, dissolved in DMSO. For efficient labeling,
it was found that 5% DMSO was required in the final reaction mixture. Labeling
was quenched using 10 molar equivalents of DTT, relative to the moles of PMIA.
This resulted in a turbid solution that was 0.2 µm filtered, then separated using
SEC.
The first peak of SEC was consistently a mixture of TSG101cc with one or as
many as three pyrene labels, as determined by mass spectrometry (supplement).
Iodoacetamide is known to react with amines and attempts to prevent this by pH
optimization did not succeed. However, the second peak I observed from SEC
was consistently a mixture of singly labeled ( 66-80%) and unlabeled protein. This
is what was used in all analytical centrifugation and fluorescence experiments
described here.
The concentration of unlabeled protein was determined by its absorbance
at 280 nm in guanidine, εTSG101cc = 5,690 M
-1cm-1 [100]. The concentration
of PMIA labeled protein was determined by its absorbance at 345 nm (44,700
M-1cm-1 Setareh Biotech). For PMIA labeled protein, extinction coefficients at
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other wavelengths were set relative to the 345 nm pyrene peak.
3.3.2 Matrix Assisted Laser Desorption IonizationMass Spec-
trometry (MALDI)
All MALDI was done using a Bruker AutoFlex III MALDI-Time of Flight/ToF. The
identity of purified protein was verified by trypsin digest (Promega sequencing
grade) followed by reflectronmass spectrometry. Labeling efficiency of TSG101cc
with pyrene was determined by linear Time of Flight (ToF) mode. The labeling
position was verified by trypsin digest with a combination of reflectron mode and
“LIFT” mode [390]. Data were analysed by mMass and then curated by hand.
3.3.3 CD
For CD measurements, protein was dialyzed to 20 mM Na2HPO4 plus 50 mM
NaCl and pH adjusted with HCl (6.7, 7.2, 7.5). All CD data shown here were
gathered using an Aviv CD spectrophotometer and a 1 mm path length, quartz
cuvette. Each wavelength scan was in 1 nm increments, with a bandwidth of 1
nm, from 250 to 195 nm. The thermal melt data shown are with 1 ºC increments
and a 2 minute incubation at each step. All CD data were averaged for five
seconds at each measurement and buffer signal was subtracted. Reversibility
(often between 70—96%) was determined by remeasuring the signal at 222
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nm and 20 ºC. I obtained my best data by diluting the protein several hours
beforehand and degassing the protein for 5 minutes before measurement.
3.3.4 DSC
Protein was dialyzed to 20 mM PIPES and 200 mM NaCl and pH adjusted with
NaOH (6.7, 7.2, 7.5). Data were collected with a microCal DSC at a scan rate of
1.5 ºC per minute and duplicated with independent protein preparations and at
least two scans. Repeated scanning of TSG101cc was highly reversible ( 99%
refolded) as long as the final temperature was ≤ 73 ºC (346 K). The data shown
here have been scan rate normalized, buffer subtracted, and then normalized to
the total concentration of monomeric protein. To circumvent baseline uncertainty
in the native region that rendered determination of ΔCp problematic, the ΔCp
was held constant at a value of 690 cal per K*mol of monomer based on the
COREX analysis.
3.3.5 Fluorescence
PMIA-labeled protein was dialyzed to the same buffer used in AUC and the
concentration was determined in the same manner. All fluorescence experiments
were done at 20 ºC.
Time-resolved fluorescence measurements were made using picosecond laser
excitation with a Time-Correlated Single Photon Counting (TCSPC) setup; the
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instrument is described elsewhere [412]. The exceptionally long excited-state
lifetime of pyrene compelled me to slow down the exciting pulse rate from 4.1
MHz to 820 kHz and to extend the time window of the TCSPC electronics from 25
ns to 100 ns. Time-Resolved Anisotropy (TRA) data and Time-Resolved Emission
Spectra (TRES) were collected using this instrument. The excitation wavelength
was close to 310 nm for both types of experiments; exciting light was vertically
polarized.
In TRA experiments, vertically and horizontally polarized fluorescence was
measured at an emission wavelength of 377 nm, where a sharp emission peak of
pyrene monomer is located; the broad emission band of pyrene excimer appears
at longer wavelengths. The TRA data analysis was done using a previously
described program polartcp [413].
In TRES experiments fluorescence emission was measured through a magic-
angle polarizer; the emission wavelength was stepped from 367 to 517 nm at 5 nm
increments. TRES of a system undergoing a chemical reaction was first described
by Laws and Brand [231]. In the case of the PMIA-labeled protein, excited-
state pyrene dimers (excimers) are formed on the time scale of fluorescence
decay, which is revealed by the TRES. The data analysis using several programs
described elsewhere [412] generated the amplitude spectra, which represent
the wavelength variation of the amplitudes associated with different exponential
terms in fluorescence intensity decay.
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Steady state fluorescence was measured using a SLM-Aminco SLM-48000S
spectrofluorometer with polarizers at the magic angle. Excitation was at 329 nm
(8 nm monochromator bandwidth) and emission was gathered from 345—550
nm (4 nm bandwidth). A Corning glass filter type 0-54 was used in series
with the exciting monochromater to cut out all tryptophan-exciting wavelengths
that were present due to off-band monochromater transmission. After non-
specific adsorption of PMIA-labelled protein to quartz was discovered at sub-µM
concentrations, I coated my cuvette first with BSA (data that is shown), to little
effect, then with silane. Even after silanization, I still observed a significant loss
of protein at the lowest concentrations. This adsorption was only observed in the
sub-µM data of Figure S2, and was not percieved in any of the other experiments
of this manuscript.
3.3.6 AUC
PMIA-labeled protein was dialyzed to 20 mM HEPES, 200 mM NaCl, and 1 mM
TCEP and adjusted to a pH of 7.2 using NaOH. Data were collected at initial
concentrations of 5, 9, and 18.2 µM pyrene-labeled TSG101cc, and the samples
were loaded into epoxy centerpieces with sapphire windows (Spin Analytical).
The Beckman XL-I was set to take absorbance measurements at 329, 336, and 345
nm. The three rotor speeds used were 29, 37, and 44 krpm, and final equilibrium
took about 18 hours per rotor speed. The data were fit globally with several
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models using HeteroAnalysis (JL Cole and JW Lary of University of Connecticut
Bioservices Center). Partial specific volume and solvent density were calculated
using SEDNTERP (J Philo). The data were replicated using a separate protein
preparation that yielded fitted values within error of those presented here.
3.3.7 COREX/BEST Calculations
Per-residue stability analysis of TSG101cc proceeded in a manner largely de-
scribed before for other proteins [148,307,440]. In this work, I used a window
size of eight residues and 100,000 Monte Carlo simulations per partition. The
entropy weighting factor was set to 1.029 to make the maximal residue stability
roughly match my CD data at 150 µM protein and a pH of 7.2. I used H++ to
calculate pKa’s for titratable residues, and used this as input for a pH dependent
COREX/BEST calculation [14]. Solvent accessible surface area calculations were
made with a 1.4 Å rolling ball from a subroutine of COREX [290], and subsequent
thermodynamic analyses proceeded similarly to the manner described by others
before [50,294,409].
3.3.8 DSC and CD Fitting Equations
Fitting of DSC and CD requires determination of the fraction folded (FU) at
every temperature [110,184], and can be referenced to moles of oligomer [246]
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Total protein concentration = PT = n ∗ [N n] + [U]
Fraction of protein in state U = FU =
[U]
[U] + n ∗ [N n]
The quantity FU can be solved by substituting into the equilibrium constant
solved for [U]: [U] = [N n]1/ n ∗K1/ n, noting that K = e–∆G/ R∗T is represented
in cooperative units of oligomer. Recasting the equilibrium expression in terms
of moles of monomer yields: k = K1/ n = e–(∆G/ n)/ R∗T , where ∆g = ∆G/ n and
corresponds to the Gibbs free energy per monomeric mole of protein.





Given FU denotes the fraction of monomeric protein and (1 – FU) denotes the
oligomeric fraction of protein:
[U] = PT ∗ FU (3.2)
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[N n] = (1 – FU) ∗ PT / n (3.3)
Substituting [U] from Equation (3.2) and [N n] from Equation (3.3) into Equa-
tion (3.1) yields:
FU









The roots of Equation (3.4) can be solved for FU.
Before enumerating the fitting equations derived from Equation (3.4), I define







= 1, with concentration having no effect on k in Equation (3.4).
In thermodynamic terms, ∆Strans is the gain in entropy due to the increase in
translational rotational degrees of freedom upon dissociation.
From the right side of Equation (3.4), one can derive an explicit entropy term
by rearranging PT and n to be part of the exponential that k represents e
– ∆g
R∗T .



















Substituting for K (i.e., K = e–∆G/ R∗T ) in Equation (3.5), and expressing in
exponential form:
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From above, note that R is in the same units as entropy:




Thus: ∆Strans = –R ∗ ln[(n ∗ Pn–1T )
–1] (3.6)
Note that for n ∗ Pn–1
T
= 1 → ∆Strans = 0 (PT = 0.25
1/ 3 Molar for tetramer),
and the concentration where translational entropy is zero will be the same
regardless of whether one uses a monomeric or oligomeric reference. Above that
concentration, ∆Strans will weakly favor binding and below that concentration
the converse is true. Because Equation (3.4) takes these terms into account, all
the fitted ∆g values are independent of concentration and equivalent to ∆g at
the hypothetical concentration where ∆Strans is zero.
For DSC, I fit the average excess change in heat capacity, which is the sum of
equations (3.7-3.9) below, namely the base and transition excess heat capacities:
Base Cp,N = (1 – FU) ∗ a (3.7)
Base Cp,U = FU ∗ b (3.8)
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where a and b are empirical folded and unfolded baseline constants. My native
baselines were not good enough to directly fit the ∆Cp. The transition heat
capacity is described by the derivative of FU with respect to temperature:




An analytical solution to δFU
δT
can be solved using Equation (3.4), above. My
derivative differs in form from the derivative described by Professor Freire in












n(1 – FU) + FU
∗ ∆H
R ∗T 2
∗ e–δg/ RT (3.10)
For CD, I fit the following equation in a global manner, using FU derived from
the roots of Equation (3.4), above (for n = 4):
Average signal (T ) = (mN ∗T + cN ) ∗ (1 – FU) + (mU ∗T + cU) ∗ FU (3.11)
The m and c parameters are empirical fits to the native and unfolded baselines.
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3.3.9 Fluorescence Methods
PMIA-labeled protein was dialyzed to the same buffer used in AUC and the
concentration was determined in the same manner. All fluorescence experiments
were done at 20 ºC.
Time-resolved fluorescence measurements were made using picosecond laser
excitation with a Time-Correlated Single Photon Counting (TCSPC) setup; the
instrument is described elsewhere [412]. The exceptionally long excited-state
lifetime of pyrene compelled me to slow down the exciting pulse rate from 4.1
MHz to 820 kHz and to extend the time window of the TCSPC electronics from 25
ns to 100 ns. Time-Resolved Anisotropy (TRA) data and Time-Resolved Emission
Spectra (TRES) were collected using this instrument. The excitation wavelength
was close to 310 nm for both types of experiments; exciting light was vertically
polarized.
In TRA experiments, vertically and horizontally polarized fluorescence was
measured at an emission wavelength of 377 nm, where a sharp emission peak of
pyrene monomer is located; the broad emission band of pyrene excimer appears
at longer wavelengths. The TRA data analysis was done using a previously
described program polartcp [413].
In TRES experiments fluorescence emission was measured through a magic-
angle polarizer; the emission wavelength was stepped from 367 to 517 nm at 5 nm
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increments. TRES of a system undergoing a chemical reaction was first described
by Laws and Brand [231]. In the case of the PMIA-labeled protein, excited-
state pyrene dimers (excimers) are formed on the time scale of fluorescence
decay, which is revealed by the TRES. The data analysis using several programs
described elsewhere [412] generated the amplitude spectra, which represent
the wavelength variation of the amplitudes associated with different exponential
terms in fluorescence intensity decay.
Steady state fluorescence was measured using a SLM-Aminco SLM-48000S
spectrofluorometer with polarizers at the magic angle. Excitation was at 329 nm
(8 nm monochromator bandwidth) and emission was gathered from 345—550
nm (4 nm bandwidth). A Corning glass filter type 0-54 was used in series with
the exciting monochromater to cut out all tryptophan-exciting wavelengths that
were present due to off-band monochromater transmission. After non-specific
adsorption of protein to quartz was discovered, I coated my cuvette first with
BSA, to little effect, then with silane. Even after silanization, I still observed a
significant loss of protein at the lowest concentrations.
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3.4 Results
3.4.1 MALDI mass spectrometry
To confirm the identity of my protein, matrix assisted laser desorption ionization
(MALDI) mass spectrometry was carried out. The general experimental set up
involves firing a UV laser at a protein sample that is embedded in an acidic and
UV absorbing matrix (α-Cyano-4-hydroxycinnamic acid is common for small MW
samples). The positively charged sample is then ejected from the sample plate,
which has a high and positively-charged voltage placed on it. The velocity of the
sample is obtained from its time of flight (ToF) in the MALDI sample chamber,
before striking the MALDI detector. The number of charges on a given analyte
can be discerned from its isotopic distribution, but is usually assumed to be +1
for MALDI. The mass of the sample is obtained thusly: V ∗ q = E = 0.5 ∗ v2 ∗m,
where V is the voltage applied to the MALDI plate, q is charge (assumed +1 in
this case), E is energy, v is velocity, and m is mass.
There are several modes of MALDI detection: 1) Linear mode uses ToF alone
to determine the mass of large molecules (MW >5,000). 2) Reflectron mode
uses an electrical field at the top of the ToF path to reflect ions back down and at
a different detector. This has a selective effect and greatly improves resolution
of small MW analytes, but the paths of large MW analytes are not bent as much
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by the electric field and thus cannot be analyzed because they hit the wall of the
chamber. 3) Laser Induced Fragmentation (LIFT) uses electrical fields to select
a particular ion that is then fragmented using a very high UV laser power [390].
Breaking up large molecules into their constituent parts helps identify the parent
molecule.
MALDI of trypsin digested TSG101cc often gave a sequence coverage exceed-
ing 90%, see part A of Figure 4.5. Identification of pyrene labeled TSG101cc pro-
ceeded in three steps: Linear MALDI-ToF of intact protein, reflectron MALDI-ToF
of trypsin digested protein, and LIFT MS/MS on the N-terminal fragment identi-
fied by reflectron MALDI. These data are presented in parts B–D of Figure 4.5.
The data show that size exclusion chromatography can separate mono-labeled
protein from multi-labeled protein. Further MS on the mono-labeled protein
showed that the pyrene moiety is attached to one of the three N-terminal amino
acids of TSG101cc, which includes the intended cysteine target.
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Figure 3.3 – MALDI Data Verifying Identity of TSG101cc Protein Used in This Study
All data are represented as arbritrary units of intensity on y-axis and mass/charge units on the
x-axis. A) Trypsin digested TSG101cc without pyrene routinely provided over 90% coverage. Peaks
consistent with TSG101cc are labeled with green circles. B) Labeling of TSG101cc with pyrene led
to two peaks on a size chromatography column. The first peak off the column, colored green, is
a mixture of differently labeled species. The second peak, colored black is mostly singly labeled
protein. C) Trypsin digestion of pyrene labeled protein yielded two fragments consistent with pyrene
on the N-terminus of TSG101cc (green circles). Note that the cysteine was engineered into the
N-terminal tag. D) LIFT of the fragment 1350 m/z units produces one fragment consistent with the
first three amino acids (GCS) and pyrene acetamide. Parent ion is labeled with an asterisk, daughter
ion is labeled with a green circle. Inset: A zoomed view of the ion of interest.
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3.4.2 Circular Dichroism (CD) Reveals α-Helical Structure
NOTE: all CD and DSC were with unlabeled TSG101cc (no pyrene and
no cysteine engineered into the N-terminus)
Circular Dichroism (CD) was used to investigate the secondary structure
of TSG101cc. As Figure 3.4 reveals, and consistent with the crystal structure,
TSG101cc is indeed highly α-helical at low temperatures, as indicated by the




Figure 3.4 – Circular Dichroism Wavelength
Scan of a Temperature Melt of TSG101cc
The data have an isodichroic point at 204 nm,
highlighted by the arrow. This particular data set is
from 24 µM protein that refolded to 72% of its origi-
nal signal at 20 ºC. The start (4 ºC) and end (68 ºC)
point temperatures are labeled. The intermediate
temperatures after 4º: 14º, 20º, 26º, 32º, 38º, 44º,
50º, 68 ºC. Two temperatures, 56º and 62º, are
omitted for clarity because they overlapped with
the 68º scan.
Heating of the TSG101cc from 4 - 68
ºC (Figure 3.4 resulted in a thermally-
induced conformational transition in
which the α-helical content was lost,
giving way to a CD spectrum that is
essentially invariant above 56 ºC and
which corresponds to the expected
spectrum of a disordered polypep-
tide (Figure 3.4). Analysis of the
temperature-dependent transition re-
veals an isodichroic point at 204 nm,
which suggests that the thermal transi-
tion, to a first approximation, involves
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just two states. Consistent with this observation, further analysis of the tem-
perature dependence of the CD spectra using singular value decomposition
(SVD) [172,384] reveals that just two singular values can explain 97.7% of the
variation in the data (see Figure 3.5 for a replotting of the first two singular
values).
Figure 3.5 – Singular Value Decomposition of
Circular Dichroism Melt Data as a Function of
Wavelenth
The original data are plotted as black lines under-
laying the singular value decomposition, in light
green lines (same line thickness). The original data
extend to a lower wavelength for context. Only the
first two singular values were used for this figure:
222.4 and 59.1 with a total trace value of 288.1
To determine whether changes in
the degree of oligomerization are as-
sociated with the conformational tran-
sition, thermal unfolding experiments
were performed at various protein con-
centrations [184,404]. The data were
fit globally with respect to tempera-
ture, concentration, and pH using the
roots of Equation (3.4). As Figure 3.6
reveals, both protein concentration
and pH affect the temperature depen-
dence of the mean residue ellipticity
([θ]MR, 222nm). The increase in apparent transition temperature (Tm) with con-
centration reveals that unfolding decreases the degree of oligomerization. The
shift of the apparent Tm (for a given protein concentration) to lower temperatures
with increasing pH, suggests that the α-helical oligomeric state binds protons
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more tightly than the unfolded state. Specifically, the average number of protons





2.303 ∗R ∗ (T ref )2
(3.12)
where ∆n is the change in the number of protons bound and
δT ref
δpH
is the slope of
a plot of the reference temperature, T ref , versus pH. The data indicate a loss
of ≈0.6 protons by each monomer upon unfolding, which corresponds to ∼2
protons per tetramer. The global fit of the data according to a two-state (folded
tetramer to unfolded monomer) transition produced the parameters shown in
Table 3.1.
pH Tref Kelvin ΔH kcal/mol ΔCp, cal/(mol*K) Average Δnprotons
6.7 350.4±3.4




Table 3.1 – Fitted Thermodynamic Values for CD of TSG101cc
Five concentrations from 25–150 µM were used at each pH. Globally fitted values are presented with
95% confidence intervals of the fit and are with respect to moles-monomer. The change in protons
bound was calculated with Equation (3.12). Note that ΔCp was determined from the temperature
dependence of ΔH obtained at the different pH values. The fitted ΔH° is the intrinsic enthalpy of
unfolding where ΔStranslation = 0, and is thus shared for all pH values.
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Figure 3.6 – Circular Dichroism Thermal Melt at Multiple pH’s and Concentrations
µM concentrations and pH are marked alongside each dataset. The best fits to a two-state, tetramer
unfolding transition are plotted over the data points and the residuals are plotted below each dataset.
Refolding for 10 minutes at 20 ºC returned 70-96% of the original signal.
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3.4.3 Differential Scanning Calorimetry (DSC) Comports with
CD Data
To further analyze the thermodynamics associated with the thermally-induced
unfolding-dissociation transition, DSC was performed on TSG101cc as a function
of concentration and pH. Because DSC directly monitors the heat associated with
the thermally-induced transition, it is unique among experimental approaches
in that it provides direct access to the partition function (i.e. the significantly
populated states and their respective energies). Specifically, the unfolding and
dissociation of an oligomeric protein N n will be reflected in the shape of a DSC
curve. Increasing n will cause an increase in the asymmetry and sharpness of
a DSC curve [110], and increasing the number of states will cause broadening
and/or extra peaks [111].
Consistent with the results obtained from CD, analysis of the DSC thermo-
grams reveals that TSG101cc exists as a tetramer that undergoes a cooperative
unfolding/dissociation reaction with temperature Figure 3.7. Also similar to
the CD experiments, lower concentrations and higher pH values were found to
destabilize the TSG101cc tetramer. Because the Tm concentration dependence
is logarithmic, the concentration-induced Tm shifts in Figure 3.7 are subtler than
those seen at the lower concentrations used in CD. Shown in Table 3.2 are the
average values from individual fits of the DSC data, using the same equations
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derived for the CD analysis. Importantly, the DSC data are in general agreement
with the CD data.




7.2 (4) 356.7±8.4 -0.30
7.5 (2) 355.9±2.2 -0.30
Table 3.2 – Fitted Thermodynamic Values for DSC of TSG101cc
Data were fit individually and averages of the fits are presented ± two standard deviations. Enthalpy
is with respect to moles-monomer. Parentheses indicate the number of independent experiments
used in the fits and averaging. ΔCp was held at a constant 690.085 (estimated by COREX). The
fitted ΔH° is the intrinsic enthalpy of unfolding where ΔStranslation = 0. See text for further description.
Proton binding was calculated with Equation (3.12).
3.4.4 Fluorescence Indicates that Pyrene Labeling of
TSG101cc Does not Disturb its Structure Significantly
I labeled the TSG101cc with pyrene in order to use fluorescence techniques to
investigate its dynamics and dissociation at low concentrations. If two or more
pyrene labels are in close proximity in the ground state, then once a pyrene label
is excited, it can form a dimer with another pyrene label in the ground state,
creating an excited state dimer, known as an excimer. The known structure of
the TSG101cc tetramer has two N-termini next to one another on either end of
the coiled-coil; thus, I expected pyrene excimers to form if labeling the protein
had negligible effect on its structure.
I carried out three experiments: steady state fluorescence, time-resolved
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Figure 3.7 – Differential Scanning Calorimetry of TSG101cc at Various pH’s and Concentra-
tions
All of these data are normalized to the moles of monomeric protein and offset vertically for visual
purposes. Data are black lines and the associated fits are grey lines. Concentration and pH are as
follows: (1) pH 6.7 a) and b) 414 µM, c) 295 µM, d) 200 µM; (2) pH 7.2, a) 590 µM, b) 414 µM, c)
295 µM, d) 147 µM; (3) pH 7.5, both at 416 µM. Each scan was reproduced with nearly 99% of the
protein refolding.
anisotropy (TRA), and time-resolved emission spectra (TRES). The goal of the first
experiment was initially to determine the equilibrium binding constant, but the
TSG101cc tenaciously adsorbs to quartz at exceedingly low concentrations, even
after multiple attempts to prevent this. Nonetheless, a dissociation event occurs
at µM concentrations, as the broad pyrene excimer emission band disappears
by 50 nM (Figure 3.8). This is qualitatively consistent with the AUC data (see
next section), where the fraction of tetrameric protein is estimated be <1% at
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100 nM.
TRA data were collected to investigate the overall structural dynamics of the
labeled TSG101cc. Data were fit to the following equations:
Iv(t) = g+
1
2 [1 + 2r(t)]I(t) (3.13)
Ih(t) = g








αn ∗ e–t/ τn (3.16)
Where Iv and Ih are the experimentally observed vertical and horizontal flu-
orescence intensities, respectively, and g equals the ratio of the instrument
sensitivities to vertical and horizontal polarization. Unlike reference [413],
where g played the role of a free fitting parameter, in this work the value of g
was measured independently and fixed. I(t) and r(t) are independent of one
another and are the total fluorescence intensity and the time-resolved anisotropy,
respectively. β is the zero time anisotropy for each correlation time, φ. α is a
weighting parameter for each fluorescence lifetime, τ .
Our data demonstrate that the pyrene label is attached at a single, homoge-
nous location, as it has only on correlation time (0.022 in Table 3.3). The protein’s
rotation is described by three correlation times that suggest a highly extended
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Figure 3.8 – Steady State Fluorescence of TSG101cc-pyrene
As TSG101cc-pyrene is diluted, the pyrene excimer fluorescence disappears (≈500 nm). This is
indicative of an oligomerization reaction and is consistent with the crystal structure.
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shape; however, my data does not perfectly match the theory of Tirado for a
perfect cylinder’s rotation [408]. My TRA data are consistent with a cylinder
of between 9.1 Å and 13.2 Å in diameter, and between 152.4 Å and 142.3 Å
in length. The crystal of the tetramer has a diameter of 30 Å and a length of
134 Å; given the concentration range I was able to use (5—20 µM), this is most
consistent with a mixture of tetrameric and monomeric protein (consistent with
AUC data). See Figure 3.9 for example polarized TCSPC data curves, Table 3.3
for fitted correlation time parameters, and Table 3.4 for the fitted intensity decay
parameters of the TRA model equations (3.13–3.16).
Figure 3.9 – Polarized TCSPC Data for TSG101cc-pyrene
This particular dataset is from protein at 20 µM and the associated fit can be seen in Table 3.3 and
Table 3.4. Data are dots and fits are black lines. The figure on the left is emission intensity for
horizontally polarized light as a function of time and the figure on the right is the same except it is for
vertical emission. The best fit to this set of data is four exponentials describing anisotropy and three
describing lifetime.
Our TCSPC instrument registered photons within a 100 ns time window that
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Table 3.3 – Fitted Correlation Time Values
φ (ns) ± standard deviation β ± standard deviation
0.0220 ± 0.0346 0.309747 ± 1.053504
2.4176 ± 0.7006 0.017678 ± 0.003157
15.8632 ± 7.1479 0.018337 ± 0.004394
69.1623 ± 8.0822 0.045040 ± 0.006541
Table 3.4 – Fitted Intensity Decay Values




was too short as compared to the excited-state lifetime of pyrene, which is of the
order of 300 ns. A longer time window would result in a significant loss of time
resolution, which would make it impossible to measure the rotational correlation
time for the pyrene label. Also it was technically impossible to expand the time
window beyond 100 ns [412]. With the 100 ns time window it was impossible to
resolve the decay of the pyrenemonomer ( 300 ns) from that of the pyrene excimer
( 80 ns) when the emission at just one wavelength was analyzed. Thus, the 187.5
ns lifetime in Table 3.4 represents two unresolved exponentials corresponding
to the monomer and the excimer. To overcome this and glean better information
on excimeric pyrene, I collected time-resolved emission spectra that were then
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αλn(λ) ∗ e–t/ τn (3.17)
Where N exp exponential terms possess the same lifetimes, τn, at each wave-
Figure 3.10 – Decay-Associated Amplitude Spectra of TSG101cc-pyrene
The TCSPC data were fit by the model in Equation (3.17). The decay time τn is printed near each
curve using the same color. Amplitudes αn calculated directly from TCSPC data are shown as points
with error bars and the fit obtained using program trspectr [412] is shown as lines. The red line is
monomeric pyrene population, unable to form excimer. The green line is excimer forming pyrene
population. The dynamics of equilibration between monomer and excimer are described by the two
exponentials depicted by the blue and purple lines. The negative amplitudes seen in the blue and
purple lines describe the build up of excimer emission during the first few nanoseconds after the end
of the excitation pulse.
length, λ, but the corresponding amplitudes αn vary with wavelength and are
therefore called amplitude spectra, αn(λ). My data are described by a series
of four exponentials Figure 3.10: One describes a population of monomeric
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pyrene that is unable to form excimers (τ = 269 ns), this includes pyrene labels
attached to proteins in a monomeric form and pyrene labels attached to proteins
that oligomerized with an unlabeled counterpart. A second describes a popu-
lation of pyrene that is able to form excimer (τ = 80.1 ns); these pyrene labels
are attached to oligomerized proteins with labeled counterparts. The third and
fourth exponentials describe the equilibration between monomeric and excimeric
pyrene (τ = 1.13 ns and 10.5 ns). Pyrene excimers do not exist immediately
after the exciting pulse, but appear several nanoseconds later as a result of an
excited-state reaction. Since the distance between pyrene labels at the time of
excitation is not uniform, the process of excimer formation is multiexponential (I
see two exponentials given my time resolution). The negative amplitudes at the
wavelengths of excimer emission describe the increase in the excimer emission at
early times, when the excimers are formed. These data confirm the long lifetime
of pyrene, and more importantly, demonstrate TSG101cc oligomerization in a
manner consistent with the crystal structure. The fluorescence data suggest
that pyrene does not perturb the structure of TSG101cc to a significant extent. I
was also able to observe dissociation of the tetramer, but adsorption prevented
attempts to extract an accurate equilibrium constant in Figure 3.8. Note that
adsorption was only perceivable for the lowest concentrations in Figure 3.8, and
had no apparent effect on the other data presented here.
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3.4.5 Analytical Ultracentrifugation (AUC) Confirms the Two
TSG101cc States
Equilibrium AUC was also used to probe TSG101cc’s oligomeric state. Thermal
denaturation has the potential to conceal unstable intermediates, as the unfolded
state rapidly increases in probability with increasing temperatures. Centrifuga-
tion of TSG101cc at 20 ºC, however, allows me to challenge the findings obtained
from CD and DSC. To increase the sensitivity to partially unfolded or different
oligomeric states, TSG101cc was end-labeled with pyrene using a Cys residue
incorporated into the N-terminal tag (see appendix for sequences), and detection
was facilitated with absorbance optics.
Shown in Figure 3.11 is a representative AUC trace at 9 µM. A two-state fit of
the data reveal a monomer-tetramer equilibrium that is consistent with the CD
and DSC results: MW = 9778±295 Daltons, stoichiometry = 3.97±0.11, ln(Kd) =
-39.41±1.51, Kd =7.66×10-18 M
3, RMSD = 0.01003. Of note is that a one-state
fit is inconsistent with the known monomeric mass ( 9313 Da monomeric mass
by MALDI, see Figure 4.5) and produces skewed residuals at higher rotor speeds
(MW = 35775±102 Daltons, RMSD = 0.01101). Similarly, a three-state fit was
precluded as it produced no justifiable improvement of the residuals over the two-
state fit. Importantly, the Kd, as measured by AUC corresponds to a stability of
23.0 ± 0.9 kcal/mol-cooperative unit at 20 ºC, which is consistent with my thermal
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Figure 3.11 – AUC of the TSG101cc
The top panel is baselined data from a channel loaded with 9 µM TSG101cc-pyrene. Data are points
and two state fits are black lines. The lower two panels are residuals from two and one state fits,
respectively. Note that at higher rotor speeds, the residuals are tilted in the one state case. The
absorbance shown is for 329, 330, and 329 nm at 29, 37, and 44 krpm, respectively.
measurements (CD at pH 7.2 and 20 ºC ΔG = 23.2 kcal/mol-oligomer, and DSC
ΔG = 15.8 kcal/mol-oligomer). The agreement between the DSC, CD and AUC
measurements strongly suggests that under native and denaturing conditions,
no appreciable amount of oligomers other than tetramer are populated.
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3.4.6 Structural Thermodynamic Analysis Using COREX/BEST
To investigate the structural stability of TSG101cc, the crystal structure of the
tetrameric complex was analyzed using the COREX/BEST algorithm [149,420].
COREX/BEST uses the high-resolution structure as a template from which to
derive an ensemble of partially unfolded states. The fundamental assumption
in the COREX algorithm is that conformational fluctuations can be modeled as
local unfolding, and that the folded regions in each state can be represented
by the high-resolution structural coordinates. Different states are generated by
systematically unfolding all regions (in 8 residue windows) of the protein in all
combinations, thus producing an ensemble that ranges from the fully unfolded
state, in which all regions are unfolded, to the fully folded state, in which no
regions are unfolded. The energetics were determined using the well-established
calorimetric parameterization of the enthalpy and heat capacity as described
elsewhere [33,82,128,128,149,294,447,448].
The output of COREX/BEST is a profile of the residue-specific stability of the
molecule, which is presented from the N to C terminus Figure 3.12. Because
COREX/BEST generates an ensemble, the residue-specific stability is described
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Figure 3.12 – Structural Thermodynamic Anal-
ysis of TSG101cc
A) COREX/BEST residue stability analysis for
chain A of pdb:3iv1, at pH 7 and 293.15 Kelvin.
The y-axis is the energy of unfolding a given
residue on the x-axis. Laid horizontally from N to
C-terminus is chain A from the tetramer structure,
depicted as a ribbon. A gray dashed line indicates
an energy of 0 and was used as the upper limit for
the red coloring of the structure. The upper limit for
blue coloring was +15. B) The molecular surface
of the TSG101cc tetramer is colored as in part A.
The N and C-termini of chains B and D are labeled
to highlight the anti-parallel nature of the tetramer
(“NB” etc.). C) Zoom in of the proposed H-bond
network is shown as solid lines, except one with
relaxed constraints as a dashed line. Chain A =
light grey, chain B = green (cut away), chain C =
pink, chain D = blue (cut away).
where the stability at any position j is
simply the ratio of the summed proba-
bility of all states wherein residue j is
in a folded region, to the summed prob-
ability of states wherein that residue is
in a non-folded region. As such, high
stability constants (i.e., RT ∗ ln[κf ])
correspond to regions where the prob-
ability of states wherein residue j is
folded is high, while lower stability con-
stants are found in regions where the
probability of states wherein residue
j is not folded is high. Importantly,
the stability constants determined by
COREX/BEST can be compared with
the protection factors obtained from
hydrogen exchange experiments under
conditions where protection reports on a stability (i.e. under EX2 conditions). The
excellent agreement between COREX and a test set of proteins suggests that the
regional differences in stability determined from COREX are meaningful [253].
Analysis of the COREX results for TSG101cc reveals two important features.
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First, both ends of the homotetrameric coiled coil are predicted to be unstable
and largely disordered in solution (parts A&B of Figure 3.12). This is consistent
with the fact that the ends of each chain are not in contact with one another
in the high-resolution structure, and thus lack the inter-helix stabilization that
is characteristic of coiled-coils [368,404]. Such fraying of coiled-coil ends has
been observed in other proteins [84, 156]. Second, the central portion of the
coiled-coil is predicted to be highly stable, which is consistent with the high
degree of inter-helical surface buried between the individual monomers in the
coiled-coil.
A slight decrease in the stability of the central portion of the coiled-coil
region is also observed. This decrease is accompanied by an increase in the
residue –specific conformational entropy of unfolding of the central portions of
the TSG101cc. The increased conformational entropy and decreased stability
is in part related to the presence of a glycine (Gly) residue in the center of
the helix (Gly268, which is a.a. 40 in part A of Figure 3.12, see Figure 3.13)
which increases the conformational entropy of states wherein Gly268 is unfolded,
thus destabilizing helical states by 1.0 kcal/mol. Indeed, it is this destabilizing
conformational entropic effect that largely accounts for the infrequency of Gly
residues within helices of folded, globular proteins [82].
I note the presence of Gly at position 268 is immediately followed by His 269,
which is part of an inter-helical H-bond network involving Glu262 of chain A,
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His269 of chain B, His269 of chain C, and Glu262 of chain D, all of which are
observed in the X-ray structure part C of Figure 3.12 (and which are predicted
to be hydrogen bonded using the program Chimera [317]). I also note that
the two H-bonding networks per tetramer would, upon dissociation, release
one proton per each histidine pair; producing a net release of two protons per
tetramer, a value that is in good quantitative agreement with my experimental
results. Interestingly, such an H-bond network could also play a role in setting
the register and orientation of the coiled-coil, as seen in some other natural and
engineered coiled-coils [56,306].
Gly268Asp264
Residue index in structure
Figure 3.13 – The Energy of ΔSconf on a Per
Residue Basis.
The solid black line is the data from COREX. The
dashed lines indicate specific residues of interest:
Asp264, grey, H-bonds its backbone to Gly268,
black.
A more detailed analysis of the
COREX/BEST results provides access
to the thermodynamic mechanism un-
derlying the homotetramer stability.
COREX calculates the unfolding en-
ergetics based on changes in solvent
accessible apolar (ΔASAap) and po-
lar (ΔASApol) surface area between
states, from which ΔCp, ΔHsolvation,
and ΔSsolvation can be determined
[148]. Two other components of the en-
tropy change can also be determined: The conformational entropy, ΔSconformation
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can be calculated based on backbone and side chain rotomers, as described
previously [82, 236], and the translational and rotational entropy, ΔStrans, for
each oligomeric state can be calculated given the stoichiometry [295].
Table 3.5 contains the structural thermodynamic analyses of the TSG101cc
homotetramer as well as the intermediate oligomeric states, generated in silico
by deletion of excess chains. The calculated ΔGtotal and ΔCp for the tetramer are
in agreement with the values measured experimentally (COREX: 5.2 kcal/mol-
monomer and 650-690 cal/K/mol-monomer, respectively), suggesting the algo-
rithm adequately captures the underlying thermodynamic basis of TSG101cc
stabilization. Inspection of the detailed mechanism reveals that the major deter-
minant of the stability of the tetramer is the apolar surface buried in the binding
interface between helical monomers. Specifically, the burial of apolar versus
polar surface area (on a per residue basis) is significantly higher for the tetramer
than for the trimer, dimer, or monomer (1.2, 1.6, 2.5 fold more ΔASAap in the
tetramer, respectively). Of note is that the lower order oligomers are predicted
by COREX/BEST to be significantly less stable than the homotetramer, which is
also consistent with the experimental results.
To estimate the relative stability of the TSG101cc heterotrimer, a structural
analysis of the yeast ESCRT-I coiled-coil (pdb:2p22) was also performed [212].
The results reveal a binding interface that is 77% apolar, compared to 75% for
the TSG101cc homotetramer (Table 3.6). Analysis of the results also reveals
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Parameter Monomer Dimer Trimer Tetramer
ΔASAApolar (Å
2) 1331 2105 2776 3382
ΔASAPolar (Å
2) 2645 2834 3077 3345
ΔCp (cal/K mol) -88 211 449 652
ΔHgeneric (kcal/mol) 75.5 63.0 55.5 50.8
ΔSsolv (cal/K mol) -70 -158 -232 -297
ΔSconf (cal/K mol) 390 420 429 449
ΔGgeneric (kcal/mol) -18 -13.7 -2.26 6.11
ΔGtrans (kcal/mol) 0 -0.77 -0.92 -0.95
ΔGtotal (kcal/mol) -18 -14 -3.2 5.2
Table 3.5 – Structural Thermodynamic Analysis of the TSG101cc at 20 ºC (293.15 K)
All values are relative to moles of monomer and refer to the unfolding reaction (positive ΔG values
indicate a stable folded state). Note that the tetramer ΔGtotal calculated here is close to the values I
measured experimentally (CD = 5.8, DSC = 4.0, AUC = 5.7 kcal/ K*mol-monomer). The translational
energy of dissociation was calculated as in [295].
the stability of the ESCRT-I coiled-coil fragment to be similar to the TSG101cc
homotetramer, suggesting that under such conditions the relevant equilibrium
would involve TSG101cc homotetramer, unfolded TSG101ccmonomer and ESCRT-
I heterotrimer, with no appreciable accumulation of the other TSG101cc homo-
oligomeric species. Consistent with my results, experimental analysis of the
full-length ESCRT-I complex revealed that it sediments as a tightly bound, single
species in AUC [212,287].
Finally, to establish context for the TSG101cc analysis presented here, I also
compared my results to other oligomeric proteins, including four coiled-coils
(thermodynamic data in Table 3.7). I excluded examples that unnecessarily
complicated comparisons to TSG101cc. For example, COREX was parameterized
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Parameter Mvb12 Vps23 Vps37 MxV23 MxV37 V2 Trimer
ΔASAApolar (Å
2) 1244 1824 2604 2329 3368 4154 4462
ΔASAPolar (Å
2) 1529 2758 2988 2327 2773 3400 3208
ΔCp (cal/K mol) 159 99 388 437 785 974 1162
ΔHgeneric (kcal/mol) 31.2 67.2 56.3 35.9 27.2 32.7 16.6
ΔSsolv (cal/K mol) -99 -127 -214 -203 -315 -389 -433
ΔSconf (cal/K mol) 290 432 490 377 428 507 467
ΔGgeneric (kcal/mol) -24.9 -22.2 -24.6 -14.9 -6.0 -1.9 6.7
ΔGtrans (kcal/mol) 0 0 0 -0.77 -0.77 -0.77 -0.92
ΔGtotal (kcal/mol) -24.9 -22.2 -24.6 -15.7 -6.7 -2.6 5.8
Table 3.6 – Structural Thermodynamic Analysis of S.cere. ESCRT-I coiled coil at 20ºC
Per unit of monomer. 2p22 also includes the vps23 stability box bound to vps28, and some poorly
resolved loops of vps37, which were deleted for this analysis of the coiled-coil alone. The dimer
names are: “MxV23”=mvb12—vps23, “MxV37”=mvb12—vps37, “V2”=vps23—vps37. Vps23 is the
TSG101 homologue. The ΔASAApolar for the binding interface is three times the trimer value, minus
each of the monomer values (7714 Å2). The ΔASAPolar for the binding interface is 2349 Å
2.
on real proteins, and artificially engineered proteins can have unusual hydropho-
bic:hydrophilic properties that could skew calculations. Thus, the criteria for
inclusion were: naturally occurring, two-state, mesophilic, having published
full-thermodynamic analyses (ΔHº, ΔCp, and Tº), and with structural data avail-
able for COREX. As Table 3.8 reveals, the packing of hydrophobic residues is
not unique to the TSG101cc. Although my results reveal a similar amount of
hydrophobic surface buried in other coiled-coil interfaces, TSG101cc is less
stable (i.e., lower Tref) than most other mesophilic, oligomeric proteins, with
the difference arising from the accumulation of small differences in polar free
energy and conformational entropy. In short, although TSG101cc has clearly
91
CHAPTER 3. STRUCTURAL STABILITY OF THE COILED-COIL DOMAIN OF
TUMOR SUSCEPTIBILITY GENE (TSG)-101
not evolved to populate homotrimeric and homodimeric states, it also does not
appear to have evolved to strongly homotetramerize, as both the calculations






























































































GroES 679 Heptamer 445.2 372.7 7.2 29 43
HIV protease 198 Dimer 190.5 360.5 3.2 14 71
SecB 620 Tetramer 509.4 358.4 10.6 26 42
p53tet 252 Tetramer 209.2 397.6 1.7 29 115
ROP 126 Dimer 174.7 358.8 2.5 16 127
H2A-H2B 255 Dimer 124.2 337 <2.6> 8.4 33
Arc repressor 106 Dimer 115.7 355.1 1.6 11 104
H3-H4 171 Dimer 86.8 359.6 1.4 7 41
GCN4 112 Dimer <69.8> <368.3> <0.269> 12 107
Melittin 104 Tetramer 147a 369a 1.8a 15a 144
TSG101cc 312 Tetramer 226 347.1 2.7 23 74
APC (a.a. 1-55) 110 Dimer 76.5a 345.7a 0.664a 8.8a 80
Table 3.7 – Review of Thermodynamic Data for Oligomeric Proteins in the Literature
Data are normalized to the moles of oligomer. “< >” indicate values that are averages of the literature data. The ΔH and Tref values are for
hypothetical concentrations at which concentration has zero net effect on the stability and ΔG = 0. aThere was not enough information in the
cited texts to readily calculate ΔG from the published fits. I digitized the cited CD data (Engauge Digitizer, Mark Mitchell) and constrained
ΔCp to the value calculated by COREX. I then fit the data, globally where possible, and present my own fitted values alongside the COREX

























































































GroES 23898 (62%) 14028 (59%) 37926 (61%) -3a [50,165]
HIV protease 9088 (63%) 1950 (61%) 11038 (63%) -2a [378,409]
SecB 30468 (63%) 3675 (66%) 34142 (63%) 3a [87,309]
p53tet 3000 (59%) 4608 (71%) 7608 (66%) 12b [184,236]
ROP 4520 (53%) 1877 (73%) 6397 (57%) 20b [35,386]
H2A-H2B 6547 (56%) 3685 (76%) 10232 (61%) 20b [17,194]
Arc repressor 2536 (44%) 2675 (68%) 5211 (53%) 24b [49,55]
H3-H4 6090 (53%) 3740 (78%) 9830 (61%) 25b [17,195]
GCN4 1270 (40%) 1435 (81%) 2704 (55%) 41c [367,404]
Melittin 2300 (47%) 3361 (88%) 5661 (65%) 41c [135,401]
TSG101cc 5324 (33%) 8204 (75%) 13528 (50%) 42c 3iv1
APC (a.a. 1-55) 1928 (35%) 1783 (79%) 3709 (48%) 44c [84,186]
Table 3.8 – Apolar Surface Area Comparison of Oligomeric Proteins in the Literature
































































































FIS 196 Dimer 2.2 200.6 374.2 23 115.4
CcdB 202 Dimer 2.8 213 371.7 21 103
MetJ 208 Dimer 2.1 156.5 343.2 15 70
N34(L6)C28: SIV 204 Trimer 2.1 165.7 361.3 17 83















FIS 5808 (53%) 2418 (77%) 8226 (59%) 24b [279,455]
CcdB 10538 (60%) 1403 (77%) 11941 (62%) 17b [31,256]
MetJ 8971 (55%) 2804 (76%) 11775 (59%) 21b [182,331]
N34(L6)C28: SIV 5476 (44%) 4615 (81%) 10091 (55%) 37c [178,259]
LPP56 2668 (28%) 4317 (76%) 6985 (46%) 48c [97,372]
Table 3.9 – Continuation of Table 3.7 and Table 3.8. Data are presented in the same manner.
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3.5 Discussion and Conclusions
3.5.1 Discussion
In this study, I set out to understand the oligomerization of the human TSG101cc
in solution. In isolation, I find that the coiled-coil domain significantly populates
only two states, a homotetramer and a monomer (the findings are summarized in
part A Figure 3.14). My thermodynamic analysis indicates that the intermediate
homo-oligomeric states would likely be unstable because hydrophobic packing
present in the homotetrameric interactions is missing in the homotrimer/dimer.
This has broader implications and immediately suggests that TSG101cc interacts
with its binding partners via large, hydrophobic interactions, a supposition
that is supported by thermodynamic analysis of the ESCRT-I coiled-coil. Without
significant hydrophobic interactions, hetero-oligomers would be unstable relative
to the TSG101cc homotetramer.
I also found that the TSG101cc tetramer releases ∼2 protons per tetramer
upon unfolding. This is consistent with my analysis of the homotetramer structure
(pdb: 3iv1). The four histidine residues at position 269 would likely release two
protons upon unfolding of the tetramer producing 0.5 protons per monomer. It
is unclear why the TSG101cc evolved to be stabilized as pH is lowered; although
I do note that cellular pH can vary from ∼5.7—7.4 depending on various cellular
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states [37,303,327,329,416,434]. Determining if these subtle pH changes affect
TSG101 function in vivo awaits further study.
Lastly, I find that the tetramer of the TSG101cc is relatively unstable. Com-
pared to the other tetramers (Table 3.7), TSG101cc has the lowest Tref and the
second lowest ΔG (20 ºC). This suggests that the unfolded monomer plays a ther-
modynamically significant role in the functional equilibrium. Even at some of the
highest TSG101cc concentrations at pH 7.2, the TSG101cc unfolding curve be-
gins in a physiological temperature range. At more physiological concentrations,
the apparent Tm of unfolding is ≈37 ºC or lower, suggesting that the reservoir
of TSG101cc is a balance of monomer and tetramer. Importantly, because the
monomer-tetramer equilibrium is poised near the midpoint, it is most sensitive to
concentration changes, meaning that any TSG101 that is sequestered by the ES-
CRT complex would be readily replenished by a shift in the tetramer to monomer
equilibrium. The fact that the stability appears to be tuned by the presence of
the conserved residues E262, G268 and H269 (and the corresponding interchain
H-bond network), suggests that functional equilibrium is subject to fine-tuning
from both pH and concentration changes.
While the TSG101cc by itself is weakly stable, I hypothesize that other inter-
actions in full-length TSG101 may stabilize a homotetramer. It has been known
for over a decade that the N-terminal, UEV domain of TSG101 binds a short pep-
tide motif, P(S/T)AP, that is present in many animal and viral proteins that bind
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TSG101 [12,170,203]. C-terminal to the coiled-coil of TSG101 is a PTAP motif
that can bind the TSG101 UEV domain [323,324]. At the time of its discovery,
Pornillos and colleagues proposed that each TSG101 molecule looped around and
bound itself—forming an autoinhibited state that other ESCRT proteins would
be unable to bind. Here, I can add to this hypothesis by proposing that each
TSG101 molecule engages in domain swapping in its tetrameric state (part B of
Figure 3.14). Because every other strand of the coiled-coil runs antiparallel to
its neighbors, the UEV domain of a neighboring strand could bind the C-terminal
PTAP motif of an adjacent strand (part B of Figure 3.14).
Although the model hypothesized in part B of Figure 3.14 is speculative, it
does provide context to the results presented here and provides potential avenues
for further study. The complex shown in part B of Figure 3.14 would likely be
highly stable and autoinhibited. There is at least some in vivo evidence for an
autoinhibited state of TSG101: mutation of mouse TSG101’s PTAP motif caused a
precipitous increase in TSG101’s association with the ESCRT0 protein, HRS, by
yeast two-hybrid [262], and in other yeast two-hybrids TSG101 has been found to
self-associate [199,268,422]. In its natural context, TSG101 could take advantage
of the homotetramer-monomer equilibrium to serve as the TSG101 reservoir,
from which the ESCRT-I complex could draw. Local increases in concentration of
TSG101 binding partners such as HRS [324] or ubiquitin [393] that both bind to
the UEV domain of TSG101, could sequester TSG101 monomers.
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In any event, the model proposed in Fig. 7B reveals numerous possibilities
for how TSG101 function can be affected by changes in stoichiometry, which can
affect both inter and intramolecular interactions, possibly in complex ways. For
instance, to bind the TSG101 UEV domain, the HRS PSAP motif may have to
displace the TSG101 PTAP motif. However, because it has been shown that the
TSG101 PTAP binds its UEV domain approximately 1.5–fold better than does the
HRS PSAP motif [324], other domains are likely to play a role in mediating this
interaction. Is it the case that binding of ubiquitin, for example, allosterically (or
directly) destabilizes binding of the TSG101 PTAP motif, thereby releasing the
UEV domain for binding to HRS? Although the answer to this question awaits
further study, the fact that the concentration of available TSG101 monomer is
within a tunable range suggests that dynamic availability of TSG101 may be a
key determinant in HRS function.
3.5.2 Conclusions
In this work, I used solution and structural thermodynamics to define the
oligomeric states of the TSG101 coiled-coil in vitro. I find evidence that TSG101cc
evolved a highly cooperative association event that is stabilized by hydrophobic
interactions and acidic pH, which gives me several clues as to how TSG101cc
forms its hetero-oligomers not just with ESCRT-I but also with nuclear hormone
receptors. The information gained here leads to new hypotheses that could
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inform future studies involving full-length TSG101 and its binding partners.
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Figure 3.14 – A) Reaction scheme depicting the main discoveries of this work. On the left,
each chain of the TSG101cc tetramer is depicted as atom spheres with carbons in darker colors
than the other atoms (pink, grey, green, blue). At the top and bottom, the TSG101cc is depicted as a
ribbon in the same colors. On the right, the TSG101cc homologue, vps23, is blue (vps27 is grey
and mvb12 is pink, adapted from pdb:2p22). The arrows are based on structural thermodynamic
analyses, presented here, and experimental data presented here for TSG101cc or elsewhere for
ESCRT-I [212,287]. B) The proposed structural model for the TSG101 tetramer. Each chain of
the coiled-coil tetramer is depicted as in part A of this figure. The N-terminal UEV domain of the pink
chain is depicted as a ribbon [170], and was docked [10] to the TSG101 PTAP sequence of the blue
chain (the original PTAP in pdb:3obu is the HIV sequence, with little difference). The structure of
the UEV domain bound to ubiquitin [393] was aligned with pdb:3obu, and ubiquitin is colored dark
grey; note that the PTAP motif does not occlude ubiquitin binding. The C-terminal S-box of the blue
TSG101cc chain is depicted as a ribbon [213]. Unstructured regions are shown as dashed lines with
arrows going from N to C-termini. There would be three other UEV domain:PTAP interactions not
shown here.
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3.6 Appendix
3.6.1 Sequences of TSG101cc constructs used
All sequences were verified using Sanger sequencing services from either Gen-







Translation (TEV cut site marked with *, TSG101cc sequence starts two a.a.
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later ”SLI...”): MHHHHHHHHHENLYFQ*GSSLISAVSDKLRWRMKEEMDRAQAE
LNALKRTEEDLKKGHQKLEEMVTRLDQEVAEVDKNIELLKKKDEELSSALEK
Construct used in AUC and TCSPC (only change is a cysteine in the N-terminal









3.6.2 PMIA labeling of cysteine
To verify the extinction coefficient of PMIA, a known mass of PMIA was reacted
with a 900 fold excess of L-cysteine in labeling buffer (see methods) with 25%
DMSO for one hour. The resulting extinction coefficient was similar to the
manufacturer’s measurement in methanol (Setareh standard: 45,000±3,000
cm-1 M-1 at 343±3 nm; Setareh Lot #14760: 44,700 cm-1 M-1 at 341 nm; my







This chapter is in collaboration with two graduate students, James Rives
and Marla Tharp, who assisted me with the single molecule force spec-
troscopy and fluorescence anisotropy, respectively. Professors E. Brad
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lucocorticoid Receptor (GR) is a steroid hormone receptor important for
the proper development and homeostasis of vertebrates. As with nearly
all steroid hormone receptors (SHR), the N-terminus of GR is a large disordered
domain that mediates the transcriptional activity of GR. It is known that these
disordered domains of SHR’s bind transcriptional cofactor proteins, but it is
poorly understood how transcriptional cofactors affect the energetic coupling
and functional output of SHR’s. I addressed these questions using a GR binding
partner, Tumor Susceptibility Gene-101 (TSG101), that is involved in endosomal
maturation and implicated in transcriptional regulation of several SHR’s. Using
numerous biophysical and cellular assays, I show that the coiled-coil of TSG101
binds and folds the disordered N-terminus of GR, that this interaction promotes
DNA-binding of GR in vitro, and that the in vivo interaction appears to promote
the transcriptional activity of most GR isoforms.
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4.2 Introduction
It is becoming increasingly apparent that to understand the molecular mechanism
of transcription factors, we must understand the underlying energetics of these
proteins [151,291]. This is an inherently difficult task, as many transcription
factors contain large disordered regions that are necessary for transcriptional
activity [214,251]. How disordered domains support the function of transcription
factors is still under investigation, but it is known that these domains are enriched
for protein binding sites and are frequently expressed as alternative isoforms [61].
Alternative isoforms can disrupt the binding of some transcriptional cofactors
[61], but less studied is how alternative isoforms could change the underlying
coupling energies between domains of a protein [291].
As others have shown for the adenoviral protein E1A and the Hilser lab has
shown for glucocorticoid receptor, alternative isoforms can drastically change the
allosteric coupling between domains of a protein, even when some of the domains
are disordered [106,242,243]. This goes against the classical view of allostery
as being a bond path or rigid body motion through a protein [91, 226, 315].
Instead, allostery depends upon the ensembles of folded and unfolded states and
how folding of one domain affects the stability of the other domains (allosteric
coupling) [150,289].
To understand how allosteric coupling affects transcription, I have turned
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to the steroid hormone receptor family of proteins, specifically glucocorticoid
receptor (GR). GR regulates a wide variety of processes in the human body
including inflammation, cell death, stress and immune responses [77,267,354,
407, 421, 456]. GR is typical of the steroid hormone receptor family: it has a
disordered N-terminal domain (NTD), a DNA-binding domain (DBD), and a ligand
binding domain (LBD). Figure 4.1 lays out these domains and describes some of
their functions, binding partners, and translational isoforms (A, B, C1, C2, C3,
D1, D2, D3).
The eight translational isoforms of GR progressively chop off the NTD and
have drastic effects on the transcriptional activity of the protein [260]. Regardless
the presence of the LBD1, cutting the NTD down to the C3 isoform increases
the transcriptional activity of GR, while removal of the C3-NTD destroys GR’s
transcriptional activity [243,260]. The Hilser lab has previously measured the
folding energy of GR NTD isoforms and found that the C3-NTD more readily
folds than the A-NTD [242]. Furthermore, the energy of folding a given GR NTD
correlated well with transcriptional activity, and both could be deconvoluted
in terms of folding free energies (ΔG) and coupling energies (Δg) between the
1The LBD of GR is dispensable to the core functions of GR, and here I use a GR construct
lacking the LBD to simplify my thermodynamic analysis. In a similar manner, there are two GR
splice isoforms that lack functional LBD’s, GR-β and P. Under normal circumstances, GR-β and P
are expressed at levels about one-hundredth or one-tenth that of the main GR-α splice isoform,
respectively [350]. However, the truncated GR’s are upregulated in some disease states: β in
both Cushings syndrome and drug-resistant asthma, and GR-P in some cancers (e.g. some forms
of acute lymphoblastic leukemia and non-Hodgkin lymphoma) [86,134,240]. Understanding the
thermodynamic coupling within GR’s first two domains will ultimately help us understand the
receptor as a whole, but it could immediately impact our understanding of the disease-associated
GR-β and P.
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domains [243,289].
The Hilser lab’s quantitative model predicts how different perturbations (ex.
mutations or binding events) will affect GR function. Because the C3-NTD is
more stable than the longer isoforms, I predicted that a transcriptional cofactor
would bind the C3 isoform better than the A isoform. However, as described in
this chapter, the actual situation appears to be more complex. There are perhaps
hundreds of transcriptional cofactors that interact with GR [255], and my choice
of transcriptional cofactor was based on several criteria: 1) known to bind the
GR NTD, 2) ease of purification, and 3) no requirement for post-translational
modifications in the binding site. This led me to tumor susceptibility gene-101.
Nearly two decades ago, it was shown that Tumor Susceptibility Gene-101
(TSG101) could alter transcriptional activity of nuclear hormone receptors [432],
and in the intervening time there has been a smattering of reports supporting
the initial observations [153,293,392]—while most TSG101 research has focused
on its conserved role in endosomal maturation (the Endosomal Sorting Complex
Required for Transport, ESCRT, see Chapter 2 and: [142,241]).
To date, the role of TSG101 in transcription is not understand .2 Indeed, it
is not clear if TSG101 forms a transcriptional complex or if it simply regulates
receptor degradation or post-translational modifications [63,299]. Conflicting
2It is worth noting that the yeast version of TSG101 has no known nuclear roles (Prof. Wend-
land, communication). To define the evolutionary course of TSG101, I have aligned the human
TSG101 sequence with ten of its homologues in Figure 4.22 in Appendix. A possible nuclear
localization sequence appears to be relatively conserved in vertebrates; thus, TSG101 was likely
neo-functionalized millions of years ago.
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reports of TSG101 activating or repressing transcription remain unexplained
[63,392]; though, some of the differences may be a result of other transcription
factors being recruited. In one example, the combination of TSG101 and Daxx
repressed transcriptional activity of GR more so than either protein alone [293].
Table 4.1 shows a comparison of literature results with regards to TSG101’s
nuclear localization, transcriptional effects, and potential binding partners. Also
see Figure 4.1 for an explanation of the TSG101 domains and functions. Of
particular interest is the coiled-coil domain of TSG101, which was shown to bind
GR’s NTD in a yeast two-hybrid assay [153].
In the work presented here, I found that the TSG101 coiled-coil (TSG101cc)
can bind and fold the GR NTD, regardless of the GR isoform. Overexpression
of TSG101 in U2-osteosarcoma cells increased GR’s activity, as long as the C3
portion of the NTD was intact, and this in vivo effect correlated with in vitro
experiments where TSG101cc allosterically promoted GR’s DNA binding affinity
via mechanisms that appear to differ between different GR isoforms. I propose
that TSG101 can form an active transcriptional complex with GR.
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Binds P(S/T)AP motifs






















































Figure 4.1 – The Domains and Functions of GR and TSG101
Domains are given as boxes oriented from N- to C-terminus, scaled with respect to the size of
each domain. A) The eight translational isoforms of GR are indicated. Some have nearly adjacent
translational start sites and are indicated with just one line (e.g. C1, C2). The longest NTD isoforms
contain a regulatory (R) region that stabilizes the DBD and destabilizes the cofactor binding region
(depicted as arrows with +/– signs). The shown allosteric interactions produce a bistable system [243].
The NTD region that binds transcriptional cofactors is also called activation function 1 (AF1) in the
literature. AF1 has been shown to bind: TSG101, Med14, TBP, CBP, Ada2, and many other
cofactors [11,153,216,425]. B) TSG101 domain functions are listed at the top, and the coiled-coil’s
nuclear involvement is highlighted. Examples of protein binding partners are listed at the bottom.
References: [63,74,117,153,199,203,212,234,262,293,393,432]
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Y AATF + AR [63]
CV-1 N/A p300 – * AR, ER, TR [392]
293T Y GR, Daxx – GR [293]
NPC-TW01 Y† Rta (viral) + Rta [74]
Hela N/A GR – GR [153]
T24
Saos-2
Y‡ N/A N/A [459]
3T3
Hela
Y‡ N/A N/A [449]
COS-1 N/A N/A
– AR, GR, ER,
TR, RAR, VDR
[432]
U2OS Y GR + Here
Table 4.1 – Compilation of Literature Data on TSG101’s Transcriptional Effects and Interac-
tions
Localization of TSG101 in these studies was determined by either immunofluorescence or fluorescent
protein tagging. Protein-protein interactions were determined by W-blotting or yeast two-hybrid.
Transcriptional effects were determined by enzyme expression (often luciferase or CAT) using arti-
ficial or viral promoters. Key: Y = Yes, N/A = Not tested/applicable, + = Activator, – = Repressor.
Cell lines: Rat-1 = rat fibroblasts, CV-1 and COS-1 = African green monkey kidney, 293T = human
embryonic kidney, NPC-TW01 = human nasopharyngeal carcinoma, Hela = human cervical cancer,
T24 = human bladder carcinoma, Saos-2 = human osteosarcoma, 3T3 = mouse embryonic fibroblast.
Addenda: *Activation was seen with a Gal4 fusion to the TSG101 UEV domain. †TSG101 was only
visibly in the nuclei of cells that were expressing the Epstein-Barr virus protein, Rta. ‡These studies
observed the cell cycle-dependent localization of TSG101 (nuclear to varying degrees in several
stages).
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4.3 Methods
4.3.1 Cloning of Plasmids ExpressingHumanGR or TSG101
All E. coli expression was achieved with the pJ411 plasmid of DNA2.0, and the
cloning of most constructs was described previously [242, 243, 438]. For the
largest GR NTD constructs (A = a.a. 1—420, C3 = a.a. 98—420), the coding
sequence was tagged with a 9x His tag on both the N and C-termini along with
TEV cut sites to remove the tags. The NTD-DBD constructs of GR (A = a.a.
1—525, C3 = a.a. 98—525) were tagged on just the N-terminus with a 6x His-
Thrombin sequence (expression problems were observed with TEV or longer
His tags). The open reading frame of the TSG101 coiled coil (a.a. 229—304 or
—339) was tagged with a 9x His tag followed by a TEV site and a serine on the
N-terminus. The TSG101 construct from a.a. 229 to 339 was produced by using
PCR to sequentially add the extra sequence to the 229—304 construct that was
described previously [438]. Note that the 339 construct extends about half-way
into the steadiness box of TSG101 and was the minimal sequence for binding GR
in a yeast two-hybrid assay [153].
I also worked with smaller fragments of the GR-NTD to discern the exact
sequence that interacts with TSG101. These smaller fragments consist of a
region historically called the activation function-1 or the τ1 region (AF1, a.a.
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77—262) that is known to bind transcriptional cofactors [11, 75, 153]. One of
my constructs was the bait used in a yeast two-hybrid study by Hittelman et al.,
called AF1107-237 hereafter [153] (Hittelman AF1 = a.a. 107—237) and the other
is the AF1 core (a.a. 187—244) that binds TATA-binding protein [11]. For bulk
experiments, the AF1 core construct was tagged with a single 9x His-TEV site on
its N-terminus (DNA2.0). For single molecule force spectroscopy, the AF1 core
and the Hittelman AF1 were tagged with a 9xHis-TEV-Avi tag on the N-terminus
(Avi = LNDIFEAQKIEWHE, receives a biotin on the K) and a ybbR tag on the
C-terminus [189,252,290,452] (Ybbr = DSLEFIASKLA, receives CoA on the first
S). The C3-NTD single molecule construct was similar, except with a 6xHis tag.
All the single molecule force spectroscopy constructs were cloned from existing
pJ411 expression plasmids using Gibson cloning.
Besides luciferase, all U2OS expression was achieved with the pJ603 plasmid
of DNA2.0, and the cloning of the GR constructs was described previously ( [243];
A = a.a. 1—525, B = a.a. 27—525, C1 = a.a. 86—525, C2 = a.a. 90—525, C3
= a.a. 98—525, D1 = a.a. 316—525, D2 = a.a. 331—525, D3 = a.a. 336—525).
Note that the pJ603 plasmid uses a constitutive promoter (cytomegalovirus) to
express the inserted gene. DNA2.0 generated the full-length TSG101 expression
plasmid with codon optimization for human cell expression. Sub-cloning of the
TSG101 pJ603 plasmid was achieved with PCR based amplification of either
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the coiled-coil (a.a. 228–304)3 or excision of the same region. To make the
pJ603 TSG101cc plasmid, I used primers designed for Gibson cloning of the
existing full-length TSG101 plasmid and insertion of an N-terminal methionine.
Gibson cloning proceeded by manufacturer specifications (NEB). Excision of
the coiled-coil was done with PCR primers that amplified out the coiled-coil and
added BamHI and KpnI sites to the N- and C-terminal ends of the cut. A linker
oligo (expressing GSGGGSGGSGGSGGSG) with BamHI and KpnI sites was then
inserted using ligation.
To tag TSG101 with Tandem Tomato fluorescent protein (tdTom), I used PCR
to amplify full-length TSG101 from pJ603 and add a BamHI site at the 3’ end.
This was then linked to a double stranded oligo that codes for a 13 a.a. linker
(GSGSGSGGSGSGT) and has BamHI on its 5’ end and KpnI on its 3’ end. TdTom
was amplified from its plasmid (pCMV-tdTom from Clontech) using primers that
added KpnI and XhoI to the 5’ and 3’ ends, respectively. All of the above fragments
were then assembled by ligation into the pJ603 plasmid and sequence verified.
See appendix for sequences.
4.3.2 Protein Expression and Purification
Expression and purification of TSG101cc and the various GR constructs used
here has largely been described before [242,243,438]. All recombinant protein
3Note that my TSG101cc pJ603 construct starts at a.a. 228 as opposed to 229 of my E. coli
construct. This was to form a more canonical Kozak consensus sequence.
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expression was done using the pJ411 vector from DNA 2.0 (see above). Each
plasmid was transformed to BL21 (DE3) pLysS cells and plated to kanamycin
plates (30 µg/mL). Individual colonies or glycerol stocks were grown overnight
at 37º C in 3 mL of LB per liter of desired expression volume. The next morning,
cultures were transferred to flasks with 10mL of LB per desired liter of expression
volume, grown for 3 hours at 37 ºC, and transferred to the final expression volume.
Growth proceeded around room temperature for about 4 hours before reaching
an O.D.600 ≈0.4, then temperature was reduced to 16º C, and induction occured
at O.D.600 ≈0.6 with 1 mM IPTG. After overnight expression, cells were pelleted
by centrifugation (3580 rcf, 10 mins, 4º C), washed with PBS, and repelleted.
The GR NTD alone (either A or C3 isoform) and TSG101cc were prepped from
inclusion bodies, often by directly lysing the cells with ∼15 mL Gdn buffer per
liter of expression (6 M Gdn HCl, 500 mM NaCl, 20 mM imidazole, 20 mM Tris
base, at pH 8). The two domain constructs of GR were prepped under native
conditions (100 mM Na2HPO4, 400 mM NaCl, 20 mM imidazole, 1 mM TCEP
added fresh, ∼5 µL DNAse I, at pH 8). Lysates were cleared by centrifugation (1
hour, 26200 rcf, 4º C) and filtered (borosilicate glass, 1 µm), before running over
Ni-NTA equilibrated with the appropriate lysis buffer. Columns were washed
with lysis buffer until a stable absorbance was detected and then eluted with
400 mM imidazole.
Nickel purified protein was then subjected to tag cleavage by Tobacco Etch
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Virus protease (TEV) or thrombin. Cleavage buffer conditions were either 20
mM HEPES, 40 mM NaCl, and 1 mM DTT at pH 8 (TEV) or 20 mM K2HPO4,
250 mM NaCl, 1 mM TCEP, and pH 8 (thrombin). TSG101cc and the GR NTD
constructs were next purified by anion exchange, and after overnight cleavage
their respective dialysis buffers were changed to 2% anion buffer B (20 mM
Tris, ∼20 mM NaCl, 5% glycerol, pH 8). Protein was then 0.2 µm filtered
and run on a 5 mL HiTrap Q column (General Electric) using a GE Äkta Pure
FPLC system. Neither anion nor cation exchange were effective for the NTD-
DBD constructs, so they were simply run over benzamidine-agarose and then
had PMSF (0.2 M in DMSO) added to 0.2 mM to remove thrombin and inhibit
protease activities, respectively. All constructs were then run back over Ni-
NTA that was equilibrated with 0 M imidazole, native buffer. Because the GR
constructs often had degradation products, I found that SEC was necessary for
reproducible results and the highest purity (Hiload 16/600 column packed with
Superdex pg-75 from GE; 20 mM HEPES, 200 mM NaCl, 1 mM TCEP at pH
7.2). Chromatography fractions were run on SDS-PAGE and stained using the
coomassie “silver” protocol Candiano2004. For experimentation, proteins were
dialysed overnight to their respective buffers (below). I must emphasize that
purification of the NTD-DBD construct of GR is not trivial and must be done
as quickly as possible to prevent oxidation and artifactual results, even in the
presence of TCEP.
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For fluorescence anisotropy of TSG101cc, a cysteine was engineered into the
expression tag (replacing a serine after the TEV site) and protein was labeled
with pyrene-iodoacetamide as described previously [438].
See Figure 4.2 for examples of GR and TSG101 protein purity.
4.3.3 Protease Protection, Cross-Linking, and Mass Spec-
trometry
Protease digestions were carried out in both the fluorescence anisotropy buffer
and the circular dichroism buffer (see below), with no observed differences.4
Saturation of GR required at least a thirty-fold excess of TSG101cc. To control for
the total amount of protein present in each digest, the ratio of trypsin and targeted
protein was held constant at 1000 µg protein : 1 µg trypsin, except where noted.
All digests occured at room temperature after allowing the protein solutions
at least 20 minutes to equilibrate. Each timepoint was taken by quenching an
aliqout of reaction in Laemli sample buffer and heating at 95º C for ∼5 minutes.
Three cross-linkers were tested as follows, with their linker lengths in paren-
theses: BS3 (11.4 Å), DST (6.4 Å), and EDC + sulfo-NHS (0 Å) from Thermo-
Scientific or ProteoChem. BS3 and EDC proved to be wholey unusable in these
circumstances, either because of too much or no cross-linking, respectively. The
4My anecdotal observations suggest that as long as a buffer has a somewhat low salt concen-
tration (< 200 mM) and a pH ∼7, binding of GR and TSG101cc can be observed.
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Figure 4.2 – GR and TSG101 Protein Purity
All of these gels were stained with coomassie and the images have been grayscaled to give better
contrast. NEB ladder marks are on the left of each image. Asterisks indicate fractions that were
taken for experimental analysis (ideally 90% purity or better). A) SEC of the A-NTD of GR on a 12%
PA gel. B) SEC of the C3-NTD of GR (left) and flow-thru from the 2nd pass of TSG101cc over Ni-NTA
(after tag removal). This is a 12% PA gel and TSG101cc runs with the loading dye. C) A 15% PA gel
overloaded with TSG101cc to show minor contaminants and the fact that TSG101cc runs slightly
high on gels (should be 9040 Da and actual mass is correct by MALDI). D) SEC fractions for the
A-DBD (left) and C3-DBD (right) of GR. More of the C3 fractions were run on the gel and the reader
will note highly degraded GR fragments left the SEC column after the main GR peak.
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rest of this manuscript only refers to DST cross-linking. The DST cross-linking
buffer was the same as the fluorescence anisotropy buffer (below). Initial reac-
tions were carried out according to the manufacturer protocols, but because
TSG101cc has a large number of lysines (11 out of 78 a.a.) I observed an exces-
sive amount of TSG101cc self cross-linking. After lowering the concentration
of DST to about one-sixth or one-twelfth the recommended amount (0.5 mM
used here) I was able to detect a GR—TSG101cc cross-link without TSG101cc
background.
All cross-linking lasted about 5 minutes at room temperature (∼20º C). After
quenching each cross-linking reaction with > 10 mM Tris for 15 minutes (1 M
stock at pH 7.5), each reaction was reduced with an excess of > 10 mM TCEP
for an hour (1 M stock with HEPES at neutral pH), and then cysteines were
alkylated with at least 10 mM iodoacetamide for an hour at room temperature
(freshly solubilized in experimental buffer and kept dark).
SDS-PAGE was used to separate products of protease protection and protein
cross-linking. After staining gels with coomassie [68], desired bands were cut
out and diced into ∼1 mm slices. A blank part of each gel was also cut out as
a negative control. Destaining was achieved with 50 mM NH4 HCO3 in 50%
acetonitrile for at least 30 minutes. Stain was discarded and the slices were
then desiccated with 100% acetonitrile for about 30 minutes. After removal of
acetonitrile solution, cold solutions of trypsin (6.25 ng/µL final; 0.1 µg/µL stock
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in 50 mM acetic acid) or trypsin + chymotrypsin (6.25 ng/µL final; 1 µg/µL stock
in 1 mM HCl) were diluted into 50 mM NH4 HCO3 and incubated with the gel
slices for an hour at 4º C. Before overnight incubation at 37º C, volumes were
adjusted with extra protease or 50 mM NH4 HCO3 to ensure complete liquid
coverage of the gel slices.
Digestions were mixed with α-cyano-4-hydroxycinnamic acid (CHCA) in 50%
acetonitrile with 0.5% tri-fluoro-acetic acid at ratios between 1 part digest : 1 to
4 parts CHCA. Protease protection digests were directly plated in this manner
for matrix assisted laser desorption ionization mass spectrometry (MALDI). To
increase signal from barely visible cross-link products, I extracted and vacu-
fuged the cross-linking digests. For extraction of gel slices, the supernatant
of each overnight digest was removed to a fresh lo-bind tube (Eppendorf), and
the gel slices were extracted for 15 minutes at 37º C with 67% acetonitrile and
1.7% formic acid (2 parts ACN : 1 part 5% FA). The tubes were then sonicated in
an ice bath, and the supernatants were combined and vacu-fuged until ∼20 µL
were left. Tubes were covered with perforated parafilm during vacu-fuging to
minimize any contamination.
MALDI mass spectrometry proceeded largely as described before [438]. A
Bruker AutoFlex III mass spectrometer was used in reflectron mode. The m/z val-
ues were standardized using the ProteoMass MALDI calibration kit (Sigma),
and further calibrated using TSG101 or GR peaks that were highly consis-
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tent. Cross-link ion masses were predicted given the following criteria: trypsin
and/or chymotrypsin were allowed to potentially miss up to five cut-sites and
carbamidomethylation (iodoacetamide) was left as a variable modification. Data
were also analyzed for up to three mono-links and any loop links, with only
TSG101cc reproducibly yielding a monolink (see Table 4.9 in Appendix). Data
were hand curated and compared to the following negative controls: a blank
piece of gel (also received proteases), DST reacted TSG101cc and its oligomeric
cross-links, DST reacted C3-NTD, unreacted C3-NTD, and unreacted TSG101cc.
4.3.4 Fluorescence Anisotropy
Preliminary experiments used a variety of buffers, and to enable experiments
involving the addition of DNA, the following buffer was used for all fluorescence
anisotropy experiments shown here: 13.2 mM HEPES, 16 mM K Acetate, 67.2
mM NaCl, 4.2 mM MgCl2, and 0.84 mM TCEP all pH’d to 7.56 using 10 M
KOH. It is difficult to purify large amounts of any GR construct that includes
the disordered NTD. In order to maximize the high concentration end of my
experiments, all the titrations presented here are dilution experiments: The
fluorophore (pyrene-TSG101cc or 6FAM-DNA) was diluted into a concentrated
solution of GR and the GR was then diluted out with a solution of fluorophore,
with the concentration of fluorophore being kept the same throughout. The
dilution solution was actively held at 20º C during the experiments to prevent
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thermal disequilibrium.
All experiments were at the very least duplicated with independent protein
preparations, and all replicate data sets were fit globally to produce the presented
values. Equilibration times were varied to check for thermodynamic equilibrium,
and because no obvious effects were discerned from 1 to∼30minutes, most of the
data presented were collected with 2 minute incubations between measurements.
The only sensitive incubation step was the first one, which needed to be about
20 minutes long to establish thermal equilibrium.
Fluorescence anisotropy of pyrene-labeled TSG101cc (always at 76 nM) was
obtained with a SLM-Aminco SLM-48000S spectrofluorometer at 20º C. Samples
were placed in a 1 cm, square quartz cuvette with a stir bar and excited at 345 nm
with a 4 nm bandwidth. Emission was detected at 377 nm with a 8 nm bandwidth
and 25 averages per measurement.
GR usually forms dimers on DNA by binding adjacent sites [263]. Such DNA
elements are called GR response elements (GRE). For anisotropy of 6-FAM DNA,
I used both the canonical GRE and a half-site DNA (single GR binding site).
The canonical GRE used was: 5’ 6-FAM-TGCCAGAACAGAGTGTTCTGACG 3’
and its unlabeled reverse complement [163] (ordered from IDT). The individual
GR binding sites are highlighted in bold font. The GR half-site DNA was: 5’ 6-
FAM-CGGCAGAACAGGACGCG 3’ and its reverse complement. Both constructs
were annealed at 50 µM using the IDT annealing buffer (100 mM K Acetate, 30
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mM HEPES at pH 7.5) and heating at 95º C for 1 minute followed by bench-top
cooling for 1 hour.
Fluorescence anisotropy of 6-FAM labeled DNA (always at 10 nM) was ob-
tained with an Aviv spectrofluorometer at 20º C. Samples were placed in a Starna
sub-micro cuvette (cat. no. 16.100F-Q-10/Z15). Excitation was at 496 nm with
a bandwidth of 5 nm, and emission was observed at four wavelengths (524,
520, 516, and 514 nm) with a bandwidth of 4 nm and 5 seconds of averaging.
Anisotropies from the four emission wavelengths were averaged for final data
analysis. Data were fit using equations of the following form:
< α >= (a + b ∗ ln[GR]) ∗ PBound (GR) + (c + d ∗ ln[GR]) ∗ PUnbound (GR) (4.1)
where < α > is the experimental observable, “a, b, c, d ” are all parameters dictat-
ing the anisotropy baselines, and P is the probability of some listed state as a
function of GR concentration (note that PUnbound = (1 – PBound )). In all fitting,
the goal was to minimize systematic residuals, without overfitting the data. For
this reason, if logarithmic baselines did not improve the fit greatly or caused
obvious overfitting, the b and/or d parameters were set to zero.
Derivation of the PBound proceeded from first principles. Several potential
derivations (single-site, two-site independent or dependent, etc.) were used to
test each data set’s compliance with the proposed binding mechanism. Only
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the equations used are discussed here. In the ideal case, the fluorophore being
observed is at a concentration much less than the Kd value. This was the case
for binding of pyrene-TSG101cc to the GR NTD. Thus:
PBound =
GR/ Kd
1 + GR/ Kd
(4.2)
where GR is assumed to be the total concentration of GR in molar and the
denominator is the partition function.
For binding of GR NTD-DBD constructs to the full-length GRE, the GRE was
often at concentrations close to the apparent Kd. For this reason, all fitting
of 6FAM-GRE data, both full and half-site, was done with the full polynomials
describing binding as a function of both GR and GRE. For the half-site GRE, the
single site binding equation is:
PBound =
GR + GRE +Kd –
√
(GR + GRE +Kd )
2 – 4 ∗ GR ∗ GRE
2 ∗ GRE
(4.3)
where GRE is the total concentration of GRE in molar.
Binding of GR to the full GRE is a two-site binding problem. It was found that
any equation including a singly bound GRE would produce wild aberrations in
the fits; thus, singly bound GRE does not exist at equilibrium and was excluded
from the fitting equation. This is the definition of an all-or-none binding process
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GREtotal = GREunbound + GRExGR2
GRtotal = GRunbound + 2 ∗ (GRExGR2)
Substitute into Kd and solve for the bound complex concentration (GRExGR2).
0 = (GREtotal – GRExGR2) ∗ (GRtotal – 2 ∗GRExGR2)
2 – GRExGR2 ∗Kd (4.4)
Solve for the positive, real root of Equation (4.4) to get GRExGR2, then divide
by the total concentration of GRE to get the probability of GRE bound, shown
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4.3.5 Circular Dichroism (CD)
Proteins were dialysed to Na2HPO4 and 50 mM NaCl at pH 7.4, and all CD
was done with an Aviv CD spectrophotometer and a 1 mm path-length, quartz
cuvette. Constant temperature experiments were done at 25º C, and spectra
were recorded in 1 nm steps with a 1 nm bandwidth and 5 seconds of averaging.
A series of Python scripts were written to deconvolve individual data sets. The
scripts subtracted buffer signal, removed data with a high dynode voltage (>
600.5), and converted data to units of molar residue ellipticity (for scripts see
appendix). The molar residue ellipticity of protein mixtures was calculated using:
millidegrees observed in mix – protein A alone – protein B alone – buffer
[Protein A] ∗ (length of A – 1) + [Protein B] ∗ (length of B – 1)
(4.6)
where proteins “A” and “B” are arbitrary names, square brackets “[ ]” indicate
concentration, and the protein length is in amino acid residues.
4.3.6 Single Molecule Force Spectroscopy
All single molecule constructs were labeled with biotin and an oligonucleotide-
CoA modification by methods previously published [189,252,290,452]. In brief,
oligonucleotides from IDT were annealed on a thermocycler (70ºC for 10 minutes,
95º C for 2 minutes, then down to 4º C in 0.1º per second steps). The double
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stranded oligo-CoA and biotin were then covalently linked to the my protein
constructs by Sfp and BirA, respectively (15 µM of target protein and oligo,
30 µM of each enzyme). Labeling was checked by SDS-PAGE. The day before
each experiment, oligo-labeled protein was ligated to complementary ∼2.8 µm
polystyrene beads, overnight at 15º C, forming a 50 base pair DNA “handle.”
The opposing polystyrene beads were ligated to 1.8 kilo-base pair DNA that has
a biotin-streptavidin on the aqueous end, which binds the biotin of the protein
construct. During single molecule experiments, the microfluidics chamber was
filled with either buffer alone (100 mM Tris base, 80 mM NaCl, 50 mM arginine
HCl at pH 7.4) or buffer plus TSG101cc (a.a. 229—304).
All experiments were of the constant velocity variety. Force was increased
from ∼2 pN to 40 or as much as 60 pN to confirm single molecule character
(DNA overstretch). Multiple refolding times were tested, from 0 to 30 seconds,
and multiple concentrations of TSG101cc were tested, from 1 to 20.5 µM.
4.3.7 Cell Culture
U2-osteosarcoma cells (U2OS) were maintained in McCoy’s 5A medium, supple-
mented with 10% fetal bovine serum and antibiotics (streptomycin and penicillin).
Cells were grown at 37º C in a 5% CO2 atmosphere and the medium was changed
every 2–3 days until passaging. Trypsin with EDTA was used for detaching cells
during passaging. For transfection, cells were plated at a density of 30000 cells
127
CHAPTER 4. THE TUMOR SUSCEPTIBILITY GENE-101 COILED-COIL BINDS
AND ALLOSTERICALLY REGULATES THE GLUCOCORTICOID RECEPTOR
per well on 96-well plates or 300000 cells per well on 6-well plates and grown to
∼90% confluence before transfecting. Xtreme GENE HP (Roche) was used to
transfect DNA per the manufacturer directions.
4.3.7.1 Luciferase Assays
Most luciferase assays were done using 96-well plates, except comparison of
TSG101 mutants proceeded by 6-well plates. The NEB Gaussia and Cypridina
plasmids were used at 40 ng each per well for each 96-well assay (or ten times as
much for 6-well plates). Two GR response elements were cloned into the promoter
of the Gaussia plasmid and the Cypridina plasmid served as a control [243]. GR
expression plasmids were transfected at 0.6 ng per well and TSG101 plasmids
were transfected from 0 up to 9.4 ng per well, with the empty pJ603 plasmid
balancing the total transfection to 10 ng of pJ603 DNA (96-well plates).
4.3.7.2 Confocal Microscopy
Cells were passaged onto German cover slips in 6-well plates. For the immunos-
taining data, there were two transfection procedures, both using 300000 cells
per well. The first addressed whether or not TSG101 is in the nucleus of U2OS
cells, with or without GR. Each pJ603 plasmid (TSG101 and/or GR) was trans-
fected at 100 ng and sonicated salmon sperm DNA was used to bring the total
amount of DNA to 1000 ng per well, and the cells were fixed about 40 hours
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after transfection. The second procedure addressed how TSG101 localization
changes in response to the luciferase assay conditions, over time. Transfection
proceeded in the exact same manner as with luciferase assays, except with a
total of 500 ng of DNA per well (10x that used on 96-well plates). Cells were
then collected for fixation 16 or 40 hours later.
TSG101-tdTom was used as an alternative verification that TSG101 is in U2OS
cell nuclei. For expression of TSG101-tdTom, 100000 cells were passaged and
the expression plasmid was transfected at 15 ng per well and sonicated salmon
sperm DNA was used to bring the total DNA amount per well to 500 ng. The
TSG101-tdTom cells were fixed ∼24 hours after transfection.
All immunostaining was done at room temperature. Cells were washed thrice
with PBS+2 mM MgCl2 (PBSM), fixed with 4% PFA for 10 minutes, and washed
thrice again with PBSM. The PFA was quenched for 10 minutes using 50 mM
NH4Cl in PBSM. Parafilm was stretched across the bench, and the cover slips
were set cell-side up on top of the parafilm. The top of the cell culture plate was
used to cover the slides and make a humid chamber.
The cells were permeabilized and DNA was first stained for 30 minutes with
150 µL of: PBS, 0.1% TX-100, 1% BSA, 0.5 µg/mL DAPI. Then the cover slips were
incubated for one hour with primary antibody at a 1:500 dilution (GR primary
was rabbit mAb from Cell Signaling D8H2; TSG101 primary was mouse mAb
from GeneTex 4A10). The cover slips were washed thrice for five minutes with
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PBSM and incubated with secondary antibody at a 1:600 dilution for 30 minutes
in the dark. The GR secondary was Life Technologies A11034 (goat anti-rabbit),
labeled with Alexa Fluor-488, and the TSG101 secondary was Cell Signaling
8890S (goat anti-mouse), labeled with Alexa Fluor-594. Cover slips were then
washed thrice for five minutes with PBSM. All antibody dilutions were made
using the aforementioned DAPI solution. Cells expressing TSG101-tdTom were
DAPI stained as above, without the antibody steps. The cover slips were mounted
using flouromount (Sigma).
All microscopy was done using the Integrated Imaging Center of Johns Hop-
kins University. The data shown were collected using either a Zeiss LSM 700
(immunostaining) or 780 (TSG101-tdTom) confocal microscope. DAPI was ex-
cited with a 405 nm diode laser, AlexaFluor 488 (GR) was excited with a 488
nm laser, and both AlexaFluor 594 and tdTom (TSG101) were excited with a 561
nm laser. All imaging was done at either 400x or 630x magnification. The gain
and digital offset were optimized for the best signal-to-noise in each image; thus,
the absolute intensities are not necessarily comparable. Analysis of images was
done using the Fiji version of ImageJ [356,357].
4.3.7.3 W-blots
Transfections were similar to the luciferase assays, except always on 6-well plates.
Cells were collected by removing medium, washing with PBS, and scraping cells
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off the bottom. After pelleting the cells by centrifugation (194 rcf, one minute),
the cells were lysed using Cell Signaling Technology’s lysis buffer supplemented
with 350 mM NaCl. A 26 gauge needle was used to break apart the cells by
rapid plunging. The lysate was cleared by centrifugation at 16873 rcf for 30
minutes. Total protein content of the supernatant was measured by Bradford
assay, with BSA as a standard (BioRad), and this was used to normalize the
amount of total protein loaded in each lane of a 4–15% Mini-PROTEAN TGX
precast gel (BioRad). A fluorescent ladder was used to detect transfer efficiency
and estimate molecular weights (Spectra multi-color, Thermo).
After running SDS-PAGE to completion, gels were transferred to methanol-
activated PVDF membranes (low-autofluorescence, BioRad) at 100 V for 25
minutes on ice. Blots were then cut horizontally along the 95 kDa ladder mark
so P150 (loading control) could be blotted separately from TSG101 and GR. All
blocking was done at room temperature for 30 minutes, using ∼4% non-fat dry
milk in PBS that was cleared for five minutes by centrifugation.Blots were then
washed thrice for 5 minutes with PBS+0.1% Tween-20 (PBST) before incubation
with primary antibodies. The primary and secondary antibodies for GR and
TSG101 were the same as the ones used for microscopy. The P150 antibody is a
mouse mAb from BD Biosciences (#610473) and the TSG101 secondary was used
to label P150 (anti-mouse Cell Signaling 8890S). Primary antibody incubations
were overnight at 4º C in PBST with 1–4% milk (no difference observed). Primary
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antibody dilutions were 1:5000 (P150), 1:2000 (TSG101), and 1:2000–4000 (GR,
no difference observed). Blots were washed thrice for 5 minutes with PBST
before incubating at room temperature with secondary antibodies in PBST with
1–4% milk (1:5000 P150, 1:5000–6000 GR, 1:2000–5000 TSG101; TSG101 was
difficult to perceive by naked eye with a 5000 fold dilution, but was detectable).
Blots were washed thrice for five minutes with PBST and excess liquid was gently
drained before letting the blots dry in the dark.
Imaging of the fluorescent blots was acheived with a FluorChem from Protein
Simple (generously shared by Prof. Wendland at Johns Hopkins). To analyze
the images, I first normalized signal in each lane to its loading control, then
normalized signal of each protein to its signal with 0 ng of TSG101 transfected. In
this way, blot-to-blot variations in absolute signal were minimized and I compared
only relative changes.
4.4 Results
4.4.1 TSG101cc Binds the NTD of GR
4.4.1.1 Protease Protection
A yeast two-hybrid study indicated that the coiled-coil of TSG101 (TSG101cc)
bound a region of GR’s disordered N-terminus, called the Activation Function-1
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(AF1), close to the C3-NTD start site [153]. I first sought to confirm the binding
of these proteins in vitro and in the process also verify the proposed binding
site on GR. Disordered proteins, such as the GR NTD, will rapidly degrade in the
presence of trypsin; however, binding partners can protect disordered proteins
from degradation [219,338]. The mechanism appears to be coupled binding and
folding, as discussed later in this chapter and by others [216,217,219,242,338].
In Figure 4.3 I digested either the A- or C3-NTD of GR in the presence or
absence of TSG101cc (see controls in Figure 4.4). By mass spectroscopy, I was
able to reproducibly observe fragments left by C3-NTD, and this is shown in
part B of Figure 4.3 (raw data in Figure 4.5). Note that the protected fragment
observed here, matches the bait used by others in a yeast two-hybrid [153].
MALDI of the A-NTD fragments was attempted multiple times, but did not yield
a strong signal; nonetheless, the gels indicate that the same region of the NTD
seems to be protected by TSG101cc in both the A- and C3-NTD. In both cases,
the presence of TSG101cc protected a series of fragments between about 14.8
to 20.9 kDa in size. This contrasts with the 9.1 kDa long fragment I actually
observed by mass spectroscopy of the protected bands (Figure 4.3B), and I am
likely missing some ions in this experiment (see cross-linking below).
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Using a constant 1:1000 μg of trypsin
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Figure 4.3 – TSG101cc Protects the N-terminus of GR from Protease Digestion
Both gels shown here were coomassie stained. A) Digestion of the C3-NTD alone (left) produces no
specific fragments. Addition of TSG101cc and more trypsin (right side, using a constant trypsin:target
ratio) causes formation of a protected fragment. B) Results of MALDI mass spectrometry of bands
cut from a gel, as shown in part A, and fully trypsinized overnight. Possible fragments are shown at
the top with trypsin cut sites (Arg or Lys) as black bars. The next two sets of boxes represent the
fragments actually observed for full-length C3-NTD and the protected band, respectively. The box at
the bottom represents the sequence used as bait in the yeast two-hybrid by Hittelman et al. [153]. C)
A trypsin digestion gel, as in part A, except using the A-NTD of GR.
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Figure 4.4 – Control Trypsin Digests
Coomassie stained gels are shown: A) Protein was digested as in Figure 4.3. In the BSA control, the
arrow indicates a possible GR fragment that disappears by 30 minutes (compare to BSA alone). The
dashed circles indicate bands that were cut out and fully trypsinized for MALDI shown in Figure 4.5
parts A and B. Note the formation of an upshifted TSG101cc digestion product (see Figure 4.5B).
B) C3-NTD was digested alone with the same ratio of trypsin that was used in the presence of
TSG101cc in part A of Figure 4.3. The dashed line and circle indicate where the protected fragment
was previously (∼19 kDa).
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A B
C D
Figure 4.5 – Mass Spectrometry of Protease Protection Assays
X and Y axes are the same units for all the plots. Ions are labeled with green circles for those consistent
with C3-NTD and purple circles for those consistent with TSG101cc. Note that some peaks in part D
are ambiguous and were excluded from Figure 4.3B. A) The undigested TSG101cc band, running at
∼9 kDa in SDS-PAGE (see Figure 4.4). B) The digested TSG101cc band running close to 19 kDa
produces ions consistent with at least a.a. 1—66 (also see Figure 4.4). C) The undigested C3-NTD
band (Figure 4.3A). D) The band protected in the C3-NTD + TSG101cc experiment (Figure 4.3).
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4.4.1.2 Cross-linking
Cross-linking of proteins can reveal the overall structural organization or even a
low-resolution structure [18,454]. Using cross-links as constraints in ROSETTA
has even been used to aid de novo structure prediction [146, 188]. By using
cross-linkers with multiple lengths, one can build a robust list of constraints.
Here I tested three cross-linkers for TSG101cc and the C3-NTD, but BS3 was
overly effective at cross-linking and EDC yielded no cross-links (11.4 Å and zero-
length cross-linkers, data not shown). Under carefully constrained conditions,
DST produced a single TSG101cc–C3-NTD cross-link without a large amount of
background (Figure 4.6). In support of the band being an oligomer of TSG101
and GR, ions indicative of both species were present in mass spectrometry
(Figure 4.6B). The data also contain several cross-link ions, shown in Figure 4.6B
and in cartoon schematic in Figure 4.7. In the previous section I showed that
TSG101cc protects a fragment of C3-NTD that may be as large as 20.9 kDa by
SDS-PAGE. Combining the mass spectrometry results of the protease protection
and the cross-linking studies shown here yields a ∼19 kDa stretch of the C3-NTD.
Based on these observations, I propose that GR and TSG101 form a pseudo-
trimer, namely the GR NTD wraps back on the TSG101cc in a manner reminiscent
of the ESCRT-I coiled-coil [212] (Figure 4.7). This would likely satisfy the hy-
drophobicity of the TSG101cc, a requirement for a stable oligomer of TSG101cc
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as I showed previously [438]. The exact alignment of the binding is unclear, but
it would likely leave the TATA-binding protein (TBP) site on GR open to bind TBP
and TSG101’s N-terminus would likely face the ubiquitination site of GR (close
to the DBD [424]). Others have shown that TSG101 can stabilize the monoubiq-
uitinated forms of androgen receptor and the E3 ligase MDM2 [63, 245]. My
tentative model would allow for a similar interaction in GR.
4.4.2 Binding of the GR NTD and TSG101cc is Coupled to
Conformational Change
Several studies have shown that when transcriptional cofactors bind the disor-
dered GR NTD, they do not simply occlude the NTD from solvent and protect it
from proteases. Instead, transcriptional cofactors bind and fold the disordered
NTD of GR [201,216,219], and this seems to be a general property of cofactor
binding to the NTD’s of many steroid hormone receptors [217, 430]. Here I
tested whether TSG101cc can promote the folding of the GR-NTD. I used circu-
lar dichroism (CD) and single molecule force spectroscopy (SMFS, colloquially
called optical tweezers). Under ideal conditions these techniques yield quan-
titative data [201,252]. Due to experimental circumstances, my data are of a
more qualitative variety, but nonetheless support folding of GR when it binds
TSG101cc.
I first used CD to measure the folding of GR. It must be noted that CD will
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Figure 4.6 – Cross-Linking of C3-NTD and TSG101cc
A) An example SDS-PAGE of my DST cross-linking reactions is shown with coomassie staining.
The GRxTSG101 cross-link was barely visible by eye and the contrast of the whole image has been
heavily shifted to make it visible in the image for the reader. The DST samples were loaded in
triplicate. TSG101cc cross-links with itself, forming the homotetramer I recently reported [438] (1x, 2x,
3x, 4x are the oligomeric cross-links). The C3-NTD—TSG101cc cross-link has a “X” directly above it.
Because the gel is overloaded, it is difficult to tell the molecular weight of the cross-link, but it appears
to be∼9 kDa larger than C3-NTD—consistent with a C3-NTDxTSG101cc heterodimer. Blue boxes
indicate the bands/controls cut out for MALDI. B) An example MALDI dataset of a cross-linked band
that was treated with both trypsin and chymotrypsin. Ions are labeled with colored circles as follows:
green = C3-NTD, purple = TSG101cc, orange = cross-link.
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Figure 4.7 – Cross-Linking Results and Speculative Model
All boxes in the main figure are scaled and positioned relative to the respective protein’s full-length
sequence. The white boxes represent the GR and TSG101 constructs used for cross-linking and the
lines between them are the cross-links discovered. The cross-linker is amine reactive and amines
are shown as blue dots (lysines or N-termini). The blue box is in reference to Figure 4.3 and the
red box at the top is in reference to the literature [11]. Inset: A tentative model of the structural
organization of the heterodimer, based on the evidence presented here. Colored boxes are as in the
main figure, but note that the protected region (blue, 86 a.a.) is slightly longer than the TSG101cc (76
a.a.). The TSG101 coil is in gray and the cross-linked lysines are shown as blue dots with lines going
roughly to the appropriate spot on GR (alignment unclear). One cross-link was ambiguous because
of adjacent lysines—it is indicated by a dashed circle. The black spheres “N” and “C” indicate N and
C-termini. Note that the TSG101 N-termius is pointed in the direction of the rest of the GR protein.
This allows for the possibility that TSG101’s UEV domain could bind the ubiquitin that GR receives
close to the DBD [424].
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Figure 4.8 – CD Reveals a Structural Change in Binding of TSG101cc and the C3-NTD
A small loss of helicity is observed when mixing 6 μM C3-NTD with 10 μM TSG101cc. This suggests
that upon binding GR, this construct of TSG101cc does not regain all the helicity present in the
TSG101cc homotetramer. This is nonetheless indicative of binding.
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actually report on structural changes in both GR and TSG101, and only by
saturating the system with one or the other can the actual change in structure
be extracted. Saturating the GR NTD with TSG101cc was not possible in CD
without saturating the dynode voltage; thus, the CD data are approximations of
the structural changes. I was able to strengthen the signal from CD by using a
longer TSG101cc construct that was shown to bind GR in a yeast two-hybrid [153].
Please note that this is the only section that makes use of this longer TSG101cc
construct, TSG101cc229-339 (a.a. 229—339). Otherwise, the rest of this chapter
uses the shorter construct because of higher yields from E. coli.
Both TSG101cc constructs produced structural changes in the presence of
C3-NTD ( and Figure 4.9). The TSG101cc229-304 construct appears to lose a small
amount of helicity upon binding GR Figure 4.8. This suggests that the GR-bound
complex contains slightly less structure than the TSG101cc homotetramer. In
contrast, TSG101cc229-339 produced a large increase in helicity upon mixing
with the C3-NTD (perhaps ∼36 a.a. of α-helix [132]), but not with my negative
control, the AF1 core that binds TBP. The TSG101cc229-339 extends partly into
the Steadiness domain of TSG101 and is less ordered than the TSG101cc229-304
construct. It is possible that binding of TSG101cc229-339 and C3-NTD folds both
proteins to some degree.
To directly measure folding of the GR NTD, I used SMFS. As shown in Fig-
ure 4.10, in the presence of TSG101cc, I was able to observe unfolding transitions
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Figure 4.9 – CD Reveals a Structural Change in Binding of TSG101cc and the C3-NTD
The data here used a longer TSG101cc construct (a.a. 229—339) than elsewhere in this chapter. It is
the same as was used in a yeast two-hybrid of TSG101 and GR [153]. A)Mixing the TSG101cc229-339
with the C3-NTD of GR, but not the AF1 core, produces an excess dichroism (C3-NTD = 3 μM,
TSG101cc229-339 = 20 μM, AF1 core = 58.4 μM shown here). See B) and C) for the raw data. The
data in A are replotted as solid black lines in B and C for comparison. The gain in helicity seen in
part A is equivalent to ∼36 a.a. folding into α-helix [132].
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Figure 4.10 – TSG101cc can Fold the N-terminus of GR
The data are offset on the x-axis for visual purposes. Unfolding and folding transitions are highlighted
with arrowheads facing down or up, respectively. A) Force ramp data of the C3-NTD in the presence
of 10 μM TSG101cc. The inset graphic is a zoom in of the low force regime for the first trace. B)
Force ramp data of AF1107-237 in the presence of 10 μM TSG101cc.
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of both the C3-NTD and the AF1 construct used in a yeast two-hybrid of TSG101
and GR, AF1107-237 [153]. Without TSG101cc present, I observed only one
transition of a confirmed single molecule of GR (Table 4.2). It must be noted
that SMFS can produce artifacts from non-specific adsorptions (Prof. C. Kaiser
communication). However, I observed no transitions of my AF1 core construct,
with or without TSG101cc (Figure 4.11). This suggests that TSG101cc alone
cannot create the transitions I observed and supports my hypothesis that these













AF1 core 8 46 0 0
AF1 core
+ TSG101cc
9 84 0 0
C3-NTD 8 33 1 (13%) 1 (3% of pulls)
C3-NTD
+ TSG101cc
28 246 13 (46%) 63 (25%)
AF1107-237 5 40 0 0
AF1107-237
+TSG101cc
10 83 3 (33%) 16 (13%)
Table 4.2 – Compilation of SMFS results
Addition of TSG101cc to the buffer produced transitions in the C3-NTD and AF1107-237.
Normally, when collecting SMFS data, one wishes to collect thousands of
transitions in order to access quantitative analyses [98, 266]. Because GR’s
NTD is normally unfolded, my default measurement state is essentially void of
transitions. My hypothesis is that only by random chance of TSG101cc binding
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AF1 core + TSG101cc
Figure 4.11 – Transitions Seen in SMFS Depend Upon the TSG101cc Binding Site of GR
Representative data are presented with individual traces offset on the x-axis for visual purposes. A)
and B) are data for the AF1 core (binds TBP, not TSG101cc) without or with 10 μM TSG101cc. C)
and D) are control data for C3-NTD and the AF1107-237, respectively.
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GR, do I see transitions. This has resulted in amuch lower experimental yield than
usual (Table 4.2), and as such I cannot make quantitative statements about these
folding events. Figure 4.23 in the Appendix provides a graph of my observed
contour lengths, which were all less than the length of the C3-NTD.
4.4.3 TSG101cc Allosterically Promotes DNA-Binding of GR
Our previous work showed that the C3 isoform is more stable than the A isoform
because of the destabilizing R-region in the A isoform [242]. Because it would
cost less energy to fold the C3 NTD, I predicted that transcriptional cofactors,
namely TSG101cc, would bind C3 better than A. To measure the binding of GR
and TSG101cc I labeled the TSG101cc with pyrene, as described before [438],
and observed fluoresence anisotropy of pyrene-TSG101cc as I titrated an NTD
isoform out of solution. As seen in Figure 4.12A, the A and C3 isoforms of GR
bind TSG101cc equally well with a Kd of about 20 µM (see Table 4.3 for the fitted
values). Though my hypothesis proved false for TSG101 (see Discussion), the
two proteins do bind and I decided to proceed with other tests of this interaction.
Numerous labs working with different steroid hormone receptors have shown
that binding DNA causes a conformational change in these proteins, often stabi-
lizing their N-terminal domains [28,29,58,131,167,215]. Thermodynamics is
a two-way street and I hypothesized that if binding DNA can stabilize a struc-
tured state of the NTD, then the NTD binding TSG101cc should promote DNA-
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binding [75,403]. If not, then TSG101 is unlikely to be directly involved in the
transcriptional functions of GR, and may only have an indirect effect through
regulation of GR degradation and/or post-translational modification [299]. As
seen in Figure 4.12B and Table 4.3, binding of TSG101cc promotes full-length
GRE-binding of both the A and C3 isoforms of GR. This is a decidedly allosteric
effect, as TSG101cc itself does not bind DNA (see the unbound baselines of the
raw data in Appendix, Figure 4.25)
A B
Figure 4.12 – Quantitative Binding of TSG101cc to GR
All of the data shown here are from fluorescence anisotropy that was globally fit and then converted
to mole fraction bound. See Table 4.3. A) Fluorescence anisotropy of pyrene labeled TSG101cc
was observed while titrating one of the NTD isoforms listed. The data were fit to a single-site binding
model. B) Fluorescence anisotropy of 6FAM-labeled GRE or GRE half-site binding to the listed
NTD-DBD isoforms of GR, in the presence or absence of 100 μM TSG101cc. The DNA element
used for each data set is indicated by the cartoon of GR DBD (blue) binding DNA as a dimer or
monomer [263]. The GRE half-site data were fit to a single site binding model. The full GRE data
could only be fit using an all-or-none, two-site binding model.
TSG101cc stabilizing GR’s binding of DNA is itself interesting, but the full-
length GRE hides the underlying mechanism of the allostery. To give mechanistic
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GR TSG101cc 6FAM-GRE Kd
A-NTD + pyrene N/A 20.9 ± 4.7 µM (3)
C3-NTD + pyrene N/A 19.6 ± 1.0 µM (3)
A-NTD-DBD – Half 1.33 ± 0.12 µM (3)
A-NTD-DBD + Half 2.05 ± 0.37 µM (2)
A-NTD-DBD – Full 201.9 ± 8.6 nM (3)
A-NTD-DBD + Full 98.3 ± 8.9 nM (3)
C3-NTD-DBD – Half 1.58 ± 0.68 µM (4)
C3-NTD-DBD + Half 0.599 ± 0.114 µM (2)
C3-NTD-DBD – Full 228.5 ± 11.8 nM (3)
C3-NTD-DBD + Full 59.9 ± 4.9 nM (2)
Table 4.3 – Table of Fitted Binding Constants
The first two rows refer to binding of GR and TSG101cc in Figure 4.12A and the rest of the table
refers to binding of GR and DNA in Figure 4.12B. Parentheses next to the fitted Kd’s indicate the
number of data sets that were globally fit. For the A and C3 isoforms of GR respectively, TSG101cc
induces a –419.2 and –779.8 cal/mol shift in binding to the full GRE, and a +252 and –565 cal/mol
shift in binding to the half-site GRE.
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insight to this work, I next measured the same DNA-binding effect except with
the GRE half-site. This is DNA that has only one GR binding site on it, illustrated
in the lower right of Figure 4.12B. If TSG101cc stabilizes the dimerization of
GR monomers, using a GRE half-site will ablate that possibility, resulting in
no change or perhaps a loss of binding with TSG101cc present. Alternatively,
TSG101cc may allosterically promote a DNA-binding conformation of the DBD.
Given a ∼1 kcal/mol shift in binding for the full GRE (C3 NTD-DBD ± TSG101cc),
I expected a ∼0.5 kcal/mol shift in binding for the half-site GRE. This is indeed
what I observed for the C3 NTD-DBD construct, but not the A NTD-DBD construct.
Thus, it appears that the A and C3 isoforms use different allosteric mechanisms
to govern DNA-binding (see Discussion).
4.4.4 TSG101 Localizes to the Nuclei of U2OS Cells
The Hilser lab uses U2OS cells because they normally do not express GR, thereby
giving us a blank slate on which to express just one GR isoform. Unfortunately,
the author is unaware of literature describing TSG101 localization in U2OS cells.
Before determining how TSG101 affects GR’s activity inside live cells, I needed
to verify literature reports that TSG101 can localize to the nucleus of several
other cell lines [63,74,293,449,459]. Shown in Figure 4.13 I transfected U2OS
cells with plasmids expressing an NTD-DBD isoform of GR and/or the full-length
TSG101 (used in vivo except where noted). TSG101 localizes to the nuclei
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endogenously and when overexpressed in these conditions, regardless of the
expression of GR. Similar results were obtained when overexpressing a tdTom
tagged version of TSG101 (Figure 4.14).
The above microscopy experiments used transfection methods slightly dif-
ferent frommy luciferase assays, below. To control for any effects of the luciferase
assay conditions, I also transfected cells with the full luciferase assay complement
(Gaussia and Cypridina luciferases, a GR isoform, TSG101). As shown in
Figure 4.15 and Figure 4.16, a cytosolic aberration appears about 40 hours
post-transfection in the group with the highest amount of TSG101 plasmid.
This coincided with cell death, as seen by floating cells in the associated wells.
Overexpression of TSG101 previously caused both of these effects in literature
data [127,459]. My analysis of TSG101’s nuclear localization indicates that at
high expression levels, TSG101 appears to saturate its nuclear binding sites and
spills over to cytosolic sites (Figure 4.17).
I sometimes observed repression of GR’s transcriptional activity at longer post-
transfection times, possibly because of these artifacts. To avoid these problems
my luciferase measurements (below) were taken 40 hours post-transfection or
earlier. Because both of my luciferases are constitutively excreted, my luciferase
measurements are largely a time average of everything occurring before the
shown artifact.
151
CHAPTER 4. THE TUMOR SUSCEPTIBILITY GENE-101 COILED-COIL BINDS
AND ALLOSTERICALLY REGULATES THE GLUCOCORTICOID RECEPTOR
Figure 4.13 – TSG101 Localizes to U2OS Nuclei
The expression plasmids transfected are on the left of each image series. In order to view the GR
channel of cells without a GR expression plasmid, the microscope gain had to be increased about
1.4 fold. All scale bars are 25 μm. GR and TSG101 were detected by immunostaining.
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Figure 4.14 – TSG101-tdTom Localizes to U2OS Nuclei
Two example image sets are shown to give the reader a sense of the variability in the data set. All
scale bars are 20 μm.
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Figure 4.15 – Overexpression of TSG101 for 16 Hours
The left hand side describes the amount of TSG101 plasmid transfected. All scale bars are 20 μm.
GR and TSG101 were detected by immunostaining. All cells were transfected with a constant 6 ng
of C3 NTD-DBD plasmid.
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Figure 4.16 – Overexpression of TSG101 Eventually Causes Endosomal Enlargement
The same experiment as in Figure 4.15, except 40 hours post-transfection. All scale bars are 20
μm. Note that the bottom set of images has been zoomed in on one cell to highlight the endosomal
enlargement (arrowhead).
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Figure 4.17 – Localization of GR and TSG101
Cells from the Figure 4.15 data set that coexpressed C3 NTD-DBD and TSG101 were analyzed
using Fiji. Error bars are 95% confidence intervals. Statistical significance was determined by a
Tukey HSD test in R: NS = not significant, ∼* P ≈0.05, * P < 0.05. A GR has a constant and high
nuclear localization. B TSG101 saturates its nuclear localization at high expression levels. Note that
the y-axis is not in absolute but relative units.
4.4.5 TSG101 Can Increase the Transcriptional Activity of
GR
Seen in Figure 4.18 transfection of increasing amounts of TSG101 plasmid in-
creased the transcriptional activity of the active isoforms of GR (A—C3NTD-DBD).
The inactive isoforms (D1—D3 NTD-DBD) and TSG101 alone cannot activate
expression of Gaussia luciferase. Note that the inactive isoforms of GR lack
the region that binds TSG101cc and other cofactors; thus the observed effects
depend on GR’s innate transcriptional activity and its ability to bind TSG101cc.
To test this further, I made two mutant TSG101 constructs: a coiled-coil deletion
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(TSG101Δcc) or the coiled-coil on its own (TSG101cc).
The TSG101cc was sufficient to cause activation of either the A or C3 NTD-
DBD isoforms of GR, while deletion of the coiled-coil ablated the effect (Fig-
ure 4.19). However, the effect of TSG101cc is much weaker than the full-length
TSG101, and the activation shown in Figure 4.19 was observed in 2 out of 3 and
4 out of 5 replicates with the A and C3 isoforms of GR, respectively. I speculate
that the TSG101cc likely acts to initially assemble a TSG101 transcriptional
complex, but the other TSG101 domains are critical to full functionality.
Lastly, it was previously reported that TSG101 could stabilize AR and GR
[63,299], so I used Western blots to determine how TSG101 affects intra-cellular
concentrations of GR in my luciferase assay. Transfection of increasing amounts
of TSG101 was associated with increases in GR (C3 NTD-DBD, see Figure 4.20).
Given the previously shown luciferase assays (Figure 4.18 and Figure 4.19),
TSG101 stabilizes a transcriptionally active form of GR.
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Figure 4.18 – TSG101 Can Activate GR
GR plasmids were transfected to 96-well plates at constant amounts as TSG101 plasmid was titrated
in increasing amounts (x-axis groups). The raw luciferase ratio was normalized to signal at 0 ng
(y-axis). The data are arranged with the A isoform on the far left and each consecutive isoform
follows in order, as shown in the inset graphic. TSG101 was transfected by iself as a negative control
and is the last bar of each group. The A and C3 bars of the 9.4 ng group are highlighted to show that
the active isoforms are activated by TSG101. Error bars are mean ± 95% CI of at least four samples.
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Figure 4.19 – TSG101’s Coiled-Coil is Necessary for Activation
All data shown here were done with 6-well plates (10x amount of DNA relative to 96-well plates).
For GR samples, a constant 6 ng of GR plasmid was transfected. T-tests were one-sided with the
alternative hypothesis being that the 0 ng group mean < experimental mean. Benjamini-Hochberg
corrections were used throughout [42]. Error bars are mean ± 95% CI of four samples. *P < 0.05,
**P < 0.01, black diamond is P < 0.001
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Figure 4.20 – TSG101 Stabilizes a Transcriptionally Active Form of GR
Cells were grown in 6-well plates and transfected with a constant 6 ng of C3-DBD while TSG101
plasmid was titrated. A) A representative W-blot. A contrast altered image is in the lower right. P150
was used as a loading control and the data of each lane were normalized to it and the respective
0 ng signal for B) Quantification of the W-blot signal. T-tests were one-sided with the alternative
hypothesis being that the 0 ng group mean < experimental mean. Benjamini-Hochberg corrections
were used throughout [42]. Error bars are mean ± 95% CI. **P < 0.01, black diamond is P < 0.001
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4.5 Discussion
In recent years, many proteins have been discovered moonlighting away from
their previously discovered roles, and this phenomenon is not unique to any
particular kingdom or domain of life (reviewed: [114,265,429,441]). Moonlight-
ing has been described for metabolic enzymes (ex. PKM2 [364]), cytoskeletal
proteins (ex. villin [312]), and even several ESCRT proteins, besides TSG101.
In its non-endosomal roles, the ESCRT-II complex binds bicoid mRNA in meta-
zoans [173] and it also forms a transcription elongation complex [192,358]. The
ESCRT-III protein, CHMP1, is involved in chromatin silencing with the polycomb
group of proteins [385], and some ESCRT-I proteins have been discovered in the
nucleus (VPS37C and MVB12A, [406]), though the exact function is unclear.
When mammalian TSG101 was discovered in 1996, it was proposed to be
a transcription factor with its coiled-coil acting as a DNA-binding leucine zip-
per [244]. However, DNA-binding leucine zippers are basic [282] and TSG101’s
coiled-coil is acidic (pI ≈5.5, SEDNTERP by John Philo). The acidity of the
TSG101cc makes it more akin to the acidic transcription-activation domains
found in many transcription factors [158,282,335], including the GR NTD [154].
Throughout the years much research on TSG101 has focused on its ESCRT func-
tions [23,102,117], but reports have trickled in of TSG101 having transcriptional
effects or being present in the nucleus [293,449,459]. TSG101’s presence in the
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nucleus could be explained away by some ESCRT functions. Epstein-Barr virus
hijacks the ESCRT system to exit the nucleus [74] and nuclear membrane repair
has been shown to be ESCRT-III dependent [330].
Yet, even the example of Epstein-Barr virus suggests there is more to nuclear
TSG101. The viral Rta protein depends on a direct interaction with TSG101 for
its transcriptional activity [74]. Several other studies have linked TSG101 to
either activation [63] or repression of transcription factors [153,293,392,432].
Some of these studies have used yeast two-hybrids or pull-down assays to check
for direct interactions [63,74,153,293,392], but a biophysical characterization
has been lacking.
Here, I confirm some previous cellular observations and extend them into
a quantitative realm. In U2OS cells, TSG101 was in the nucleus constitutively
and it activated glucocorticoid receptor in a manner that depended on both the
TSG101 binding site (TSG101cc) and the GR binding site (the C3-NTD region).
Transfection of TSG101 also appeared to increase the amount of GR in the cells,
similar to previous reports of TSG101 inhibiting the degradation of GR and
AR [63,299].
In vitro, protease protection patterns confirmed the TSG101cc–GR NTD
interaction site that was first identified by others in a yeast two-hybrid [153],
but the protected fragments were much larger than the combined mass of the
fragments observed in MALDI. Cross-linking TSG101cc and C3 NTD produced
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several cross-links out to a.a. 296 on GR, resolving the discrepancy in my
protease protection experiments. It is worth noting that my model of TSG101cc
binding to the GR NTD is consistent with the most N-terminal portion of GR (R
region) being close to the DBD in the transcriptionally active state, as I previously
proposed [243]. I further characterized the binding of TSG101cc and the GR
NTD by CD and SMFS.
CD suggested that both TSG101cc and GR may go through conformational
transitions, potentially conflating any analysis of the CD data. But in agree-
ment with a yeast two-hybrid of GR and TSG101 [153], a large fragment of the
TSG101cc (a.a. 229—339) bound the C3-NTD, and I observed a gain in α-helical
structure, similar to previous reports with GR and other cofactors [201, 219].
In contrast, a fragment of the GR NTD (AF1 core) that is next to the TSG101
binding site does not seem to bind TSG101cc, as it and TSG101cc produced no
change in dichroism. I next used SMFS to confirm that specifically GR was going
through conformational transitions. The AF1 core was used in SMFS to control
for experimental artifacts, and it had no transitions regardless the presence
of TSG101cc. The C3-NTD and the AF1-binding site of TSG101 both produced
transitions in the presence of TSG101cc and only one without it. This suggests
that the GR NTD can fold in the presence of the TSG101cc.
To quantify the binding of TSG101 and GR, I used fluorescence anisotropy
of TSG101cc and GRE, separately. The TSG101cc bound the A and C3 isoforms
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of the GR NTD equally well (Kd
∼= 20 µM). This was unexpected because the
C3 isoform is thermodynamically more stable and thus predicted to fold and
bind transcriptional cofactors more readily [242], which would have explained
previous observations that the C3 isoform is transcriptionally more active [41,
260]. It is unclear why my hypothesis was false, but it may be related to the
TSG101cc folding only a portion of the NTD. Previous Hilser lab measurements
used an osmolyte to completely fold the GR NTD [242], thereas the data here
suggest that TSG101cc is binding and folding only a portion of the GR NTD.
Other transcriptional cofactors may bind the osmolyte-folded state and produce
both the thermodynamic and transcriptional differences between the A and C3
isoforms (there are over a hundred transcriptional cofactors [255]).
GRE binding experiments demonstrated that the TSG101cc can allosterically
promote DNA-binding by both the A and C3 isoforms of GR, to a similar degree.
However, the exact mechanism differs between the two isoforms. Experiments
with the GRE half-site revealed that TSG101cc promotes a DNA-binding state of
the C3 isoform’s DBD, but promotes the dimerization energy of the A isoform.
This suggests that TSG101 could affect the DBD conformational ensemble dif-
ferently depending on the GR isoform. I speculate that such conformational
heterogeneity could cause the TSG101xGR interaction to be targeted to specific
DNA elements in an isoform-dependent manner. It has already been shown
that the GR translational isoforms affect unique but overlapping sets of genes
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[260], and binding of different DNA sequences is associated with different DBD
conformations [278] (conformational heterogeneity is important for the specificity
of other DNA-binding proteins too [4,191,379]). Furthermore, GRE sequence
has already been shown to affect binding of another transcriptional cofactor of
GR, BATF3 [44].
If the TSG101 interaction with steroid hormone receptors depends on the
promoter that the receptor binds, then it would explain some of the effects seen
in the literature. Numerous authors have reported TSG101 both activating and
repressing various transcription factors (see Table 4.1 and associated references).
Different labs have used cognate response elements or various viral promoters
to measure the effect of TSG101 on steroid hormone receptors [63,74,293,432].
Besides using different reporter assays, the same labs also used a wide variety
of cell lines, which may have expressed varying amounts of cofactors important
for TSG101’s interaction with steroid receptors (Table 4.1). In particular, the
transcription factor Daxx and the cofactor AATF appear to modulate the effect of
TSG101 on GR and AR, respectively [63,293]. At the moment it is not clear what
has produced conflicting results (activation versus repression) in the literature,
and I believe that this matter warrants further study.
Figure 4.21 summarizes my results and hypothetical model of TSG101cc
binding to GR based on the above observations and literature data. In this
study, I have defined TSG101 as a transcriptional cofactor that stabilizes an
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active, DNA-binding form of GR in vivo. Open questions include which genes
are naturally controlled by this interaction and how this ties in, if at all, with
ESCRT-II’s transcriptional activity. My quantification of the allosteric energies
present in GR enables future studies to build organizing principles out of this
system’s thermodynamics.
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Figure 4.21 – TSG101 May Directly Activate GR
The results of this study are schematized in the boxed in area. GR (blue) bound to its GRE (grey) is
shown as before. Each GR NTD forms a pseudo-trimer with one TSG101cc (grey coils, pdb:3iv1).
The individual GR NTD’s do not interact (our data only show heterodimers of GR and TSG101cc).
Also note that the Hilser lab previously showed that the R region of GR (A NTD) binds the DBD and
this schematic model allows for that association. TSG101’s interaction with GR does not depend on
the TBP binding site (pink), possibly leaving it open for interaction with TBP. On the right, TBP is
shown in pink. Others demonstrated that TBP binds two AF1 core elements of GR [75]. The series
of arrows represent subsequent recruitment events, eventually producing an active transcriptional
complex (yellow). Structures: [141,263,302]
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4.6 Appendix
4.6.1 Tables of MS Ions Observed
Table 4.4 – Ions Detected in MS of Protease Protection
The left two columns are for full-length C3-NTD that was extracted from the gel. The right two
columns are for the fragments of GR protected by TSG101cc. Italics indicates a fragment that was
excluded from the dataset shown in the main text because it could ambiguously be from TSG101cc.
Note that the fragment is in the GR alone dataset, though. All amino acid numbers are relative to the
holo-protein sequence.
C3NTD alone: +TSG101cc
ion ± error a.a. ion ± error a.a.
1018.46 + 0.03 207-214 1018.46 + 0.07 207-214
1032.5 - 0.09 172-184 1032.5 - 0.06 172-182
1271.7 + 0.05 121-131 1495.7 + 0.01 159-171
1495.7 + 0.04 159-171 1807.9 + 0.01 141-158
1807.9 + 0.01 141-158 2211.1 - 0.03 121-140
1821.9 -0 278-293 2649.3 + 0.01 184-207
2049.0 + 0.01 367-386
2224.1 - 0.01 257-277
2479.18 - 0.03 97-119
2649.2 - 0.02 183-206
3310.6 + 0.02 387-419
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Table 4.5 – Ions Detected in MS of Unreacted C3NTD and TSG101cc
C3NTD data are on top and TSG101cc is below. An ambiguous ion is italicized to show that it exists
in both GR and TSG101 MS. All amino acid numbers are relative to the tag-cleaved construct.
C3NTD unreacted
Trypsin Tryp+Chymotryp
ion ± error Da a.a. ion ± error Da a.a.
1271.695 - 0.37 25-35 787.36 + 0.35 291-297
1495.71 + 0.78 63-75 958.48 - 0.07 36-44
1018.46 - 0.06 111-118
1271.695 - 0.02 25-35
1495.71 - 0.01 63-75
1807.01 - 0.3 45-62
2088.98 - 0.39 76-95
2224.22 - 0.43 161-181
2246.11 - 0.47 36-58
TSG101cc unreacted
Trypsin Tryp+Chymotryp
ion ± error Da a.a. ion ± error Da a.a.
597.34 + 0.13 39-43 597.35 -0.17 39-43
729.45 - 0.04 61-66 729.45 - 0.01 61-66
862.45 - 0.07 33-39 734.36 + 0.01 33-38
877.44 + 0.03 44-50 877.45 - 0.07 44-50
928.4 +0 16-22 938.41 - 0.12 16-22
957.52 +0.02 23-31 1018.55 - 0.09 32-39
1018.55 + 0.02 32-39 1063.56 - 0.17 1-11
1063.56 - 0.01 1-11 1145.57 - 0.04 51-60
1113.64 + 0.02 23-32 1248.63 - 0.09 68-78
1248.63 - 0.07 68-78
1332.75 - 0.07 1-13
1376.73 - 0.08 67-78
1856.0 + 0.04 51-66
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Table 4.6 – Ions Consistent with GR or TSG101 in MS of Reacted C3NTD and TSG101cc #1
C3NTD data are on top and TSG101cc are below. An ambiguous ion is italicized to show that it
exists in both GR and TSG101 MS. All amino acid numbers are relative to the tag-cleaved construct.
C3NTD DST reacted
Trypsin Tryp+Chymotryp
ion ± error Da a.a. ion ± error Da a.a.
520.28 - 0.59 59-62 552.30 + 0.03 201-205
926.46 + 0.12 324-330 787.36 + 0.08 291-297
958.48 + 0.17 36-44 926.46 -0.02 324-330
1018.46 + 0.22 111-118 958.48 - 0 36-44
1271.7 + 0.34 25-35 1018.46 - 0.07 111-118
1306.65 + 0.38 45-58 1271.7 - 0.13 25-35
1495.71 +0.46 63-75 1495.71 - 0.12 63-75
1807.91 + 0.57 45-62 1592.78 - 0.04 96-110
2224.22 + 0.6 161-181 1618.75 - 0.13 104-118
2246.12 + 0.55 36-58 1711.78 - 0.03 220-236
2649.26 + 0.46 87-110 1807.91 + 0.02 45-62
2224.22 + 0.69 161-181
TSG101cc DST reacted monomer
Trypsin Tryp+Chymotryp
ion ± error Da a.a. ion ± error Da a.a.
957.54 - 0.04 23-31 597.35 - 0.11 39-43
938.41 - 0.085 16-22 679.27 + 0.14 18-22
877.45 + 0.03 44-50 729.45 + 0.2 61-66
862.45 - 0.02 33-39 734.36 + 0.23 33-38
729.45 - 0.01 61-66 862.45 + 0.34 33-39
597.35 + 0 39-43 877.45 +0.37 44-50
1856.0 +0.77 51-66 938.41 + 0.45 16-22
1376.73 +0 67-78 1018.55 + 0.55 32-39
1332.75 - 0.07 1-13 1063.56 + 0.63 1-11
1248.63 - 0.06 68-78 1113.64 +0.53 23-32
1113.64 + 0.05 23-32 1248.63 + 0.57 68-78
1063.56 - 0.07 1-11 1327.68 + 0.61 40-50
1018.55 - 0 32-39 1376.73 + 0.61 67-78
1856.0 + 0.72 51-66
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Table 4.7 – Ions Consistent with GR or TSG101 in MS of Reacted C3NTD and TSG101cc #2
TSG101cc dimer data are at the top and trimer is below. An ambiguous ion is italicized. Of the higher
order oligomers, only the trimer + trypsin experiment yielded good mass spectra. All amino acid
numbers are relative to the tag-cleaved construct.
TSG101cc DST reacted dimer
Trypsin Tryp+Chymotryp
ion ± error Da a.a. ion ± error Da a.a.
957.54 - 0.04 23-31 862.45 + 0.34 33-39
938.41 + 0.05 16-22 877.45 +0.37 40-50
877.45 + 0.05 44-50 938.41 + 0.45 16-22
862.45 + 0.01 33-39 1018.55 + 0.55 32-39
729.45 -0 61-66 1113.64 + 0.53 23-32
597.35 - 0.02 39-43 1327.68 + 0.61 40-50
1856.0 +0.04 51-66 1376.73 + 0.614 67-78
1376.73 +0.02 67-78 1856.0 + 0.72 51-66
1332.75 - 0.07 1-13
1248.63 - 0.06 68-78
1113.64 - 0.07 23-32
1063.56 - 0.08 1-11
1018.55 + 0 32-39
TSG101cc DST reacted trimer
Trypsin
ion ± error Da a.a.
729.45 + 0.1 61-66
877.45 + 0.5 44-50
938.41 + 0.56 16-22
957.54 + 0.41 23-31
1114.64 + 0.61 23-32
1856.0 +0.58 51-66
Table 4.8 – TSG101cc X-links to Itself
Amino acid numbers here refer to the tag-cleaved construct. Some of the X-links have ambiguous
lysine linkages and are italicized. For reconcilable lysines, the closest Euclidean distances have
been calculated directly from pdb:3iv1. DST has a maximum linker length of ∼6 Å [130]; thus, at least
some of the x-links could only occur with conformational heterogeneity in the TSG101cc tetramer, as
I have published before [438].
TSG101cc DST reacted X-links
Trypsin Tryp+Chymotryp
ion ± error Da a.a. Dist. Å ion ± error Da a.a. Dist. Å
1249.7 - 0.52 16-17x61-67 1249.7 - 0.51 16-17x61-67
1327.62 + 0.67 16-22x67-68 1327.62 + 0.7 16-22x67-68
1894.92 - 0.06 32-38x32-38 3.2 1728.82 - 0.25 40-43x51-60 33.3
2778.3 + 0.18 32-38x18-32 10.8 1765.93 + 0.39 67-68x67-78
2510.31 - 0.03 1-11x1-13 25.9
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Table 4.9 – Ions of C3NTD and TSG101cc Observed After X-linking
These data are from the TSG101cc-C3NTD cross-link band. On the left are ions consistent with GR
or TSG101cc, unreacted. Cross-linked amino acids are listed relative to the holo-protein sequence.
All other amino acids are relative to the tag-cleaved construct. One TSG101cc mono-link was
observed: 601.25 + 0.07 Da and a.a. 267-270 of holo-protein sequence.
C3NTD+TSG101cc DST X-link Ions
Trypsin
ion ± error Da TSG a.a. GR a.a.
1475.75 + 0.04 250-258 294-296
Trypsin+Chymotrypsin
ion ± error Da TSG a.a. GR a.a.
1329.65 - 0.21 243-244 294-301
1448.74 - 0.11 250-258 278-280
1615.76 - 0.01 267-270 172-182
1744.79 + 0.04 260-266 278-283
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4.6.2 TSG101 Evolutionary Alignment
Figure 4.22 – Amino Acid Alignment of Human TSG101 and Ten Homologues (next three
pages)
Alignment was done using MUSCLE [101]. The species are presented as three letter acronyms on
the left of each stretch of sequence: T.th = Tetrahymena thermophila, T.br = Trypanosoma brucei,
S.ce = Sacharomyces cerevisiae, V.vi = Vitis vinifera (wine grape), C.el = Caenorhabditis elegans,
D.me = Drosophila melanogaster, X.tr = Xenopus tropicalis, D.re = Danio rerio, G.ga = Gallus gallus,
H.sa = Homo sapiens, M.mu = Mus musculus. At the bottom of each text block are marks indicating
conservation of sequence, where ”.” is weakly similar, ”:” is very similar, and ”*” is perfect identity.
Note that there are many sections where perfect conservation with human TSG101 is broken by
only a few of the sequences. Perfect conservation with the human sequence is highlighted in yellow
within the coiled-coil region of the alignment.
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Figure 4.22
174
CHAPTER 4. THE TUMOR SUSCEPTIBILITY GENE-101 COILED-COIL BINDS
AND ALLOSTERICALLY REGULATES THE GLUCOCORTICOID RECEPTOR
Figure 4.22
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Figure 4.22
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4.6.3 Contour Length Analysis for C3-NTD+TSG101cc
76 a.a. unfolding (TSG101cc length)7 a.a.
Figure 4.23 – Compilation of C3-NTD Force Ramp Data
The Worm-like Chain model was used to extract the contour lengths shown here [64]. C3-NTD was in
the presence of at least 1 μM TSG101cc for all data shown here. Isolated rips occured alone in one
pulling cycle, while co-occurent rips are multiple rips from one cycle. Co-occurent rip contour lengths
can be added and the force can be back calculated, which is shown as the orange “Deconvolution”
points. The largest contour length shown is ∼262 a.a., which is less than the C3-NTD length (323
a.a.) and longer than the TSG101cc construct used (78 a.a.).
177
CHAPTER 4. THE TUMOR SUSCEPTIBILITY GENE-101 COILED-COIL BINDS


















 of Co-oc. Rips
Figure 4.24 – Compilation of AF1107-237 Force Ramp Data
Data are plotted as above (Figure 4.23). AF1107-237 was in the presence of 10 μM TSG101cc for all
data shown here. The largest contour length shown is ∼96 a.a., which is less than the AF1107-237
length (131 a.a.).
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4.6.4 Raw Data of 6FAM-DNA Fluorescence Anisotropy
Figure 4.25 – TSG101cc Does Not Directly Bind DNA
The C3 NTD-DBD construct of GR was titrated out of a solution of full-length GRE, labeled with
6-FAM (observed anisotropy). For the sample with TSG101cc, 100 μM TSG101cc was maintained
throughout the entire titration. Note that the unbound DNA baselines around 10-8 Molar are the
same with or without TSG101cc.
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4.6.5 Nucleotide and Amino Acid Sequences of Plasmids
Cloned in This Work
4.6.5.1 Bacterial Expression Construct (pJ411 plasmid)







Translation of above (TEV cleavage will leave GS from tag):
MHHHHHHHHHENLYFQGSSLISAVSDKLRWRMKEEMDRAQAELNALKRTEEDLKKGHQKLE
EMVTRLDQEVAEVDKNIELLKKKDEELSSALEKMENQSENNDIDEVIIPTAPLYKQILNLYAEENAIE








AF1τ for single molecule force spectroscopy, ORF:
ATGCACCACCACCACCATCATCACCATCACGAAAACTTATACTTCCAGGGTCTGAATGATATCT
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Translation of above AF1τ single molecule construct:
MHHHHHHHHHENLYFQGLNDIFEAQKIEWHEDQSTFDILQDLEFSSGSPGKETNESPWRSDL
LIDENCLLSPLAGEDDSFLLEGNSNEDDSLEFIASKLA
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Code Used to Parse CD Data:
#! / usr / bin / python
#Jordan White 2013
import sys
import numpy as np #I am using numpy because i t has useful matrix
operations not i n t r i n s i c to python .
#Usage : in a terminal window input :
# $ python3 <path to th i s scr ipt> <path to blank CD scan> <path to next
data f i l e >
# Input the values the sc r ip t prompts you for .
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# The output w i l l be a csv f i l e of the data along with a header to each
column . Make sure to choose the locat ion you want for the new f i l e .
Change np . savetxt ’ s f i r s t object to change the save f i l e locat ion .
# Line 33 d ic ta tes where the data w i l l be cut o f f . A cut o f f dynode
voltage of 600.5 i s pretty conservat ive . I have seen good data that
had a dynode voltage closer to 700 or 800. User d i scre t ion advised .
This sc r ip t adds zeros at over – voltage l i nes for two reasons : i t
maintains the data structure ( eas ier to code for ) and I had trouble
when try ing to t e l l Python to read in an empty data value . *****
IMPORTANT: Because th i s replaces over – voltaged l i nes with zeros , you
should input your lowest concentration data ( lowest dynode voltage )
for th i s sc r ip t . This gives you your maximum wavelength range .
CD_Data_Parser_MRE_additional . py w i l l then add add i t iona l data to
the csv f i l e . * * * * * * At the end you can delete the zeros by hand (
excel ) before importing to R or you can use s l i c e notat ion in R.
def main ( ) :
#Inputs
basel ine = sys . argv [1 ]
i n pu t f i l e = sys . argv [2 ] #di rec t terminal input of f i l e alongside the
invocat ion of th i s sc r ip t
residue_concentrat ion = f l o a t ( input ( ’What␣i s␣the␣residue␣length␣
minus␣one␣of␣your␣protein␣times␣i t s␣**Molar **␣concentration ?␣ ’ ) )
hat = input ( ’What␣header␣do␣you␣want␣for␣your␣data?␣ ’ )
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#
#
#Def in i t i on of data arrays and the header , ”head” , for the output
raw = np . genfromtxt ( i npu t f i l e , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (0 , 1 , 2 , 6) ) #open my data ,
use two white spaces as the del imiter , skip the header and
footer ( footer changes depending on how many wavelengths are
scanned ) , and only import the relevant columns . I f you need to
change sk ip_ footer : t r i a l and error can f i x minor o f f s e t s or you
can use bash ( $ t a i l –n–160) to get a sense of what l i nes are
gett ing chopped by sk ip_ footer .
blank = np . genfromtxt ( baseline , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (0 ,1) ) # Same as above except th i s
i s for the blank . Change sk ip_ footer i f the blank has a
d i f f e ren t wavelength range than the sample .
data = np . array ( [ ] )




raw [ : , 1 : 2 ] = raw [ : , 1 : 2 ] – blank [ : , 1 : 2 ] #th i s does two things :
subtracts the blank from my data and then replaces the ent i re
data s igna l column with the blank subtracted s igna l
zeroed = np . array ( [0 ,0 ,0 ] ) #row to add to over – voltage l i nes
for l i ne in raw :
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i f l i ne [3 :4 ] <= 600.5: #ignore data with a dynode s igna l > 600
data = np . concatenate ( ( data , l i ne [ 0 : 3 ] ) , ax is = 0) #add the
data to the matrix ”data ”
else :
data = np . concatenate ( ( data , zeroed [ 0 : 3 ] ) , ax is = 0) # adds
zeros to l i nes with maxed out voltage
data . shape = ( len ( data ) /3 , 3) # reshapes the rows and columns
MRE = data *[1 , 1 / ( residue_concentrat ion *1000) , 1 / (
residue_concentrat ion *1000) ]
np . savetxt ( ’ / Users / jordanwhite / Documents /My_Research / Hilser_Lab /CD/
DATA. csv ’ , MRE, de l imi ter = ’ , ’ , header = head , comments = ’ ’ ) #
writes output held in ”data ”
pr in t ( ’Done ’ )
pr in t ( ’ ’ )
i f __name__ == ”__main__ ” :
main ( )
Additional data was added using this:
#! / usr / bin / python
#Jordan White 2013
import sys
import numpy as np
#Usage : in a terminal window input :
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# $ python3 <path to th i s scr ipt> <path to blank CD scan> <path to csv
f i l e of data already parsed> <path to next data f i l e >
# input the values the sc r ip t prompts you for
# the output w i l l be a csv f i l e of the previously parsed data plus the
next dataset . Make sure to choose the locat ion you want for the new
f i l e . Change np . savetxt ’ s f i r s t object as required .
def main ( ) :
#Input
basel ine = sys . argv [1 ]
previous = sys . argv [2 ]
i n pu t f i l e = sys . argv [3 ] #di rec t terminal input of f i l e alongside the
invocat ion of th i s sc r ip t
residue_concentrat ion = f l o a t ( input ( ’What␣i s␣the␣residue␣length␣of␣
your␣protein␣times␣i t s␣**Molar **␣concentration ?␣ ’ ) )
hat = input ( ’What␣header␣do␣you␣want␣for␣your␣data?␣ ’ )
#
#Def in i t i on of arrays
raw = np . genfromtxt ( i npu t f i l e , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (1 , 2 , 5) ) #open my data , skip
the header and footer , only import the relevant columns
blank = np . genfromtxt ( baseline , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (0 ,1) ) #same as above except for
blank , change sk ip_ footer i f the blank has a d i f f e ren t
wavelength range than the sample
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dataset = np . genfromtxt ( previous , de l imi ter = ’ , ’ , skip_header = 1)
dataset_csv = csv . reader ( open ( previous ) )
data = np . array ( [ ] )
dataset_header = ’ , ’ . j o i n ( next ( dataset_csv ) ) #reads in f i r s t l i ne of
previous data set ( the header ) and uses comma separation
head = dataset_header +’ , ’+ hat + ’ , ’+ hat + ’ _error ’ #appends
previous and current headers
#
#Math
raw [ : , 0 : 1 ] = raw [ : , 0 : 1 ] – blank [ : , 1 : 2 ] #th i s does two things :
subtracts the blank from my data and then replaces the ent i re
data s igna l column with the blank subtracted s igna l
zeroed = np . array ( [ 0 , 0 ] )
for l i ne in raw :
i f l i ne [2 :3 ] <= 600.5: #ignore data with a dynode s igna l > 600
data = np . concatenate ( ( data , l i ne [ 0 : 2 ] ) , ax is = 0) #add the
data to the matrix ”data ”
else :
data = np . concatenate ( ( data , zeroed [ 0 : 2 ] ) , ax is = 0)
data . shape = ( len ( data ) /2 , 2)
MRE = data * [ 1 / ( residue_concentrat ion *1000) , 1 / ( residue_concentrat ion
*1000) ]
output = np . concatenate ( ( dataset , MRE) , ax is = 1) # appends previous
dataset to the current dataset
np . savetxt ( ’ / Users / jordanwhite / Documents /My_Research / Hilser_Lab /CD/
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DATA. csv ’ , output , de l imi ter = ’ , ’ , header = head , comments = ’ ’
) #writes output held in ”data ”
pr in t ( ’Done ’ )
pr in t ( ’ ’ )
#
i f __name__ == ”__main__ ” :
main ( )
When mixing two proteins together, the difference spectrum was de-
termined using the following:
#! / usr / bin / python
import sys
import csv
import numpy as np
#This w i l l determine the di f ference between measured and expected CD
spectra of protein mixtures . The input requires that there already
be a DATA f i l e , and the output i s in MRE.
#Usage : in a terminal window input :
# $ python3 <path to th i s scr ipt> <path to blank CD scan> <path to csv
f i l e of data already parsed> <path to next data f i l e >
# input the values the sc r ip t prompts you for
# the output w i l l be a csv f i l e of the previously parsed data plus the
next dataset . Make sure to choose the locat ion you want for the new
193
CHAPTER 4. THE TUMOR SUSCEPTIBILITY GENE-101 COILED-COIL BINDS
AND ALLOSTERICALLY REGULATES THE GLUCOCORTICOID RECEPTOR
f i l e . Change np . savetxt ’ s f i r s t object as required .
def main ( ) :
basel ine = sys . argv [1 ]
previous = sys . argv [2 ]
i n pu t f i l e = sys . argv [3 ] #di rec t terminal input of f i l e alongside the
invocat ion of th i s sc r ip t
proteinA = sys . argv [4 ] #CD spectrum of one of the proteins by i t s e l f
**** This requires that th i s CD spectrum i s at the same
concentration as the protein measured **** Otherwise , there i s a
l inear concentration fac tor that mul t ip l i e s the mdeg measured ,
assuming no aggregation .
proteinB = sys . argv [5 ] #CD spectrum of the other protein by i t s e l f .
Same caveat as above .
residue_concentrat ion = f l o a t ( input ( ’What␣i s␣the␣residue␣length␣of␣
your␣protein␣times␣i t s␣**Molar **␣concentration ?␣ ’ ) ) #[ ProteinA
] * ( length of A – 1)+[ProteinB ] * ( length of B – 1)
hat = input ( ’What␣header␣do␣you␣want␣for␣your␣data?␣ ’ )
raw = np . genfromtxt ( i npu t f i l e , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (1 , 2 , 5) ) #open my data , skip
the header and footer , only import the relevant columns
blank = np . genfromtxt ( baseline , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 165 , usecols = (0 ,1) ) #same as above except for
blank , change sk ip_ footer i f the blank has a d i f f e ren t
wavelength range than the sample
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protA = np . genfromtxt ( proteinA , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (0 ,1) )
protB = np . genfromtxt ( proteinB , de l imi ter = ’␣␣ ’ , skip_header = 19 ,
sk ip_ footer = 160 , usecols = (0 ,1) )
dataset = np . genfromtxt ( previous , de l imi ter = ’ , ’ , skip_header = 1)
dataset_csv = csv . reader ( open ( previous ) )
data = np . array ( [ ] )
#
dataset_header = ’ , ’ . j o i n ( next ( dataset_csv ) )
head = dataset_header +’ , ’+ hat + ’ , ’+ hat + ’ _error ’
#
#
raw [ : , 0 : 1 ] = raw [ : , 0 : 1 ] + blank [ : , 1 : 2 ] – protA [ : , 1 : 2 ] – protB [ : , 1 : 2 ]
#th i s does two things : subtracts the blank from my data and
then replaces the ent i re data s igna l column with the blank
subtracted s igna l **Note : The raw data of protein A and B
contain the buffer s igna l . Thus , when the raw protein A and B
s igna ls are subtracted from the combined signal , buf fer i s
subtracted twice ; therefore , one buffer s igna l must be added
back . * *
zeroed = np . array ( [ 0 , 0 ] )
for l i ne in raw :
i f l i ne [2 :3 ] <= 600.5: #ignore data with a dynode s igna l > 600
data = np . concatenate ( ( data , l i ne [ 0 : 2 ] ) , ax is = 0) #add the
data to the matrix ”data ”
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else :
data = np . concatenate ( ( data , zeroed [ 0 : 2 ] ) , ax is = 0)
data . shape = ( len ( data ) /2 , 2)
MRE = data * [ 1 / ( residue_concentrat ion *1000) , 1 / ( residue_concentrat ion
*1000) ]
output = np . concatenate ( ( dataset , MRE) , ax is = 1)
np . savetxt ( ’ / Users / jordanwhite / Documents /My_Research / Hilser_Lab /CD/
DATA. csv ’ , output , de l imi ter = ’ , ’ , header = head , comments = ’ ’
) #writes output held in ”data ”
pr in t ( ’ I \ ’m␣done␣bitch ’ )
pr in t ( ’ ’ )
#









lucocorticoid receptor (GR) is a desirable drug target because of its con-
nection to a wide variety of disease states, including: suicide/depression,
both activation and suppression of the immune system, prostate and breast
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cancer, and cardiovascular dysfunction [19,145,187,275,308,456]. All current
glucocorticoid drugs target the ligand binding domain (see Figure 5.1). This is a
vulnerability in our drug inventories because the ligand binding domain (LBD)
is disposable to GR function. Removal of the LBD causes GR to constitutively
localize in the nucleus of cells where it binds DNA and alters the expression of a






Figure 5.1 – The Domain Organization of GR
The disordered N-terminal domain (NTD) has eight translational isoforms (three are shown). The NTD
binds transcriptional cofactor proteins close to the C3 isoform start site [260]. Because the D1 isoform
is missing the region that is critical for transcriptional activation, it (or the DBD alone) can only act as
a repressor. The DNA-binding domain (DBD) binds DNA response elements as a dimer or monomer
(glucocorticoid response elements, GRE’s). The ligand-binding domain (LBD) binds steroids and
controls GR’s nuclear localization, but it is dispensable for GR’s core functions. The themodynamic
interactions within GR were characterized by a previous student (Dr. Li), and are shown as arrows
with “+” for stabilizing and “-” for destabilizing interactions. Note that the Regulatory-region (R-region)
of the NTD can have both negative and positive effects on transcriptional activity [242,243]. The
domains are scaled to their respective lengths.
For a disease that evolves, namely cancer, it could mutate GR such that the
ligand binding domain would no longer bind drugs. Indeed, the natural GR gene
(NR3C1) already produces at least two splice isoforms without functional ligand
binding domains [350], and it has been shown that several hematological cancers
can upregulate the production of one such isoform, called GR-P [86]. The P
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isoform cannot bind glucocorticoid drugs and this is one of several ways in which
these cancers can become refractory to glucocorticoid treatment.
If we discover drugs that bind the GR DNA-binding domain (DBD), then we
will gain a fundamentally different glucocorticoid drug. Not only would such a
drug be resistant to loss of the ligand binding domain, but it would also open
up a whole new field of GR drug design. By directly targeting the DBD, we may
gain more control over what genes GR targets for transcriptional regulation.
Previously, a student in the Hilser lab, Dr. Jing Li, determined that there was
a Regulatory (R) region within the GR N-Terminal Domain (NTD) [242]. The R-
region destabilizes the folded state of the NTD, in particular the cofactor binding
region close to the C3-isoform start site (Figure 5.1). However, the R-region
also stabilizes the DBD. This stabilization leads to enhanced DNA-binding which
can stabilize the cofactor binding region of the NTD [218]. These conflicting
roles of the R-region produce a bistable system where small perturbations can
lead to large changes in transcriptional activity. To determine the residues that
mediate the DBD to R-region interaction, Dr. Li mutated several conserved DBD
residues and found some that were necessary for the DBD to R-region interaction.
Strikingly, the residues form a surface on the DBD structure. The Hilser lab
proposed this surface was an allosteric site [243], and my collaborator, Dr. E.
Brad Thompson, suggested that I dock small molecules onto this DBD site, in
the hopes of finding a drug lead.
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The effect such a drug would have on GR activity can be predicted because
of the thermodynamic model that Dr. Li built using the Hilser lab’s ensemble
allosteric model [243, 289]. Such a drug could either block the NTD to DBD
interaction or mimic the interaction. In both cases, the probability of the A
isoform of GR being active would go from about 10% to 30%. Increasing the
activity of the A isoform could push leukemias into apoptosis [407] (given other
chemotherapy drugs) or it could give us a targeted therapy against some other
disease: the A isoform is expressed to a different degree in different tissues [260].
In the proceeding chapter, I detail my verification of the allosteric site and
my attempts to find drug-leads using the DOCK 6.6 software.
5.2 Methods
5.2.1 Luciferase assays
U2OS cells were grown in a 5% CO2 atmosphere at 37º C and transfected at 90%
confluence using XtremeGENE HP (Roche). The luciferase plasmids expressed
either Gaussia luciferase or Cypridina luciferase (both in Mini-TK 2 vector of
NEB). GR normally binds specific DNA sites, GR response elements (GRE), as
a dimer. A GRE can be split in half, yielding a single GR binding site, without
the convoluting effect of dimerization. To prevent dimerization effects in the
mutational analysis, four GRE half-sites were cloned into the Gaussia promoter.
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As any given plasmid was titrated, an empty pJ603 backbone was used to balance
the total amount of DNA transfected.
Two luciferase assays are presented in this section. In both assays, Gaussia
and Cypridina luciferases and a C3-DBD expression plasmid (pJ603, DNA2.0)
were transfected at constant amounts (40 ng, 40 ng, and 3 ng, respectively).
The first experiment was to determine the residues of the DBD required for the
interaction of the DBD with the R-region. In this case, the cells were transfected
with up to 16 ng of a competitor, DBD expressing plasmid (WT, C431Y, V435A, or
L436A). As a control, some cells were transfected with 16 ng of the DBD plasmid
and no C3-DBD plasmid. The second experiment was to confirm the DBD to
R-region interaction by expressing the R-region (up to 12 ng of plasmid) in the
presence of a C3-DBD construct (WT or triple mutant: C431Y, V435A, L436A).
The medium of the cells was collected two days after transfection and lu-
ciferase activity was measured using kits from NEB and a Berthold luminometer.
The data were baselined for Gaussia and Cypridina signal in untransfected
wells. The averages presented here are from four to six replicates ± 95% con-
fidence intervals. T-tests were done in R 3.1.2, with a Benjamini-Hochberg
correction applied at an alpha of 1% [42].
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5.2.2 Cloning of constructs
A GeneBlock was synthesized by IDT to contain the GR R-region (1-97 a.a.), a
GSx2 linker, the GR nuclear localization sequence (488-505 a.a.), a GSx3 linker,
and the FLAG tag (DYKDDDDK). This GeneBlock was restriction digested with
NheI and XhoI, then inserted into the pJ603 vector (DNA2.0) for mammalian
expression. Clones were sequenced using the Sanger method (Genewiz).
Other plasmids used here were cloned by Dr. Jing Li during her thesis research.
The R-DBD constructs have the R-region of GR (a.a. 1-97) attached to the DBD
via an 11a.a. linker (GTGGSGGSGGS), and the related control construct lacks
the R-region (see Figure 5.2, part A).
5.2.3 Immunofluorescence
U2OS cells were grown in 6-well plates and transfected with 100 ng of R-
NLS-FLAG expressing plasmid and 900 ng of salmon sperm DNA. Cells were
grown on German, circular cover slips for two days before being washed with
PBS+2mM MgCl2 (PBSM) and fixed with 4% PFA. After 10 minutes, the cells
were washed with PBSM three times and quenched with 50 mM NH4Cl for 10
minutes. Cells were permeabilized with the following solution (BTPAD) for 30
minutes: PBS+0.1% TX-100+1% BSA+0.5 µg/mL DAPI. Anti-FLAG antibody
(Mus M2 from Sigma, gift of Kuruvilla lab at Johns Hopkins) was used at 1:1000
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in BTPAD to label the R-NLS-FLAG construct for one hour. After washing three
times with PBSM, secondary antibody at 1:400 was incubated for 30 minutes
(Cell Signaling Technologies, goat anti-mus Alexa 594) and washed off with PBSM
three times. Slides were mounted with fluoromount (Sigma) and dried overnight.
Images were taken using a Zeiss LSM 700 confocal microscope.
5.2.4 Docking
Ligands for docking were obtained from the ZINC clean-leads database, which
is curated to be filled with non-toxic and drug-like molecules that mostly follow
Lipinski’s Rules of Five [174,250]. After docking the clean-leads, Prof. Freire
communicated to me that most corporations use fragment screening because
the downstream optimization is easier and more reliable. After finding pockets
that bind ligand fragments, one can link the fragments and form a full lead-like
molecule. I have also docked the ZINC frags-now database (see appendix), but
all the analyses presented here are for the clean-leads.
The DOCK 6.6 suite of programs [220,221] was used for docking of ligands
to the known structure of the GR DBD of rat [263] (the rat and human DBD’s
have 100% sequence identity—a fact that may not have been known when the
crystal was solved in 1991). The DBDs of other steroid hormone receptors were
prepared for docking via UCSF’s Chimera [99,317]. Docking proceeded first by
grid scoring, then by AMBER scoring of the top hits [159,427,428] (see appendix
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for input scripts). All grid computations were done using a cluster of four AMD
Opteron processors running CentOS, and following grid scoring, the hits were
screened manually for any unrealistic binding modes. All AMBER scoring was
done using a 2.6 GHz Intel i7 processor core of a 2012 Macbook Pro running
OSX 10.9.4. Jobs were submitted to the CentOS cluster using HTCondor [402].
For AMBER docking, the DBD of GR was prepped using H++ version 3.1 at a
pH of 7.2 [14], and the docking proceeded in a parallel fashion using MPICH2
(http://www.mpich.org). After AMBER docking, the top hits were run through
SciFinder and one hit (ZINC 06002995) was found to already act as a drug for
carbonic anhydrase.
Dendrograms and heat maps were created using the ChemmineR package
of R [70]. The top hits were converted into their binary, chemical fingerprints
and then clustered using complete linkage. Quantitative Structure Activity
Relationship (QSAR) analysis was attempted, but failed cross-validation checks
(using the Open3DQSAR package).
5.2.5 Alignment of the steroid hormone receptors (SHR’s)
Chimera was used to align the structures and sequences of GR and five other
SHRs. Sequence alignment was done with a BLOSSUM80 matrix because
the DBDs of various SHRs are highly related. The following is a list of the
SHRs used along with citations for the structures: glucocorticoid, progesterone,
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mineralocorticoid, androgen, estrogen-1, and an ancestral resurrected recep-
tor [164,263,276,344,361,365].
5.3 Results
5.3.1 Verification of the allosteric site
The allosteric site that Dr. Jing Li discovered is made of residues C431, V435,
and L436 in the DBD of GR. To discover this site, Dr. Li attached the DBD to the
R-region via a flexible, eleven amino acid linker (R-11aa-DBD). She then mutated
several conserved residues on the DBD (the mutation strategy is described in her
thesis), and used the same construct minus the R-region as a control (11aa-DBD).
Each of these constructs could bind the promoter of the Gaussia luciferase
plasmid, but they could only block transcription. Thus, transfection of either
the R-11aa-DBD or 11aa-DBD construct lowered the transcriptional activity of
the active, C3-DBD construct through competitive inhibition (Figure 5.2). By
transfecting increasing amounts of the mutant DBD constructs, Dr. Li quantified
the inhibition strength of each construct—called the IC50 here, that is the amount
of DBD plasmid that brings the assay to 50% of its initial signal.
In this assay, the R-11aa-DBD construct inhibits the C3-DBD construct more
readily than DBD alone because the R-region stabilizes the attached DBD, in-
creasing its DNA-binding affinity. Mutations that disrupt the R to DBD coupling
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Figure 5.2 – Verification of the DBD Allosteric Site
A) The C3-DBD construct is inhibited by increasing amounts of either an R-DBD or DBD expression
plasmid. This is Dr. Li’s wild type data (R-DBD IC50 = 1.51±0.09 ng; DBD IC50 = 4.65±0.42 ng). The
inset diagrams represent the constructs used here. B) Dr. Li’s data for L436A, reanalysed (R-DBD
IC50 = 4.01±0.35 ng; DBD IC50 = 3.85±0.18 ng). C) Dr. Li’s data for V435A, reanalysed (R-DBD
IC50 = 2.01±0.13 ng; DBD IC50 = 3.83±0.25 ng). D) The author’s replication of the C431Y data
(R-DBD IC50 = 4.81±0.58 ng; DBD IC50 = 5.88±0.89 ng).
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will cause the R-11aa-DBD construct to have the same IC50 as the control DBD
construct. Mutations that disrupt the DBD will cause both IC50’s to shift, and
some mutations will have no effect. As a first step in verifying Dr. Li’s allosteric
site, I reanalyzed her data. There are two equations to be considered, and the
first describes the luciferase activity relative to zero competitor plasmid (y-axis
of Figure 5.2):




Where Y is a sample’s luciferase ratio, B is the baseline activity observed after
transfecting 16 ng of RDBD or DBD construct alone, and Z is the luciferase ratio
given 0 ng of competitor plasmid (C3DBD construct alone). The data were then
fit to the following equation, describing the IC50:
y = 1 –
1
1 + (IC50X )
p (5.2)
where X is the ng of competitor plasmid and p is an arbitrary fitting parameter
that accounts for the cooperativity in the curves.
Much of Figure 5.2 (parts a-c) is Dr. Li’s data with my analysis. One mutant,
C431Y yielded a borderline positive result upon reanalysis; thus, I recollected
the data myself and present my own data in Figure 5.2d. I am omitting data for
five other mutations because they are not involved in the allosteric site (L422,
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S425, V449, L482, T493). My conclusions were unchanged by the reanalysis,
thus I moved to an alternative test of the allosteric site.
I realized that instead of just inhibiting the C3-DBD construct, I could also
activate it using the R-region of GR. The R-region would bind and stabilize the
DBD of the C3 isoform, thereby increasing the transcriptional activity observed.
Because the R-region would be dislocated from its natural position next to the
C3-NTD, the R-region would likely be unable to destabilize the C3-NTD (large
entropic penalty). If the allosteric site is truly the point of R and DBD interaction,
then mutating it will ablate the interaction (C431Y, V435A, L436A). For this
experiment to work, I designed an R-region construct that translocates into the
nucleus on its own (Figure 5.3 and see Docking Methods section). As seen in
Figure 5.4, the R-region activates the wild type C3 isoform of GR better than the
triple mutant of GR.
Figure 5.3 – Confocal Immunofluorescence of the R-NLS-FLAG Construct
Our R-region construct largely localizes to the nucleus (quantification = 48% nuclear ±5% given a
95% confidence interval, n = 7 cells). From left to right, the first panel is DAPI staining the DNA
of the U2OS cells (signal inverted), an anti-FLAG antibody labeling the R-region construct (signal
inverted), and a composite image with DAPI colored blue and the FLAG labeling colored yellow.
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-DBD
-DBD
Figure 5.4 – Luciferase Assay of C3-DBD with the R-NLS-FLAG Construct
Increasing amounts of the R plasmid cause increasing activity of the C3 isoform of GR. However,
the wild type C3 isoform is activated more than the DBD mutant (C431Y, V435A, L436A). Bars are
means ± 95% confidence intervals and asterisks indicate statistically significant differences between
bars with the same x-axis value (t-tests with Benjamini-Hochberg correction, P < 0.01).
5.3.2 In silico drug-lead screening
To find drugs that bind the DBD of GR, I used in silico drug-lead screening.
This is a method whereby millions of small molecules are “docked” to the known
structure of your favorite protein. The docking process is described in greater
detail in the methods of this chapter. Briefly, the allosteric site of GR’s DBD was
targeted for docking and molecular force fields were used to calculate a docking
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Figure 5.5 – The Allosteric Surface of the GR DBD
In both images, the DBD is colored as a gray surface with the three allosteric residues colored red.
Note that they form a contiguous surface. A) The highest scoring hit (ZINC ID 94463428) docked to
the DBD of GR. B) The top 105 hits docked to the DBD of GR. Note that the hits generally cluster
around the allosteric site or next to it.
score for each drug-lead. The more negative the score, the better. See Figure 5.5
for images of the clean drug-leads docked to GR’s DBD. Table 5.2 and Table 5.3
in the appendix list the top clean leads and frags-now leads, respectively, and
Figure 5.6 has the structures of some of the top hits. The clean-lead results have
been analyzed to the greatest degree and are presented in the main section here.
The frags-now top hits are presented as an addendum in the appendix.
Clustering the top-hits of a drug screen can reveal recurring motifs and
potentially aid future design of drugs. Figure 5.7 shows the clustering of the top
105 hits by chemical similarity. This revealed six major clusters with diverging
chemical properties. There are a few commonalities among the clusters: An
enrichment of aromatic and sulfa or carboxyl moieties (see Table 5.1).
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Figure 5.6 – Structures of Top Hits
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Aromatic groups contribute to hydrophobic and pi-stacking interactions. How-
ever, the likely interaction in this case is hydrophobic. The drug-leads are not
forming pi-stacking interactions with the DBD because the closest aromatic
amino acid is tyrosine-433 and it faces away on its β-strand. The enrichment in
sulfa and carboxyl moieties is likely related to the large number of basic residues
in the GR DBD. The allosteric site of the DBD is next to two lysines and two
arginines, and the drug-leads often docked with negatively charged moieties
facing these positively charged residues of the DBD. Future development of these
drug-leads should focus on optimizing these binding characteristics.
Table 5.1 – Chemical Make Up of the Drug-Lead Clusters
The first column is the cluster from Figure 5.7 (see the top dendrogram). Subsequent columns
declare the percentage of molecules in a cluster that have a given chemical moiety. Within a given
column, some of the clusters appear enriched with certain chemical groups and are highlighted for
the reader.
Cluster Aromatic Urea Amide Sulfa Carboxyl Halogen
1Aa 21% 29% 14% 57% 100% 7%
1Ab 88% 13% 17% 88% 75% 4%
1B 50% 10% 0% 100% 100% 0%
2A 100% 20% 20% 80% 60% 0%
2Ba 100% 18% 12% 94% 59% 41%
2Bb 100% 28% 20% 100% 40% 8%
Typically, when one does in silico drug screening, there should be a positive
control that is known to bind the target protein. The simulations shown here
are completely de novo, thus I did not have the luxury of a positive control.
To test the specificity of the docked ligands, I subsequently docked my top hits
to the DBD’s of five other steroid hormone receptors (SHR’s). These SHR’s
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Figure 5.7 – Clustering of the Top 105 Docked Molecules
The top 105 hits cluster largely into two groups of chemical similarity. The names of prominent
clusters are on the top dendrogram. See Table 5.1 for a break-down of the chemical moieties that
are common in each cluster. The colors in this graphic depict chemical similarity, with blue being
the least similar, yellow being similar, and white being the same or very similar. There are blocks of
white near the diagonal because some of the hits are enantiomers.
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are all closely related to GR (53—89% identity between the various DBD’s),
and their structures are strikingly similar (aligned backbone RMSD of between
0.540—0.768 Å). Figure 5.8 shows the structural alignment of the six DBD’s and
the sequence alignment around the allosteric site of GR.
Figure 5.8 – Alignment of other Steroid Hormone Receptors to GR
Left: A structural alignment of GR (blue) and five other steroid hormone receptors (SHR’s in red).
The SHR’s presented are as follows: progesterone (PR), mineralocorticoid (MR), androgen (AR),
estrogen 1 (ER1), and an ancestral resurrected receptor (AncR). The allosteric site of GR is circled
with a dashed, gray circle. Right: The sequence alignment around the allosteric site of GR. The
dashed boxes indicate the relative position of the allosteric site residues (C…VL in GR). Blue letters
indicate differences relative to the GR sequence.
In order to compare the docking scores, I calculated preference ratios, defined
as the average docking score of a given receptor, divided by the average docking
score of GR. A preference ratio greater than one indicates that the alternative
receptor docks to the GR drug-leads better than GR itself. Based on the sequence
alignment, I expected progesterone receptor to dock well to my top drug-leads,
and it does indeed have the highest preference ratio (1.29). The other receptor
214
CHAPTER 5. IDENTIFICATION OF POTENTIAL GR DRUG-LEADS
preference ratios are as follows: ancestral = 0.42, mineralocorticoid = 0.65,
androgen = 0.36, and estrogen-1 = 0.68 (see Figure 5.9 and Figure 5.10 for
comparison of raw docking scores).
The high preference ratio of progesterone receptor suggests that it may
bind these drug-leads better than GR does. There are two mitigating pieces of
information. First, the drug-leads dock to progesterone receptor in a manner that
is less specific to the allosteric site and occluded by DNA-binding (see right side
of Figure 5.10). Second, it is sometimes desirable to target both progesterone
and glucocorticoid receptors in the clinic; thus, off-target effects on progesterone
receptor may be desirable (personal communication with my collaborator Dr. E.
Brad Thompson).
5.4 Conclusions
For decades, the ligand binding domain has been our only drug target for gluco-
corticoid receptor. This produced great medical advances, but was inherently
limiting. In this chapter (and in Dr. Li’s thesis), I describe an alternative drug
target on GR—an allosteric site on the DBD. Over a million small molecules were
docked to the DBD site, and the top hits found here will inform future drug
discovery efforts. The top hits yielded information on the chemical composition
we should expect of a GR DBD drug. Future work in the Hilser lab will identify
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A B
C D
Figure 5.9 – Comparison of GR Docking Scores Versus Other SHR’s
For parts A) to D), the x-axes are all the GR docking scores and the y-axes are, respectively, the
docking scores for AncR, MR, AR, and ER1. A dashed line along the diagonal indicates scores
that are the same. Values above the diagonal line dock to GR better than the alternative SHR. A
vertical dashed line indicates the weakest limit of GR docking and is replicated across the horizontal
to indicate molecules that dock GR much better than the alternative SHR.
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Figure 5.10 – Comparison of GR and PR Docking
Left: Comparison of PR and GR docking scores. The figure style is as in Figure 5.9. Right: The
top image is of PR docked to the top hits of GR and the bottom image is of GR and its top hits. The
dashed lines indicate roughly where DNA-binding occurs. Note, that the PR cluster of hits spreads
into the area of DNA-binding.
the true positive hits. I have already ordered five of the lead compounds, and
I have done ITC on one of the top hits, ZINC16188505 (negative result). I am
retaining the small amounts of the other compounds so another graduate student,
Emily Grasso, can detect any binding events by NMR. NMR is a better way to
detect weak binding than ITC, and it also reveals the location of binding [81,322].
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Table 5.2 – List of the top 105 docked drug-like molecules
The first column is the ZINC ID of a molecule (http://zinc.docking.org), the second column is the
docking score (more negative is better), and the third column is the cluster that a molecule belongs
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Table 5.2 – continued from previous page
ZINC-ID Score Cluster
ZINC94236236 -32.368546 2Ba
Figure 5.11 – Top two fragment screening hits
Table 5.3 – List of the top 61 docked fragment molecules
The first column is the ZINC ID of a molecule (http://zinc.docking.org), the second column is the
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